Justice's Biotech Brief

TRTACs — TROP2, the most crowded target in ADCs, gets repurposed as the shuttle instead of the target, degrading EGFR, HER2 and PD-L1

Thu, 27 Aug 2026 09:30:00 -0700

A preprint from East China University of Science and Technology (posted 2026-08-19, body rendered 2026-08-26) inverts the standard use of TROP2: instead of building another TROP2 antibody-drug conjugate, it uses TROP2 as a lysosome-targeting receptor (LTR) to drag other proteins into the lysosome. Extracellular targeted protein degradation (eTPD) has historically relied on LYTAC-style handles — the cation-independent mannose-6-phosphate receptor, or IGF2 — which are expressed on essentially every cell, so the mechanism carries no intrinsic tumor selectivity. The authors screened six clinically validated ADC targets (HER2, TROP2, folate receptor alpha, tissue factor, claudin-18.2, CD44) as candidate LTRs by fusing a nanobody against each to the EGFR nanobody 7D12 and running all six in the same two cell backgrounds (HeLa, SKBR3). TROP2 won outright, CLDN18.2 was second, the rest were near-inert — and TROP2 was not the most abundant of the six on those cells, so the advantage is trafficking, not expression. The resulting molecules (TRTACs) are ~30 kDa nanobody–nanobody fusions with no Fc. 7D12-TROP2Nb outperformed the IGF2 benchmark 7D12-IGF2 on EGFR degradation; neither arm alone worked, so the chimeric architecture is required. Internalization is clathrin-dependent; bafilomycin A1 rescues intracellular EGFR without blocking surface internalization, confirming lysosomal degradation. 100 nM for 24 h removes 47–59% of intracellular EGFR, dose- and time-dependent, no hook effect. The load-bearing result: across six cancer lines EGFR was degraded, while lung fibroblasts (MRC-5) and HUVECs showed essentially none — despite both normal lines expressing appreciable TROP2. Selectivity therefore does not come from a tumor-versus-normal expression gap but from differential internalization/endosomal sorting in malignant cells, a claim the authors support by citation rather than demonstration, and the single biggest assumption in the platform. Scope generalizes: swapping the substrate nanobody degrades PD-L1 (KN035-TROP2Nb on MDA-MB-231) and HER2 (11A4-TROP2Nb on SKBR3, active down to 4 nM), both beating IGF2-based controls; a soluble target (EGFP) is also cleared. The second half converts TRTACs into TRTAC-drug conjugates via a terminal cysteine and mal-vcMMAE: 11A4-TROP2Nb-MMAE killed 50% of SKBR3 cells at 0.2 nM while 11A4-MMAE and TROP2Nb-MMAE were inactive at that concentration, held up in spheroids, and beat both non-chimeric conjugates in NCI-N87 and HeLa xenografts; doxorubicin worked as an alternative payload. The conceptual payoff is that a conventional ADC forces one antigen to be the binding target, the internalization route, and the tumor-selectivity filter simultaneously; this architecture splits those jobs, so the substrate arm chooses what is removed while TROP2 supplies internalization — opening up targets that internalize poorly. Four caveats: every in vivo experiment is in nude mice, so the PD-L1 degrader (the most provocative substrate) is never tested in an immunocompetent setting where degrading rather than blocking PD-L1 would matter; there is no PK data at all, and 30 kDa is below the renal filtration cutoff (dosed q2d for 5–8 doses), with the authors conceding half-life extension is required — which adds mass and erodes the penetration argument; the TKI-resistance claim is oversold, since the conjugate was less potent against gefitinib-resistant PC-9/GR than parental PC-9 at high concentrations and better only at 12.5–25 nM; and every head-to-head is against IGF2 chimeras rather than a TROP2 ADC, the comparator that actually exists in the clinic. Strategically, routine TROP2 IHC means the stratification infrastructure exists on day one, and if TROP2 is genuinely upregulated by chemotherapy and enriched in drug-tolerant populations, the shuttle becomes more available in exactly the refractory setting where it would be used. Also noted: Akeso and Summit reported that ivonescimab plus chemotherapy beat durvalumab plus chemotherapy on OS in first-line advanced biliary tract cancer (HARMONi-GI1/AK112-309, 682 patients) — the first Phase 3 OS win in BTC and the first non-lung Phase 3 readout for a PD-1xVEGF bispecific, but with no numbers released and a China-only trial population.

Zanidatamab (Ziihera) — a biparatopic HER2 bispecific unseats trastuzumab in first-line gastroesophageal cancer, on a control arm the U.S. had already abandoned

Wed, 26 Aug 2026 09:30:00 -0700

On 2026-08-25 the FDA approved two Ziihera (zanidatamab) regimens for first-line unresectable locally advanced or metastatic HER2-positive gastric, gastroesophageal junction and esophageal adenocarcinoma: zanidatamab plus Tevimbra (tislelizumab, BeOne's PD-1 antibody) plus fluoropyrimidine/platinum chemotherapy for IHC 3+ and IHC 2+/ISH+ disease regardless of PD-L1 status, and zanidatamab plus chemotherapy alone for IHC 3+. This is the first displacement of trastuzumab from the front line of this disease since ToGA in 2010, and it was won by binding geometry rather than by a new target. Zanidatamab is biparatopic — it carries trastuzumab's ECD4 specificity and pertuzumab's ECD2 specificity on one molecule, which lets it bind adjacent HER2 receptors in trans rather than within a single receptor in cis. Trans-crosslinking gives roughly 1.5-fold higher cell-surface saturation and drives large HER2 clusters and polarized surface caps that neither antibody produces alone; those clusters recycle poorly out of early endosomes, so the receptor is internalized and degraded rather than merely antagonized, and the crosslinking sterically blocks both homo- and heterodimerization (hence ligand-independent as well as ligand-dependent signal inhibition). The immunologically distinctive consequence is complement-dependent cytotoxicity, which trastuzumab and trastuzumab-plus-pertuzumab do not meaningfully mediate: C1q engagement is a geometry problem requiring a dense ordered Fc array, so forcing receptors into caps builds a C1q docking surface out of the therapeutic antibody itself, on top of ADCC and ADCP. The same internalization property is why biparatopics are attractive ADC scaffolds. HERIZON-GEA-01 (NCT05152147) randomized 914 patients between December 2021 and February 2025 across more than 30 countries to three arms, with PFS and OS both primary by blinded independent central review. Triplet: median PFS 12.4 vs 8.1 months (HR 0.63), median OS 26.4 vs 19.2 months (HR 0.72). Doublet: median PFS also 12.4 months (HR 0.65) but median OS 24.4 months, HR 0.80, p = 0.06 — a miss, yet the arm still earned a label for IHC 3+ on the co-primary PFS win. Two skeptical reads. First, the control arm was trastuzumab plus chemotherapy with no checkpoint inhibitor, while KEYNOTE-811 had made pembrolizumab plus trastuzumab plus chemotherapy the US standard (accelerated 2021, full approval late 2023 for CPS 1 or greater, final median OS 20.0 vs 16.8 months) — enrollment ran to February 2025, so for most of accrual the comparator was not the American standard of care, and the question of whether a biparatopic beats trastuzumab on the same PD-1 backbone was never asked. Cross-trial arithmetic (26.4 vs KEYNOTE-811's 20.0) still leans zanidatamab's way but is not a head-to-head. Second, the PD-L1 subgroups run backwards: 29.7 vs 15.8 months in PD-L1-negative patients versus 26.4 vs 21.2 in PD-L1-positive, i.e. the largest apparent benefit in the patients least likely to respond to the PD-1 antibody in the regimen. The anomalous figure is the control arm's 15.8, not the experimental 29.7, and the assay is tislelizumab's tumor area positivity score rather than CPS, so this is not the population a CPS-calibrated intuition expects. The honest doublet-versus-triplet read is that tislelizumab bought roughly two months of median OS and the difference between clearing and missing an interim boundary. Tolerability is a real cost and oddly shaped for a monoclonal: grade 3+ AEs 83.3% (triplet) vs 74.5% (control), diarrhea 48% any grade with about a quarter at grade 3+ and a boxed warning — a TKI-shaped toxicity plausibly arising from the mechanism itself, with an ECD2 arm plus forced clustering shutting down HER-family signaling in gut epithelium harder than single-epitope occupancy. Left ventricular dysfunction (decline greater than 10 points to below 50%) occurred in 4.3%, resolving in 70%. Zanidatamab's first approval was accelerated, in second-line biliary tract cancer in late 2024; this is its move into a large first-line indication. The transferable lesson for engager and conjugate design is that on the most saturated target in oncology the win came from valency and binding orientation, and it paid out in three separable currencies at once — signaling blockade, receptor disposal, and complement recruitment.

Paused — download an episode to resume your daily briefing

Tue, 25 Aug 2026 09:00:09 +0000

Your daily briefing has been paused because no downloads have been detected in about two weeks. As soon as you download an episode, generation will automatically resume.

CD3×BCMA bispecifics — a day-4 CXCL10 spike and a lymphocyte crash separate responders from non-responders, and CRS doesn't

Mon, 24 Aug 2026 09:30:00 -0700

A bioRxiv preprint from Yannick Simoni's group at Institut Cochin (Universite Paris Cite / INSERM / CNRS; posted 2026-08-21, DOI 10.64898/2026.08.17.743749) profiles the first month of CD3xBCMA bispecific antibody therapy (teclistamab/elranatamab class) in relapsed-refractory multiple myeloma at high temporal resolution — baseline, day 4, week 1, then weekly — with mass cytometry on circulating T cells, plasma cytokine ELISAs and routine clinical labs in 14 patients across 5 timepoints, deliberately trading cohort size for depth. Every patient shows the same first-week pharmacodynamics: circulating lymphocytes fall 64.1% by day 4 to under 200 cells/uL (already detectable at 24 h), plasma CXCL10 rises from a baseline mean of 77.9 pg/mL (healthy donors 9.8) to 299.4 pg/mL by day 4, and gamma-delta and CD8+ T cells transiently upregulate CD69, CD38 and HLA-DR before everything returns to baseline by weeks 3-4. The key structural claim is a negative one: despite continued weekly dosing there is no second lymphopenia, no second CXCL10 wave and no re-induction of activation — the immune event is first-dose-dominated, with later doses maintaining target engagement rather than re-activating T cells, which the authors read as mechanistic support for response-adapted dosing after the first week. For response, 14 clinical and 193 immunological features were integrated by factorial analysis of mixed data (FAMD), a correlation network was built in that space, and each association was then re-checked in raw non-imputed data (the KIR and NKG2A associations did not survive) before validation in an extended cohort of up to 47 patients. Surviving correlates of response: a larger day-4 CXCL10 rise (336.0 vs 173.2 pg/mL in non-responders), a deeper day-4/week-1 lymphocyte drop, a roughly two-fold day-4 increase in CD69+ CD8+ T cells, lower soluble BCMA sustained through the first month, fewer baseline bone lesions, and fewer baseline exhausted CD8+ T cells (1.5% vs 5.9%). Notably, cytokine release syndrome, age and line of therapy showed no association with response, and neither did baseline T-cell differentiation state or cytotoxic profile — nor CD38+ Tregs or effector CD8+ frequencies, both previously reported baseline correlates, a discrepancy the authors flag directly. Caveats: the deep arm is a 14-patient pilot; the extended cohort validates the plasma and clinical findings but not the full immunophenotype; the bone-lesion association is a trend (Fisher's exact p = 0.21 in the extended cohort, 54.8% vs 85.7% with more than 3 lesions); and the FAMD network rests on imputed data, a limitation the authors raise themselves and partially address with the raw-data check. The transferable point for engager developers, which the authors extend to trispecifics: if response is largely a function of pre-existing T-cell fitness plus the capacity to mount a fast first-dose redistribution, a third specificity does not obviously rescue a patient who cannot produce the day-4 event — and the readout for asking that question is a chemokine and a complete blood count.

LIME — tumor-tropic E. coli displaying tandem scFvs become living T and NK cell engagers, and beat tarlatamab head-to-head in small cell lung cancer

Sun, 23 Aug 2026 09:30:00 -0700

A bioRxiv preprint from the Romee and Aguirre groups at Dana-Farber (posted 2026-08-20, DOI 10.64898/2026.08.18.745642) describes LIME — live immune modulating engagers — in which non-pathogenic, tumor-tropic E. coli K-12 display two single-chain variable fragments in tandem on an intimin (Neae) surface scaffold: one against a tumor-associated antigen, one against an activating receptor on T cells (CD3) or NK cells (CD16, NKG2D, NKp46). The arms are independently swappable; the authors show binding, effector activation and cytotoxicity across CLDN18.2, DLL3, EGFR, MSLN, HER2, CD123 and CD19 constructs in PDAC, glioblastoma, SCLC, NSCLC, breast, AML, BPDCN and lymphoma lines, plus killing of patient-derived CLDN18.2+ PDAC organoids. The headline experiment is a direct benchmark against the approved DLL3xCD3 engager tarlatamab in DLL3+ H69 small cell lung cancer xenografts in NSG mice reconstituted with human T cells: three IV doses of DLL3 T-LIME (2 x 10^8 CFU) versus three IP doses of tarlatamab (3 mg/kg) on the same schedule. DLL3 T-LIME beat tarlatamab on tumor growth (p = 0.0185) and survival (p = 0.0463), and reduced hepatic metastatic burden more in an IV metastasis model. Biodistribution explains the mechanism of the win: bacteria exceeded 10^10 CFU per gram of tumor, five to six orders of magnitude above normal organs, and the pharmacology followed — high intratumoral IFN-gamma, IL-6 and TNF with low plasma levels, while tarlatamab showed the inverse (higher circulating IFN-gamma, lower intratumoral cytokine). Intratumoral T cells after LIME also expressed less PD-1 than after tarlatamab. In immunocompetent models, CD19 T-LIME cured 3 of 6 A20 lymphoma mice (anti-PD-1 alone 1 of 6; the combination 6 of 7), and all 17 tumor-free mice rejected contralateral rechallenge at day 60. In KPC pancreatic tumors, anti-PD-1 added nothing, but combining MSLN LIME with the RAS(ON) multi-selective inhibitor RMC-7977 roughly doubled median survival (52.5-56 days vs 29-32 for monotherapies); that combination induced PD-L1 across intratumoral dendritic cells, macrophages, granulocytes and monocytes, and adding anti-PD-L1 as a third agent carried 66.6% of mice past day 60 with large established tumors. Caveats worth holding: the bare bacterial scaffold alone induces a broad inflammatory transcriptional program in human T cells (the engager arms add the proliferative machinery — mTORC1, glycolysis, MYC, G2M), so bacterial adjuvancy is not fully separable from engager activity; the paper's claim of minimal CRS risk is not testable in NSG or syngeneic murine models and overreaches what low plasma cytokines can support; the authors concede they cannot explain how a 1-2 micrometer bacterium supports cytotoxicity given a ~13 nm productive synaptic distance; and the clinical precedent for IV live bacteria in oncology (attenuated Salmonella VNP20009: safe, zero objective responses) is not encouraging. The transferable idea for engager developers is that the therapeutic-window problem may be a delivery problem rather than a molecular-format problem — tropism buying what masking chemistry is trying to buy.

WTX-124 — a conditionally activated IL-2 with an FDA-blessed registration path becomes a "legacy asset," as a reverse merger prices Werewolf's whole tumor-protease-activation platform at $47.5M

Sat, 22 Aug 2026 09:30:00 -0700

On August 21, 2026 Werewolf Therapeutics (Nasdaq: HOWL) and privately held Ambros Therapeutics signed a definitive all-stock merger agreement, alongside an oversubscribed $150M concurrent private placement co-led by RA Capital Management and Janus Henderson. The combined company takes the Ambros name, relocates to San Diego, is expected to trade as AMBX, and will advance neridronate — a bisphosphonate already approved in Italy and dosed in ~600,000 patients — through the pivotal Phase 3 CRPS-RISE trial in warm complex regional pain syndrome type 1 (~270 patients, 400 mg cumulative IV over 10 days, primary endpoint change in 11-point NRS pain intensity at week 12, topline 2028). The exchange ratio implies $500M for Ambros pre-placement and $47.5M for Werewolf; pre-merger Werewolf holders end with ~6.8% of the combined company plus a contingent value right on proceeds from disposition of Werewolf's "pre-transaction legacy assets." HOWL rose ~120% premarket on the announcement. Close expected by Q1 2027. Why this leads the brief: $47.5M is the price the market just put on tumor-conditional activation, and that is a design principle sitting directly next to masked T cell engagers and proximity-gated ADCs. Werewolf's PREDATOR platform built INDUKINE molecules — a cytokine fused to a high-affinity receptor-blocking domain plus a half-life extension domain, joined by a tumor-protease-cleavable linker: inert prodrug in circulation, cleaved to release free cytokine in the tumor microenvironment. The two clinical assets targeted precisely the two cytokines where systemic delivery is historically intolerable: WTX-124 (IL-2, Phase 1/1b, NCT05479812) and WTX-330 (IL-12, Phase 1b/2, NCT06939283). The data did not fail. Per Werewolf's December 18, 2025 pipeline update (data as of October 30, 2025): WTX-124 monotherapy ORR 21% in heavily pretreated advanced/metastatic cutaneous melanoma — which the company framed, accurately, as consistent with historical high-dose IL-2 activity — and 30% ORR in the subset with prior response to any immunotherapy regimen (i.e. not primary-resistant); tumor regression in ~33% of tumors at 12 or 18 mg across RCC, cutaneous SCC, NSCLC and other solid tumors; objective durable responses also in cutaneous SCC and gastroesophageal junction cancer as monotherapy and in melanoma, NSCLC and RCC with pembrolizumab; Grade 3 related TEAEs 25.5% (27/106) and Grade 4 1.9% (2/106); NO evidence of vascular leak syndrome — the toxicity that made high-dose IL-2 an ICU drug — and no recurrence of prior immune-related AEs. At an End of Phase 1 meeting the FDA accepted 18 mg as the recommended dose and gave initial guidance for a monotherapy WTX-124 registration path in post-ICI advanced/metastatic relapsed/refractory melanoma. WTX-330 is the cleaner mechanistic demonstration: at all dose levels free IL-12 was 0.12% of prodrug exposure, with a 17-fold higher Cmax than published rhIL-12 at 0.024 mg/kg IV Q2W, plus one confirmed partial response (45% target-lesion reduction, RECIST 1.1) in metastatic gallbladder cancer among the first 12 patients. So: not a failed molecule — a platform that produced a drug with an agency-endorsed registration path and ran out of money before it could run the trial. Q2 2026 (July 31): cash $22.0M, runway into Q2 2027, R&D $6.2M vs $13.1M year-ago, K2 HealthVentures loan repaid, JZP898 (IL-18) sold outright to Jazz Pharmaceuticals Ireland for a $21.0M payment, strategic-alternatives process running with Piper Sandler. The part that should sting for a TCE engineer: in December 2025 Werewolf declared its 2026 priority was not the cytokines but INDUCER — a MASKED T CELL ENGAGER platform using the same clinically validated cleavable-linker chemistry, with candidates WTX-1011 (STEAP1, prostate) and WTX-2022 (CDH6, ovarian/renal), claiming robust silencing, reversible masking, efficient activation in human tumor tissue, potent xenograft activity, and prevention of cytokine release in non-human primates, and stating the ambition to become "the leading T cell engager company." Two INDs planned for mid-2027, pending additional funding. Eight months later those programs are legally "legacy assets subject to disposition." The generalizable lesson is not that masking fails — 0.12% free IL-12 IS masking working. It is about the asymmetric cost of proving it. A masked biologic makes two claims: active where you want, inactive where you don't. The first is a response rate, and response rates are cheap. The second is a claim about the ABSENCE of an event, and you cannot establish "this does not uncork in normal tissue" from 106 patients, because the toxicity being ruled out lives in the tail. So conditional-activation programs get trapped: efficacy reads as merely comparable to the unmasked cytokine — because the unmasked cytokine IS the historical benchmark — while the differentiating safety claim needs a trial nobody funds off Phase 1 data. WTX-124's 21% looking like high-dose IL-2's activity was the whole point, and also, commercially, the problem. Counterweight: Jazz bought the IL-18 INDUKINE outright, so the chemistry has buyers, just not at company scale. Also still shelved and available for partnering: WTX-712 (IL-21), WTX-518 (IL-18), WTX-921 (IL-10 for IBD). Practical takeaway for anyone designing masked engagers — watch where the INDUCER assets land. The CVR guarantees somebody will be shopping them, and a masked STEAP1 engager with non-human-primate cytokine-release data is going to be cheap. Sources: Werewolf/Ambros merger press release, August 21, 2026; Werewolf pipeline and business update, December 18, 2025; Werewolf Q2 2026 results, July 31, 2026; ClinicalTrials.gov NCT05479812, NCT06939283. Link in show notes.

ABBV-1480 (RC148) — AbbVie's PD-1×VEGF bispecific posts a 90% response rate in first-line squamous lung cancer, right before a 940-patient head-to-head against Keytruda

Fri, 21 Aug 2026 09:30:00 -0700

On August 21, 2026 AbbVie issued a WCLC 2026 conference preview containing the first clinical data on ABBV-1480 (RC148), the PD-1×VEGF bispecific antibody it licensed from RemeGen in January 2026 for $650M upfront plus up to $4.95B in milestones (ex-Greater China rights). In a Phase 1b study of RC148 plus platinum chemotherapy in first-line advanced NSCLC (NCT06883630; n=121, 24 sites, all in China, ORR as primary endpoint), the 10 mg/kg dose — now the recommended Phase 3 dose — produced an ORR of 90.0% in squamous disease (27/30) and 75.9% in non-squamous (22/29). Most common treatment-related AEs were decreased white blood cell, neutrophil and platelet counts and anemia; no grade ≥3 hemorrhages were seen with the 10 mg combinations. Oral presentation OA14.01.03. Why the 90% is not the number that matters: this is a single-arm, open-label, China-only Phase 1b cohort of thirty patients, and the obvious benchmark — 58.4% ORR for pembrolizumab plus carboplatin/taxane in KEYNOTE-407 — came from a randomized, blinded, 559-patient global Phase 3. Cross-trial comparison at these Ns is the classic oncology trap, and the fourteen-point squamous-over-non-squamous gap (30 vs 29 patients) is noise-scale. The load-bearing datum is the hemorrhage line. Squamous histology has been bevacizumab's absolute contraindication in lung cancer for roughly two decades after a Phase 2 showed major hemoptysis and fatal pulmonary hemorrhage; squamous tumors are central, cavitating, and erode large vessels. The whole expansion of the PD-(L)1×VEGF class into squamous disease is a bet that a bispecific format concentrating VEGF neutralization in tumor rather than systemically declaws that risk. Ivonescimab made that bet first and won it: HARMONi-6, roughly 500 patients, grade ≥3 hemorrhage 1.9% vs 0.8%, with ~30% of patients having a hemoptysis history. Zero events in ~59 RC148 patients is reassuring in direction and nearly uninformative in magnitude — an upper bound around 5-6%, fully consistent with a true 2% rate. Right question, underpowered answer. Design intuition: RC148 is a humanized IgG1 with a silenced Fc, and its mechanistic bet differs from ivonescimab's cooperative-binding story. VEGF is a dimer, so the anti-VEGF arms can crosslink it, giving avidity-driven trapping wherever VEGF concentration is highest (tumor stroma), with PD-1 binding activity enhanced as a consequence of that enrichment — the VEGF arm as localization mechanism, checkpoint blockade as the cargo that rides along. The silenced Fc is the tell that they meant it: you do not want ADCC against the PD-1-positive T cells you just decorated. What to watch: two Phase 3 programs with two very different control arms. RemeGen's China Phase 3 (NCT07416474, started April 3, 2026; 574 patients, 78 sites) runs RC148 plus carboplatin/paclitaxel against TISLELIZUMAB plus the same chemotherapy in first-line squamous NSCLC — the identical, softer control arm HARMONi-6 used. AbbVie's own global trial (NCT07756645, not yet recruiting, start date September 22, 2026) is 940 patients across ~250 sites, squamous only, against PEMBROLIZUMAB plus carboplatin and a taxane, with PFS and OS as CO-PRIMARY endpoints and ORR demoted to secondary. That is the honest experiment in this class and nobody has finished one; Summit's ex-China ivonescimab program produced a PFS win without establishing survival. AbbVie went straight to co-primary OS against the actual global standard of care. Finally, the part that explains the price: AbbVie did not pay ~$5.6B for a monotherapy, it bought a chemotherapy-free immune-plus-antiangiogenic backbone for its own conjugates, and the same release says so. Telisotuzumab adizutecan (c-Met ADC, topoisomerase-I payload) is entering Phase 1b/2 M24-536 (NCT06772623) with a PD-1 inhibitor and no platinum in first-line non-squamous NSCLC, plus a study with osimertinib in EGFR-mutant disease (NCT07155187). ABBV-706 (SEZ6 ADC) showed 82% ORR in relapsed/refractory SCLC after platinum (n=17), with SEZ6 expressed in 91% of SCLC and >96% of those with brain or liver metastases; safety across 240 monotherapy patients showed grade ≥3 pneumonitis/ILD at 1.7% and serious treatment-related AEs at 12.5%. RemeGen has already run RC148 with disitamab vedotin and with its mesothelin ADC RC88. And Biokin is starting a first-line squamous trial pairing a bispecific ADC with a PD-1×VEGF bispecific. Everyone is converging on the same architecture from opposite directions: replace chemotherapy in the backbone with a checkpoint-plus-antiangiogenic bispecific, then add a conjugate as the cytotoxic. The 90% is the press release; the question is whether the backbone holds. Sources: AbbVie newsroom, August 21, 2026; AbbVie-RemeGen licensing announcement, January 12, 2026; ClinicalTrials.gov NCT06883630, NCT07416474, NCT07756645. Link in show notes.

Iza-bren (BL-B01D1) — EGFR×HER3 bispecific ADC becomes the first bispecific ADC to hit a Phase 3 primary endpoint in lung cancer, and it hit the easy one

Thu, 20 Aug 2026 09:30:00 -0700

On August 18, 2026 Sichuan Baili Tianheng (Biokin, Chengdu) filed a voluntary disclosure with the Shanghai Stock Exchange (announcement 2026-060) stating that iza-bren / izalontamab brengitecan (BL-B01D1), its EGFR×HER3 bispecific antibody-drug conjugate, met the progression-free survival primary endpoint at a prespecified interim analysis of the Phase 3 PANKU-Lung01 trial (BL-B01D1-301, NCT06382116), as judged by the independent data monitoring committee; on overall survival the filing reports only that "a trend toward benefit was observed." Biokin calls it the fourth Phase 3 this molecule has won and the first Phase 3 anywhere in which a bispecific ADC has met its primary endpoint in NSCLC. Bristol Myers Squibb paid $800M upfront and committed up to $8.4B for rights outside China. Why it leads the brief: the design logic is different from the checkpoint bispecifics we have been covering. In volrustomig, ivonescimab or pumitamig the second arm adds pharmacology — a second pathway blocked, or one arm used as an address label to make a toxic mechanism selective. Iza-bren does neither. It is an anti-EGFR IgG1 with anti-HER3 single-chain fragments fused through glycine-serine linkers, carrying the camptothecin-derived topoisomerase-I payload Ed-04 on a cleavable tetrapeptide linker at a drug-to-antibody ratio of roughly 8. Neither arm shuts a pathway down; both exist to get the warhead inside the cell. Engaging two receptors on the same membrane buys avidity and receptor crosslinking, driving internalization and lysosomal trafficking harder than either arm alone — so a meaningful payload dose reaches tumors where each individual antigen is only modestly expressed. The second arm is a DELIVERY AMPLIFIER, not a second mechanism. And the pairing is not arbitrary: EGFR is abundant on these tumors but also on normal skin and gut epithelium, so EGFR alone buys uptake without selectivity, while HER3 is upregulated as a resistance response to EGFR TKI therapy — meaning in exactly this trial's population the second antigen is enriched by the prior treatment. The trial: 432 patients, locally advanced or metastatic non-squamous NSCLC with classical EGFR mutations, all progressed on a third-generation EGFR TKI, none having received systemic therapy other than EGFR TKIs, randomized against pemetrexed plus cisplatin or carboplatin. PFS by blinded independent review was the SOLE primary endpoint; OS is a secondary endpoint. That distinction is the story, because this exact trial has been run before and it won and then lost: Daiichi Sankyo and Merck's patritumab deruxtecan (HER3-DXd), a single-target HER3 ADC with a topoisomerase-I payload, ran HERTHENA-Lung02 in the same slot against the same comparator, announced a statistically significant PFS win in September 2024, and reported medians of 5.8 vs 5.4 months (HR 0.77) — four tenths of a month of median separation — followed by OS of 16.0 vs 15.9 months (HR 0.98). Flat. The companies voluntarily withdrew the US BLA on May 29, 2025, three days before the ASCO presentation. So beating platinum doublet on PFS in this setting is already known not to establish a survival benefit — and Biokin disclosed no hazard ratio, no medians, no event counts, no data cutoff and no safety data. The number that would distinguish this readout from the last one is exactly the number missing from the filing. The case for optimism is magnitude: at WCLC 2025 a Phase 2 subgroup of chemotherapy-naive patients who had failed a third-generation TKI — essentially this trial's population — showed a median PFS of 12.5 months on iza-bren, roughly double HER3-DXd's 5.8. Discount heavily (single-arm, Phase 2, Chinese population, cross-trial comparison is the oldest way to fool yourself in oncology) but it is the right shape of prior: if the true effect is near that size, OS has room to follow; if it is another HR in the high 0.7s, this readout means about as much as the last one did. Two more things to file. The unaddressed caveat: dual EGFR and HER3 targeting with a topo-I payload at DAR 8 is not an obviously gentle combination, and the exclusion criteria show what the sponsors feared — no prior topo-I ADC, no history of interstitial lung disease requiring steroids, no active pneumonitis. ILD is the class problem for deruxtecan-type payloads, and a readout with efficacy but no safety tells you half of what you need. And the one that touches the VEGF beat directly: Biokin is starting a China Phase 3, Panku-Lung05, combining iza-bren with a PD-1×VEGF bispecific antibody in first-line squamous NSCLC — bispecific ADC plus bispecific checkpoint-plus-antiangiogenic, in the front line. Roughly 20 Phase 3 or Phase 2/3 trials are now running on this one molecule between Biokin and BMS, including a global first-line study pairing it with osimertinib (Izabright-Lung02) and the global Phase 2/3 Izabright-Lung01 (started November 2025, expected to read out 2028). Iza-bren is already approved in China in recurrent or metastatic nasopharyngeal carcinoma and esophageal squamous cell carcinoma, with a TNBC NDA accepted by CDE. Honest summary: a bispecific ADC has cleared a Phase 3 bar in lung cancer that no bispecific ADC had cleared before — a real platform milestone for the format, evidence that dual targeting for delivery moves a randomized endpoint — and it is also, specifically, the bar the last HER3 ADC cleared on its way to being withdrawn. Watch for the hazard ratio and the survival curves before repricing the $8.4B bet. Sources: Sichuan Baili Tianheng SSE voluntary disclosure, August 18, 2026; Fierce Pharma, August 18, 2026; ClinicalTrials.gov NCT06382116. Link in show notes.

REGN7041 — first-in-human anti-CD3 antibody for uveitis terminated after a single patient, cause unidentified

Wed, 19 Aug 2026 09:30:00 -0700

Regeneron has terminated TITAN (NCT07218770), the Phase 1/2a and only clinical trial of REGN7041, its anti-CD3 monoclonal antibody, in active noninfectious uveitis affecting the posterior segment. The registry reason is "unfavorable benefit-risk assessment"; a company spokesperson told BioSpace on August 18 that the decision "follows an updated risk-benefit assessment for the study treatment, prompted by a thorough review of a safety event observed in the trial," declining to specify the event and noting the cause "has not been identified." The load-bearing number is the enrollment field: ACTUAL ENROLLMENT ONE. The study opened December 17, 2025, completed July 21, 2026, and the record was updated to TERMINATED on August 17 — one patient dosed, program's only trial dead. Why it leads the brief: CD3 is the same complex every T cell engager grabs, but there is a second, older pharmacology at the same receptor — bind CD3 without crosslinking it to a second target, with an Fc that doesn't recruit effector function, and you get partial unproductive signaling, receptor downmodulation, anergy and a shift toward Tregs. That is tolerance induction, and it is approved: teplizumab delays type 1 diabetes on exactly that mechanism, with foralumab and otelixizumab the same idea. The recurring failure mode has never been the target but the window — the engagement that eventually tolerizes first activates, so first-dose cytokine release, lymphopenia and viral reactivation define the ceiling, and otelixizumab failed in T1D because the tolerable dose wasn't the effective one. Which makes the eye a clever bet on paper: uveitis is T cell-driven disease in a small semi-enclosed compartment, so acting locally should deliver tolerizing pharmacology at micrograms rather than milligrams and never approach systemic exposure. The compartment does what masking or conditional activation does in an engager — it restricts where the drug is active. Regeneron has NOT disclosed route of administration (the intervention description reads only "administered as per the protocol") and the episode does not assert it, but the design shows what they were watching: PK in serum AND in intraocular fluid at multiple timepoints, ADA incidence and magnitude, TEAEs as the primary endpoint through week 24, sequential single-ascending then multiple-ascending dose cohorts, and all five sites retina practices (Sacramento; Oak Park, IL; Nashville; Bellaire and Katy, TX). It stopped at patient one. The gap is the story: event unknown, severity unknown, ocular versus systemic unknown, and the sponsor investigated and still doesn't know the cause. That is worse than it sounds — a dose-dependent CRS event in cohort one is workable (lower the dose, premedicate, step-dose, exactly what the engager field learned), but an unexplained event at the starting dose leaves nothing to titrate against and no defensible starting dose for a next protocol. Transferable lesson for CD3-directed biologics: the field's answer to engager toxicity has been to constrain WHERE the molecule is active — protease-cleaved masked engagers, costimulation split across arms so full activation needs two addresses, deliberately low-affinity CD3 arms requiring high target density. Compartmental delivery is a cousin of all of those: restriction by geography rather than biochemistry. This is a datapoint that geography is not a firewall — antibody leaves the vitreous, T cells traffic in and out, and a small compartment leaves very little room for an inflammatory response you didn't intend. Company context: this lands on a Regeneron already absorbing hits — itepekimab (IL-33, the hoped-for Dupixent follow-up) missed one of two Phase 3 COPD trials, a LAG-3-containing melanoma combination lost head-to-head to Keytruda in Phase 3, and with roughly $18B of cash and analysts pressing for M&A, CEO Leonard Schleifer keeps answering with the word "disciplined." Killing an early asset over an unexplained safety event is the right call and an expensive one. Final note on disclosure: this surfaced not via press release or investor update but as a registry record quietly flipped to terminated with an enrollment count of one, noticed by a reporter who then asked — the current disclosure floor for a first-in-human failure. Sources: ClinicalTrials.gov NCT07218770 (record updated August 17, 2026); BioSpace, August 18, 2026. Link in show notes.

Volrustomig — PD-1×CTLA-4 bispecific fails to beat Keytruda plus chemo in first-line lung cancer, and AstraZeneca kills the Phase 3

Tue, 18 Aug 2026 09:30:00 -0700

On August 17, 2026 AstraZeneca discontinued eVOLVE-Lung02 (NCT05984277), the Phase 3 of volrustomig (MEDI5752) — its PD-1×CTLA-4 bispecific — plus chemotherapy versus pembrolizumab plus chemotherapy in first-line metastatic NSCLC with PD-L1 <50%. 895 patients, 25 countries, enrolling since October 2023; at a planned interim the independent data monitoring committee concluded volrustomig was unlikely to hit either dual primary endpoint (PFS or OS in the PD-L1-negative, <1% subgroup). No new safety signals. Why it leads the brief: volrustomig is not a naive combination in one package but a monovalent IgG1 bispecific engineered so the PD-1 arm drives binding and the CTLA-4 arm rides along — full PD-1 blockade plus PREFERENTIAL CTLA-4 blockade on PD-1-positive T cells. The design logic is format-as-targeting: CTLA-4 blockade works (ipilimumab proved it) but is systemically toxic because CTLA-4 brakes priming everywhere, whereas PD-1 goes up on antigen-experienced T cells and so serves as a rough address label for the tumor — tether the dangerous mechanism to a PD-1 binder and you concentrate it intratumorally and spare the periphery. Same instinct as masked engagers and proximity antigens. The population was the right test, not a fishing expedition: PD-L1-low/negative is where checkpoint-plus-chemo does worst and where prior CTLA-4-containing evidence (AstraZeneca's own tremelimumab experience) was most credible, run head-to-head against the real standard of care with the primaries reserved for PD-L1 <1%. The useful interpretation is not "dual checkpoint blockade doesn't work" (it's approved in melanoma, RCC, mesothelioma) but what the engineering did and didn't buy: it bought pharmacology (first-in-human receptor occupancy and PD biomarker changes as predicted) but not a therapeutic window — ~1/3 of Phase 1 patients discontinued for adverse events — and not efficacy in near-PD-L1-null tumors. Mechanistically that tracks: a drug whose selectivity depends on finding PD-1-high antigen-experienced T cells inside the tumor has aimed very precisely at something that isn't there when the tumor is cold. The contrast is the real signal: six days earlier China's NMPA approved ivonescimab plus chemo in 1L squamous NSCLC (Akeso/Summit's PD-1×VEGF bispecific, third China indication) on HARMONi-6, where it beat tislelizumab plus chemo on OS — median 27.9 vs 23.7 months, HR 0.66, a 34% reduction in risk of death, the first regimen ever to beat a PD-1-plus-chemo standard on survival in a randomized 1L NSCLC Phase 3. Inside one week: dual-checkpoint bispecific can't beat pembro-chemo; checkpoint-plus-VEGF bispecific beats a PD-1-chemo standard. The transferable lesson for anyone designing multispecifics is how you choose the second arm — CTLA-4 amplifies along one axis (two brakes on the same T cell, paid for in immune toxicity) while VEGF blockade changes the environment the T cell works in (vasculature, myeloid suppression, trafficking), an orthogonal axis with real standalone activity. Orthogonality may be worth more than amplification, and format elegance is not a substitute for target selection. Two reservations: the PD-1×VEGF class isn't a free lunch either — ivonescimab's benefit estimates have been sensitive to follow-up duration, moving in both directions across data cuts, and Endpoints reported August 17 that the China numbers softened on longer follow-up (underlying analysis not readable; a flag, not a finding). And volrustomig isn't dead — Phase 3s continue in cervical cancer, head and neck squamous cell carcinoma, and mesothelioma, the last a setting where CTLA-4 blockade has a strong prior. What's gone is the biggest indication, from a pipeline AstraZeneca is counting on to reach $80bn in sales by 2030. Susan Galbraith, EVP Oncology Haematology R&D: "While we are disappointed, we will learn from this trial and are determined to continue pioneering new medicines." PD-L1-low lung cancer remains what it has been for a decade: the graveyard where good IO hypotheses go to be disproven. Sources: AstraZeneca press release and CancerNetwork, August 17, 2026; ClinicalTrials.gov NCT05984277. Link in show notes.

Felzartamab — anti-CD38 antibody clears its first global approval, in China for myeloma; Biogen's real bet is antibody-driven kidney disease

Sun, 16 Aug 2026 09:30:00 -0700

On August 14, 2026 China's NMPA approved felzartamab — a humanized anti-CD38 monoclonal antibody (originally MorphoSys's MOR202) — for second-line multiple myeloma in combination with lenalidomide and dexamethasone, sold as Jingfei, manufactured by TJ Biopharma in Hangzhou (China's first domestically produced anti-CD38 for myeloma). The hook for Justice: this is felzartamab's FIRST approval anywhere in the world, and it landed in a strange place. Anti-CD38 is mature, crowded ground — daratumumab (Darzalex) owns ~nine of ten global anti-CD38 doses and ~$7bn/yr — so felzartamab enters as roughly the fourth player on convenience and cost, not novelty: TJ reported efficacy/safety comparable to daratumumab in the len-dex combo but with a ~1.5-hour infusion vs. up to 7 hours for IV daratumumab, plus a domestic-sourcing price edge in China's procurement system. The honest caveat is that subcutaneous daratumumab (Darzalex Faspro) already doses in 3–5 minutes, blunting the convenience angle; analysts see felzartamab taking ~15% of a small Chinese myeloma anti-CD38 market by 2029. On its own, a validation event, not a revenue event. The real story is who owns the rest of the molecule and why: outside greater China, felzartamab belongs to Biogen, which paid over $1.15bn up front in 2024 to acquire Human Immunology Biosciences — not for a fourth-place myeloma antibody but for a plasma-cell-depleting antibody aimed at antibody-driven kidney disease. Same mechanism you know from myeloma (CD38 marks long-lived plasma cells), flipped: in autoimmune/transplant settings those plasma cells are the factories making the pathogenic antibodies that wreck the kidney, so depleting them shuts the antibody off at its source — something anti-CD20 (rituximab) can't reach because it spares plasma cells. Biogen has THREE global Phase 3 programs running — antibody-mediated rejection in kidney transplant, IgA nephropathy, and primary membranous nephropathy — with FDA Breakthrough Therapy and Orphan designations in two, and Phase 2 data already showing reduced proteinuria and stabilized kidney function. Editorial read for Justice: felzartamab's first global approval landed in the indication that matters least to its owner (a me-too anti-CD38 in Chinese myeloma) while the indications Biogen actually paid up for are still reading out — but that myeloma label is the first real-world proof the antibody depletes CD38 plasma cells safely and effectively enough to clear a regulator, the identical mechanistic bet underneath the kidney franchise. The cleanest current example of one plasma-cell-targeting antibody straddling oncology and autoimmunity — CD38 migrating from killing cancer cells to silencing the plasma cells behind antibody-mediated disease. Watch the Phase 3 kidney readouts. Source: Endpoints News, August 14, 2026 (with Biogen/TJ Biopharma deal and HI-Bio acquisition context). Link in show notes.

Zenbexus (iberdomide) — first CELMoD protein degrader wins FDA approval in myeloma, on a minimal-residual-disease endpoint

Sat, 15 Aug 2026 09:30:00 -0700

On August 13, 2026 the FDA granted accelerated approval to Zenbexus (iberdomide, Bristol Myers Squibb) with daratumumab and dexamethasone for multiple myeloma after at least one prior line — and the reason it leads a translational-immunology brief is that iberdomide is the FIRST approved CELMoD, a cereblon-modulating protein degrader, the successor class to thalidomide/lenalidomide/pomalidomide and the first thing from BMS's targeted protein degradation platform to reach patients. Mechanism worth Justice's attention: like the older IMiDs, iberdomide binds cereblon and redirects that E3 ubiquitin ligase to degrade the transcription factors Ikaros and Aiolos — but faster and more completely than lenalidomide — buying two things at once: direct myeloma-cell killing (those factors sit atop the myeloma survival program) AND a stronger immune kick (more T-cell and NK-cell activation). That immune-stimulatory arm is why CELMoDs are becoming the immune-conditioning backbone layered under antibodies (here, anti-CD38 daratumumab) and, increasingly, under T-cell engagers and CAR-T — the potentiator, not the passenger. The data and the part to circle: approval came off the Phase 3 EXCALIBER-RRMM trial — iberdomide triplet (ZDd, n=207) vs. standard daratumumab-bortezomib-dexamethasone (DVd, n=213), ~420 patients — and the primary endpoint was NOT PFS or ORR but minimal residual disease (MRD)-negative complete response, which the iberdomide arm doubled: 41% vs. 21% at 16 months' median follow-up (p<0.0001). This is the first approval ever in relapsed/refractory myeloma based on MRD-negative CR — a regulatory precedent arguably worth more than the drug: deep MRD-negativity is a surrogate regulators have circled for years, and if it's now registrational, the next wave of myeloma combinations (including TCE and antibody regimens) can register on a biomarker readout instead of waiting for survival curves to separate. Caveats are real: accelerated approval on a surrogate (confirmatory PFS/OS still owed; MRD-negativity predicts survival, doesn't guarantee it), plus boxed warnings for embryo-fetal toxicity and thromboembolism, neutropenia in 90% and infections in ~79% of treated patients, second primary malignancies, and ~4.9% fatal adverse events. Editorial read for Justice (translational immunologist, Rodgers/Calibr; TCE/CAR-T/ADC/checkpoint beat): don't read this as one more myeloma triplet — read it as the first CELMoD across the line, validating a degrader platform that generates immune-potentiating backbones for exactly the antibody and T-cell-engager combinations at the center of his work, and as the approval that put MRD-negative CR on the map as a registrational endpoint. Both outlive this one label. Source: Bristol Myers Squibb press release and FDA, August 13, 2026. Link in show notes.

IDP-001 — a proximity-guided EGFR bispecific ADC enters the clinic, testing InduPro's "tumor proximity antigen" platform

Fri, 14 Aug 2026 12:00:00 +0000

On August 12, 2026 InduPro (Seattle and Cambridge, MA) closed a $77M Series B and dosed the first patient in a first-in-human Phase 1 of its lead oncology program, IDP-001 — and the reason it earns the slot is the discovery idea, not the money. IDP-001 is a potential first-in-class, proximity-based bispecific antibody-drug conjugate targeting EGFR and TAPA-E1, a novel "Tumor-Associated Proximity Antigen" (undisclosed). The platform's thesis: instead of hunting for a single tumor-clean antigen (EGFR isn't — it's on skin/gut, hence the narrow-window rash/diarrhea tox of EGFR agents), use high-resolution proximity labeling to map which surface proteins sit physically adjacent on tumor cells, and pick a PAIR that co-localizes on cancer but not normal tissue. IDP-001's two arms (EGFR + TAPA-E1) are meant to engage/deliver payload preferentially where both coexist in that tumor-specific spatial pattern — EGFR supplies the address and internalization, the proximity antigen supplies selectivity — widening the therapeutic window by requiring a coincidence healthy tissue doesn't reproduce. That's a conceptual shift for an ADC field that mostly competes on payloads, linkers, and single-target affinity. Trial (NCT07602842): open-label monotherapy in advanced/metastatic squamous and non-squamous NSCLC and other squamous solid tumors progressed on standard of care; CMO Amanda Redig frames squamous cancers as underserved — they lack the driver mutations and clean surface targets the approved ADCs were built on. Financing led by The Column Group; existing backers Vida Ventures and Merck's MRL Ventures Fund; new investors Solasta Ventures, Sanofi, and Eli Lilly. Editorial read for Justice: hold it as a platform-validation bet, not a working drug — no efficacy data, TAPA-E1 undisclosed (can't sanity-check the thesis), and first-in-human ADCs fail on tolerability all the time. But the tell is three separate large pharmas (Merck's arm, Sanofi, Lilly) circling one antibody-engineering platform at Series B — the same "buy proximity to the engine" pattern as Attovia and yesterday's Infinimmune. Most important for solid-tumor immunotherapy: InduPro says the same proximity-antigen map also feeds T-cell engagers, which is exactly the target-selectivity problem holding solid-tumor TCEs back. The ADC is the first shot; the platform is the thing to watch. Source: BioSpace, August 12, 2026. Link in show notes.

IFX-101 and IFX-201 — Infinimmune's IL-22 and IL-13 antibodies raise $75M from Regeneron and Merck to chase Dupixent in eczema

Thu, 13 Aug 2026 12:00:00 +0000

On August 11, 2026 Infinimmune (Alameda, CA; founded by ex-10x Genomics single-cell scientists, CEO Wyatt McDonnell) closed a $75M Series A — and the story is the syndicate and the discovery platform, not the two drugs. The round was co-led by Playground Global and Regeneron's venture arm, with RA Capital Management, the Merck Global Health Innovation Fund, and nine other backers; Infinimmune already had prior research collaborations with Merck & Co. and Immunome. The tell: Regeneron makes Dupixent, the atopic-dermatitis franchise Infinimmune is explicitly chasing — so the incumbent whose market this targets, plus a second big pharma, are paying to sit close to the platform, which is the real asset. Infinimmune's pitch is an antibody-discovery engine (out of the single-cell genomics world) claiming to yield "more durable and powerful" molecules — an unquantified promise with no data behind it yet, but one sophisticated antibody investors evidently want optionality on. The two lead assets show the strategy: IFX-201, an anti-IL-13 antibody, is the de-risked me-better play in a fully validated axis (Dupixent blocks IL-4Rα/IL-4+IL-13; standalone IL-13 blockers lebrikizumab and tralokinumab are already approved) — competing on durability and dosing, not novelty. IFX-101, an anti-IL-22 antibody positioned "first and best-in-class," is the swing: IL-22 is not a validated AD driver (it's established in psoriasis, IBD, kidney), so it's the platform going after an un-de-risked target. Both target IL-22/IL-13, which reach beyond eczema into IgA nephropathy and ulcerative colitis — atopic dermatitis is the beachhead, not the ambition. Both are only slated to reach the clinic in 2027, and McDonnell called AD "clinically crowded, but not commercially crowded." Editorial read for Justice: not a drug story (no clinical data) but a read on where antibody-engineering value is migrating — the discovery-side counterpart to the recent format stories (Attovia's VHH multispecific IPO, sonelokimab's Nanobody phase 3). The smart money is buying the engine that made the antibodies, not the two eczema antibodies. Source: BioPharma Dive, August 11, 2026. Link in show notes.

L1CAMxCD3 bispecific T-cell engager — a pancreatic-cancer TCE keeps working in patient tumor slices with the full immunosuppressive microenvironment intact

Wed, 12 Aug 2026 12:00:00 +0000

A bioRxiv preprint (posted August 11, 2026) from Susanne Sebens's group at Kiel University develops two L1CAMxCD3 bispecific T-cell engagers against pancreatic ductal adenocarcinoma — and the notable part is the test bed, not the molecule. Both are IgG-(L)-scFv bispecifics: a fully humanized anti-L1CAM IgG1 with an anti-CD3 scFv fused to each light chain via a (G4S)3 linker; one uses an OKT3-derived CD3 arm, the other a humanized SP34 arm. The Fc is silenced (L236A/L237A) to abolish ADCC/CDC/ADCP, so killing is pure CD3-mediated T-cell redirection; L1CAM affinity is sub-nanomolar (~0.15–0.22 nM). Target rationale: L1CAM is expressed in ~80% of PDAC, concentrated at the invasive front, a negative prognostic marker that drives progression and therapy resistance — a rare usable handle in an antigen-poor tumor. The models climb in stringency: matched L1CAM-positive/-negative lines confirm strict antigen dependence (no killing without L1CAM, without CD3, or without effector cells); 3D spheroids still killed; and — the key stress test — adding pancreatic myofibroblasts and macrophages, the two dominant immunosuppressive stromal populations, did not blunt killing. It also worked with immune cells from PDAC patients (functionally exhausted), though more variably. The crown jewel: patient-derived organotypic tissue slice cultures from four freshly resected, treatment-naïve tumors, with intact architecture and the patient's own tumor-infiltrating T cells as the ONLY effectors (no healthy-donor add-back). The SP34 construct drove significantly more cleaved-caspase-3 tumor apoptosis, fewer Ki67+ cells, and trends toward more IFN-γ and granzyme B — even though L1CAM levels in those tumors were low. Honest caveats: n=4, most slice-culture effects are trends with only caspase-3 reaching significance, only one construct was taken that far, no in-vivo efficacy, and L1CAM's expression on normal neurons/epithelia leaves on-target/off-tumor safety untouched. Editorial read for Justice: hold it not as a new drug but as a raised bar — most solid-tumor T-cell-engager programs never test in an autologous-TIL, TME-complete model before phase 1, which is exactly where PDAC engagers die; getting a signal here at low antigen density with the stroma present is a more credible read than the usual donor-PBMC-plus-cell-line assay. Companion to last Friday's IM1240 capped-CD3 trispecific (the same solid-tumor-engager problem attacked from the toxicity side; here it's the model-validity side). The molecule may or may not become a drug — the way they asked the question is the contribution. Preprint, not peer-reviewed. Link in show notes.

Sonelokimab — a trivalent IL-17A/F Nanobody clears its first Phase 3 in psoriatic arthritis, though the placebo delta stays blinded

Tue, 11 Aug 2026 12:00:00 +0000

On August 10, 2026 MoonLake Immunotherapeutics reported positive topline results from IZAR-1, the first of two registrational Phase 3 trials of sonelokimab in psoriatic arthritis; in biologic-naïve adults the drug met its primary endpoint and every key secondary at Week 16. The pick isn't about the disease — it's about the format. Sonelokimab is a ~40 kDa humanized Nanobody: three single-domain VHH building blocks (the heavy-chain-only camelid domains) on glycine-serine spacers, two binding IL-17A and IL-17F (neutralizing the A/A, A/F and F/F dimers) and a third binding human albumin — a half-life extender that also concentrates drug at sites of inflammatory edema. The thesis: a molecule a third the size of an IgG penetrates inflamed tissue better and delivers where albumin leaks. The numbers: 42% ACR50 (primary), 66% ACR20, 41% minimal disease activity, 61% PASI90 in those with skin involvement, plus meaningful gains in HAQ-DI and SF-36 physical function; blinded safety showed no new signals, low dropout. The catch is large: this topline is absolute response only for the 60 mg-with-induction arm — the placebo delta and treatment-arm comparisons stay blinded until the full Week 52 readout in H1 2027, and IZAR-1 has no active comparator (IZAR-2, in TNF-refractory patients, runs head-to-head vs risankizumab). And MoonLake's CEO called the data "consistent with other IL-17A/F programs" — i.e., bimekizumab, an approved conventional antibody — so the pitch is that sonelokimab matches, not beats, on efficacy; the whole case rests on the format (tissue penetration, dosing, manufacturing), not a higher response ceiling. Editorial read for Justice: genuine validation of the VHH platform thesis — the same antibody-engineering migration from oncology into immunology as last week's Attovia episode — and the furthest-along proof point, with a hidradenitis suppurativa BLA expected end of September and a PDUFA decision ~end of November, meaning VHH multispecifics are about to be a marketed reality in inflammation. What's unproven, and what the blinded placebo delta and the IZAR-2 head-to-head will decide, is whether the format buys anything a well-made conventional antibody doesn't. Watch the H1 2027 readout. Source: MoonLake press release, August 10, 2026. Link in show notes.

Lacutamab — first-in-class anti-KIR3DL2 antibody heads into a confirmatory Phase 3 in cutaneous T-cell lymphoma on a Sobi partnership

Mon, 10 Aug 2026 12:00:00 +0000

Today's pick is a Monday corporate item from Innate Pharma, but the interesting part is the target. On August 10, 2026 Innate signed a strategic partnership with Sobi (the Swedish rare-disease company) to license and fund lacutamab, and is taking it into a confirmatory Phase 3 (TELLOMAK-3) in cutaneous T-cell lymphoma; it also named a new CMO. The science angle for Justice: lacutamab is a first-in-class antibody against KIR3DL2, a killer immunoglobulin-like receptor. Normally KIR3DL2 is an inhibitory receptor — functionally a self-tolerance checkpoint — so you'd expect a checkpoint blocker. It isn't. In CTCL the malignant T cells overexpress KIR3DL2 (>85% of Sézary syndrome patients), and lacutamab exploits it purely as a lineage marker: a naked depleting antibody that kills tumor cells by antibody-dependent cellular cytotoxicity and phagocytosis, recruiting NK cells and macrophages. The lesson — sometimes a "checkpoint" receptor's value is just being the cleanest surface address on the cell you want dead. The disease: Sézary syndrome is the aggressive leukemic form of CTCL, with little left after mogamulizumab — a true orphan unmet need. Data behind the Phase 3: in TELLOMAK Phase 2, relapsed/refractory Sézary patients (≥2 prior systemic therapies including mogamulizumab) had ~43% ORR with a median duration of response of 25.6 months, and grade 3+ treatment-related events in under 10% — durability and tolerability you don't get from a T-cell engager; activity showed up regardless of baseline KIR3DL2 level. Mycosis fungoides was weaker (~20% ORR), which shapes the design: TELLOMAK-3 is open-label, randomized, multicenter with two cohorts — a confirmatory Sézary cohort (accelerated approval) and a registrational mycosis fungoides cohort (full approval), primary endpoint PFS, eligibility now at one prior line. Lacutamab carries FDA Fast Track and Breakthrough Therapy plus EMA PRIME. Editorial read for Justice: read the deal honestly — Sobi pays $75M upfront, up to $40M near-term Sézary milestones, then up to ~$465M tied to an option for full development rights plus later milestones, with tiered double-digit royalties; it extends Innate's runway only into Q3 2027. This is as much a survival-and-de-risking move for a small company whose accelerated path had stumbled as it is a scientific milestone. Why it's on the radar: in a field obsessed with trispecifics, masked engagers and dual-payload conjugates, lacutamab is the opposite argument — a plain depleting antibody that works because the target is almost perfectly restricted to the malignant cell. Target selection still wins. Watch the TELLOMAK-3 confirmatory readout. Source: Innate Pharma press release, August 10, 2026. Link in show notes.

BI-1808 — first-in-class anti-TNFR2 antibody takes FDA Fast Track in platinum-resistant ovarian cancer on a Treg-depleting, checkpoint-reviving mechanism

Sun, 09 Aug 2026 12:00:00 +0000

A thin weekend on Justice's beat (no fresh on-target preprints or clinical readouts; mostly Q2 earnings), so today's pick is Friday's regulatory milestone on a differentiated mechanism. On August 7, 2026 BioInvent announced the FDA granted Fast Track designation to BI-1808 — a first-in-class anti-TNFR2 antibody — in combination with pembrolizumab for platinum-resistant ovarian cancer. Why the target matters: TNFR2 (the second TNF receptor) is heavily upregulated on the immunosuppressive regulatory T cells that sit inside tumors, and also on myeloid and some peripheral effector cells — which is why the field long argued whether to agonize or block it. BioInvent's bet is a ligand-blocking, Fc-gamma-receptor-engaging antibody that does two jobs at once: it blocks TNFR2 signaling and, because it engages Fc receptors, physically depletes the Treg population that overexpresses the receptor rather than merely quieting it, while reprogramming myeloid cells and reactivating CD8 T cells. Instead of releasing a brake on the effector T cell (PD-1/CTLA-4 style), it clears the suppressive population itself — the same theme as last week's ipilimumab episode (Treg destabilization inside the tumor), swapped onto a receptor Tregs happen to overexpress. Data behind the designation: an interim Phase 2a cohort presented at ASCO 2026 in heavily pretreated, platinum-resistant ovarian cancer showed BI-1808 plus pembrolizumab — notably chemo-free — producing a 24% confirmed objective response rate, 56% disease control rate, and preliminary median PFS of 10.3 months, with responses across high-grade serous and clear cell subtypes and several ongoing past 10 months. The weight comes from the benchmark: pembrolizumab monotherapy historically gets ~8% in this cold, checkpoint-resistant tumor, so tripling the response rate by adding a Treg-depleting antibody is a real mechanistic signal, not ride-along. Editorial read for Justice (translational immunologist, Rodgers/Calibr; cancer immunotherapy, checkpoint biology): hold it as early — 24% is a minority of patients, this is a small single-arm Phase 2a with no control (cross-trial comparison to historical pembro is suggestive, not definitive), Fast Track is a process designation about unmet need and rolling review rather than an efficacy verdict, and TNFR2 remains genuinely double-edged (suppressive on Tregs, co-stimulatory on effectors elsewhere), so the depletion-vs-collateral margin needs randomized data. But the most credible path through immunotherapy-cold ovarian cancer isn't a better checkpoint antibody — it's remodeling the suppressive microenvironment so the checkpoint drug you already have starts working, and BI-1808 is a clean example aimed at a target most companies avoided. Expansion cohorts in high-grade serous and clear cell are enrolling now, with another data cut expected in the second half of 2026 — that's the readout that matters. Source: BioInvent press release, August 7, 2026. Link in show notes.

IM1240 — a "capped-CD3" trispecific engaging both T cells and NK cells posts preclinical data aimed at the T-cell-engager cytokine-release problem

Sat, 08 Aug 2026 12:00:00 +0000

Purple Biotech's Q2 2026 update (August 7, 2026) is a financial report, but it disclosed new preclinical data on IM1240 — a molecule that sits squarely on one of Justice's stated interests, trispecific T-cell engagers, and was the freshest genuinely on-target item on the board. IM1240 is a tri-specific antibody with the format capped-CD3 x 5T4 x NKG2A, from Purple's CAPTN-3 platform. The three arms: a CD3 arm to recruit T cells; a 5T4 (trophoblast glycoprotein) arm as the tumor-targeting handle — an oncofetal antigen re-expressed across many solid tumors and largely silent in normal adult tissue; and an NKG2A arm that does double duty, physically recruiting NK cells (and some CD8 T cells) while relieving the NKG2A/HLA-E inhibitory checkpoint tumors use to switch killer cells off. So one molecule bridges two killer populations and lifts a brake at once. The headline is the "capping": the CD3 arm is masked so the engager stays quiet until it reaches tumor tissue — the field's current bet for decoupling tumor killing from the systemic T-cell activation and cytokine release that has kept CD3 bispecifics boxed into hematology. The preclinical case: in non-human primates the capped version showed roughly 8-fold longer half-life and 16-fold greater systemic exposure than the uncapped variant, and produced minimal IL-6 and TNF-alpha at 10 mg/kg while the uncapped version drove robust cytokine release at 0.03 mg/kg — a more-than-two-log shift in the dose that triggers a cytokine storm. On the tumor side, all tested patient-derived samples responded, including PD-1-resistant head and neck cancer and checkpoint-inhibitor-resistant bladder cancer, and one lung sample showed IM1240 inducing tertiary lymphoid structures while pulling in CD8 T cells and NK cells. Editorial read for Justice (translational immunologist, Rodgers/Calibr; trispecific TCEs are a named interest): hold it as early — this is preclinical data in an earnings release, not a peer-reviewed paper or clinical readout, and IM1240 isn't slated for the clinic until 2027; the solid-tumor-TCE graveyard is full of molecules that looked clean preclinically then lit up in patients, and masking strategies still have to prove the mask is both tight in circulation and reliably cleaved in the tumor across tumor types. But the combination of conditional activation plus NK engagement plus a checkpoint-relieving arm is a genuinely differentiated take on the therapeutic-window problem, and it's the exact engineering conversation happening across the trispecific field now — if capping works, the template generalizes far past this one asset. Watch the 2027 first-in-human data. For context, Purple's lead clinical assets are CM24 (a CEACAM1-blocking antibody with improved outcomes across efficacy endpoints in a Phase 2 pancreatic study) and NT219 (a dual IRS1/2 and STAT3 inhibitor that finished Phase 2 in head and neck cancer). Source: Purple Biotech Q2 2026 results release, August 7, 2026. Link in show notes.

Tudriqev — RP1's oncolytic virus clears the FDA on the third try, with a political assist and a confirmatory trial as the price of admission

Fri, 07 Aug 2026 12:00:00 +0000

The FDA granted accelerated approval on August 6, 2026 to Tudriqev (vusolimogene oderparepvec, formerly RP1) in combination with Bristol Myers Squibb's nivolumab (Opdivo), for adults with unresectable advanced cutaneous melanoma that has progressed on a PD-1-based regimen — Replimune's third submission after two prior rejections, this time following a July 30 advisory committee vote of 10-3 in favor despite the FDA's own reviewers writing that the pivotal IGNYTE trial wasn't adequate and well-controlled, and, per multiple reports, vocal trial-investigator advocacy plus a reported White House intervention on the company's behalf. RP1 is an engineered oncolytic herpes simplex virus armed with a fusogenic glycoprotein and GM-CSF, injected directly into a tumor to lyse cancer cells and prime an immune response that nivolumab then amplifies — mechanism this show already covered in depth around the July 30 advisory committee vote. The approved label rests on a 91-patient non-injected-lesion analysis (IGNYTE had no control arm, so isolating the virus's own contribution required looking only at tumors it never touched): objective response rate about 24.2%, median duration of response 14.1 months. Approval is accelerated and explicitly contingent on the ongoing randomized Phase 3 confirmatory trial, IGNYTE-3 (RP1 plus nivolumab vs. standard therapy), reading out in late 2027 — a miss pulls the drug back off the market. It's only the second oncolytic virus ever approved in the U.S., after Amgen's Imlygic in 2015, which never commercially scaled because intratumoral dosing is logistically hard and its near-monotherapy benefit was modest; Replimune priced Tudriqev at $450,000 per course and is betting the checkpoint combination succeeds where Imlygic didn't. Editorial read for Justice (translational immunologist, Rodgers/Calibr; T-cell engagers, CAR-T, ADCs, combination immunotherapy): the biology is a rerun of what we've already discussed, but the regulatory story is new and directly relevant to his own work — this is a textbook contribution-of-components problem, the exact issue any combination biologic paired with a checkpoint or chemo backbone eventually hits in a single-arm trial, and Replimune's workaround (a non-injected-lesion sub-analysis plus vocal outside advocacy) is now both a template for other sponsors and a data point in the FDA's institutional memory. The thing that actually settles whether intratumoral oncolytic viruses are a real modality is IGNYTE-3's 2027 readout, not this week's approval. Source: BioPharma Dive and Replimune's FDA approval announcement, August 6, 2026. Link in show notes.

ATTOBODY — Attovia's biparatopic VHH multispecific platform lands a $289M IPO, from an IL-31 itch biologic to a trispecific for IBD

Thu, 06 Aug 2026 12:00:00 +0000

Attovia Therapeutics priced an upsized ~$289M IPO on Aug 5, 2026 (closing Aug 6) — worth Justice's attention not for the raise but for what the company is: a pure-play multispecific-antibody shop that has pointed the whole toolkit at immunology and inflammation rather than oncology, the same modality migration (bispecifics/trispecifics moving from cancer into autoimmune/allergic disease) he tracks from the T-cell-engager side. The differentiator is the ATTOBODY platform (in-licensed from Alamar Biosciences): camelid single-domain (VHH) antibodies joined by a proprietary peptide linker, with two VHHs binding two different epitopes on the same target — biparatopic binding — for higher avidity and a modular, Lego-like system that builds monospecifics, multispecifics, or conditional AND-gated bispecifics. Pipeline: (1) ATTO-1310, an IL-31 ("itch cytokine") biologic that finished Phase 1 dosing in early 2026 — well tolerated, low immunogenicity, PK/target-engagement supporting infrequent extended dosing; Phase 1b in chronic pruritus and high-itch atopic dermatitis showed rapid deep itch relief plus lesion control, with a pan-pruritic strategy (any elevated IL-31, incl. CKD-associated itch). (2) ATTO-2306, a half-life-extended bispecific hitting IL-13 and IL-31 — the two validated AD pathways in one molecule (anti-IL-13 derived from lebrikizumab; same IL-31 VHHs as ATTO-1310) — designed to sidestep the reverse dose-efficacy of IL-31Ra drugs and the TMDD of IL-4Rα agents (dupilumab's target); IND-enabling, Phase 1 expected 2027. (3) ATTO-1091, the boldest bet — a trispecific Fc-fusion blocking TL1A, IL-23 and integrin a4b7 simultaneously in IBD, three separately validated mechanisms folded into one construct (combination pharmacology, not combination therapy); IND-enabling. Editorial read for Justice (translational immunologist, Rodgers/Calibr; autoimmune biologics + trispecific TCEs are stated interests): hold it skeptically but with real interest — every franchise is crowded (nemolizumab in IL-31; dupilumab/lebrikizumab in AD; a wall of IBD biologics), so a platform play only wins if biparatopic multispecifics deliver less-frequent dosing, deeper responses, or a differentiated three-in-one no combo regimen matches. The IL-31 data are early Phase 1 and the two most interesting assets are still preclinical, but the reason to watch is the platform bet itself: if biparatopic VHH multispecifics can be built cleanly, dosed infrequently, and stacked up to three targets deep in autoimmune disease, that template reaches well past dermatology and the gut — the same engineering conversation Justice is having in oncology, targets swapped out. Source: Attovia IPO pricing release (GlobeNewswire, Aug 5, 2026) and Form S-1. Link in show notes.

Pumitamig — BioNTech and Bristol Myers push their PD-L1×VEGF bispecific into a seven-trial pivotal program

Wed, 05 Aug 2026 12:00:00 +0000

BioNTech's Q2 2026 corporate update (released August 4, 2026) is a financial report, but it contains the clearest picture yet of one of the largest bets in oncology on a class Justice tracks closely: the PD-L1×VEGF bispecific. The asset is pumitamig (BNT327/BMS986545), a single antibody that both blocks PD-L1 (releasing the checkpoint brake on T cells) and neutralizes VEGF-A (denying tumors the leaky, immunosuppressive vasculature they build) — the mechanism Akeso/Summit's ivonescimab put on the map when it beat Keytruda on PFS in Chinese NSCLC. Pumitamig is partnered with Bristol Myers — the same BMS in this week's AstraZeneca merger chatter. The news in the update: pumitamig is now in SEVEN pivotal trials across the ROSETTA program, five of them launched in H1 2026 alone, spanning triple-negative breast cancer, colorectal cancer, gastric cancer, and two NSCLC settings (unresectable stage III; advanced PD-L1 ≥ 50%). A global Phase 2/3 (ROSETTA Lung-02) runs pumitamig+chemo head-to-head against pembrolizumab+chemo in first-line NSCLC; earlier trials cover 1L HCC, 2L GBM, 1L PDAC, and 1L RCC. Editorial read for Justice (translational immunologist, Rodgers/Calibr; VEGF×PD-L1 is his stated #1 interest): the VEGF×PD-(L)1 class is genuinely contested — the Chinese PFS wins were striking but the Western OS story has been murkier — and BioNTech/BMS are answering the skeptics not with one confirmatory trial but a seven-trial blitz, a conviction bet that the mechanism generalizes into a solid-tumor backbone rather than a one-indication lung drug. The piece that lands squarely in his lab's work: the novel/novel combination strategy pairing pumitamig with BioNTech's own B7-H3 ADC, elfetabart drozuntecan (BNT324/DB-1311) — over 1,000 patients dosed across 10+ tumor types, including 400 in combination with pumitamig. That is the checkpoint-plus-anti-angiogenic-plus-payload logic tested at real scale. What to watch: the head-to-head lung trial against standard of care (beating pembro+chemo is the real bar), and the novel/novel combination readouts BioNTech says are due in 2026. The encouraging seed is the ASCO 2026 Phase 2 first-line NSCLC data — high response rates across squamous and non-squamous disease and across PD-L1 levels — but the pivotal Phase 3 survival data is still ahead. Source: BioNTech press release, August 4, 2026. Link in show notes.

AstraZeneca–Bristol Myers — a ~$400B megamerger rumor that would put two of the biggest checkpoint and ADC franchises under one roof

Tue, 04 Aug 2026 12:00:00 +0000

The Financial Times reported Saturday (Aug 2 2026), with Reuters confirming via its own sources, that AstraZeneca and Bristol Myers Squibb held early-stage talks about combining — a company worth roughly $400B (AZ ~$264B, BMS ~$133B), one of the largest mergers pharma has contemplated. Preliminary only; no structure confirmed; sources say it may never happen. The cleanest rationale is U.S. revenue (AZ ~42% of sales in the U.S., BMS ~69%), following AZ's recent NYSE listing; oncology already drives ~44% of AZ's ~$59B annual revenue. The wrinkle that has analysts perplexed: BMS is facing a serious patent cliff — Eliquis and Opdivo (anti-PD-1) together are ~half of sales and both lose exclusivity later this decade — so AZ, the strongest organic grower in big pharma under Pascal Soriot, would be buying a patent-cliff problem it doesn't have. Jefferies called it a "head scratcher" ("AZ doesn't need financial engineering"); RBC flagged that agreeing on price could kill it. The market punished AZ (stock down >8%, ~$22B erased); BMS barely moved. Editorial read for Justice (translational immunologist, Rodgers/Calibr; IO/ADC/cell-therapy beat): the reason it's HIS story is what it would concentrate. BMS invented the checkpoint era (Opdivo/Yervoy — literally yesterday's episode) and owns two approved CD19/BCMA cell therapies (Breyanzi, Abecma); AZ has become the ADC powerhouse via its Daiichi Sankyo alliance (Enhertu, Datroway) plus Imfinzi. "Complementary" — AZ strong in solid tumors/ADCs, BMS in blood cancers/cell therapy — is the polite way of saying one company would hold an enormous slice of the checkpoint + ADC + cell-therapy pipeline at once. For someone developing T-cell engagers, CAR-T, ADCs, and checkpoint-adjacent biologics, that reshapes who your combination partner is, who prices the backbone your asset must beat, and which internal shots on goal get funded vs. killed — and the checkpoint overlap is exactly where U.S./EU/UK antitrust would push back (AZ is treated as a cornerstone of British R&D). Hold it lightly — it's a rumor about early talks and the base rate on "explored a deal" becoming a signed deal is low, especially when the acquirer's own shareholders are punishing the idea. But the durable signal underneath is that big pharma is short on organic answers to the coming patent cliffs and is reaching for scale — and here the scale on the table is two of the defining IO and ADC franchises of the last 15 years.

Ipilimumab — anti-CTLA-4 destabilizes tumor Tregs by agonizing CTLA-4 to fire TGF-β signaling, not by blocking it

Mon, 03 Aug 2026 12:00:00 +0000

bioRxiv preprint (posted August 1 2026, not peer-reviewed), WanJun Chen lab, NIH/NIDCR — a mechanism paper reopening the oldest unsettled question about the first approved checkpoint inhibitor: how does anti-CTLA-4 (ipilimumab/Yervoy, approved 2011) actually work? Two camps have competed for a decade — (1) the antibody blocks CTLA-4 on T cells so CD28 wins the B7 contest and effectors stay on; (2) the Fc tail flags CTLA-4-high intratumoral Tregs for macrophage killing (ADCC/ADCP depletion). This paper argues both miss the switch: on intratumoral Tregs, which express CTLA-4 very highly, anti-CTLA-4 does not block but agonizes CTLA-4 — cross-linking it turns UP TGF-β signaling through TβRI, which paradoxically DEstabilizes the Treg (downregulates CD25/IL-2 survival signaling and lactate metabolism, loss of Foxp3, impaired suppression, death), within 15h–3d. The genetics are the strength: Treg-specific TβRI knockout completely abolishes anti-CTLA-4 efficacy (no Treg loss, no tumor control), and Treg-specific CTLA-4 knockout does the OPPOSITE of the drug — tumors unaffected, MORE intratumoral Tregs — which a pure-blockade model can't explain. The effect still requires FcγR (specifically FcγRIV) — but for cross-linking/agonism, not killing, reframing why Fc matters. Same antibody, opposite actions by CTLA-4 density: on low-CTLA-4 effector CD4/CD8 and peripheral Tregs it blocks (effectors expand); only on high-CTLA-4 tumor Tregs it flips agonist. Human translation: ipilimumab upregulates TGFBR1 and knocks down IL2RA/lactate metabolism in human Tregs in vitro and suppresses tumors in humanized mice. Editorial read for Justice (translational immunologist, Rodgers/Calibr; checkpoint/immunotherapy beat): if it holds, it rewrites the design brief for anti-CTLA-4 — the field's Fc-enhanced antibodies (botensilimab) were built for better ADCC-driven Treg depletion, but this says you should tune for cross-linking geometry and agonism, with intra-Treg TGF-β as the effector arm. It's also a warning for TGF-β-blockade-plus-checkpoint combinations: block TGF-β systemically and you may blunt the mechanism clearing your tumor Tregs — context-dependent TGF-β (stabilizing in one setting, destabilizing in another) is the kind of thing that quietly burns a combo trial. Caveats: preprint, mouse-heavy, and the depletion camp won't fold on one paper; the honest read is all three mechanisms likely coexist, weighted by tumor, Fc, and CTLA-4 density.

Satralizumab (Enspryng) — anti–IL-6 receptor antibody filed for MOGAD, the first phase-3-backed relapse-prevention therapy in the disease (68% risk cut)

Sun, 02 Aug 2026 12:00:00 +0000

Chugai press release, July 31 2026 — Chugai filed satralizumab (Enspryng), a pH-dependent recycling anti–IL-6 receptor monoclonal, with Japan's health ministry to prevent relapses in MOG antibody-associated disease (MOGAD). The peg is a single-country supplemental filing; the substance is the trial under it. Satralizumab is already approved in ~90 countries for neuromyelitis optica (NMOSD), where the driver is anti-aquaporin-4 antibody and B-cell depletion works well. MOGAD looks similar — antibody-mediated CNS demyelination, optic neuritis and myelitis — but the autoantigen is myelin oligodendrocyte glycoprotein, and anti-CD20 has underdelivered here (rituximab data mixed; standard of care an evidence-thin mix of steroids, IVIG, off-label immunosuppression, with no approved relapse-prevention therapy). The pivotal global phase 3 METEOROID, in adults and adolescents down to age 12, cut relapse risk 68% vs placebo. Editorial read for Justice (translational immunologist, Rodgers/Calibr; autoimmune-biologics beat): the interesting part isn't that a drug worked, it's which node worked — IL-6 both licenses the plasmablasts making anti-MOG antibody and drives downstream Th17/BBB inflammation, and blocking the receptor beats emptying the B-cell compartment. That's a real mechanistic dissociation between two diseases usually lumped together: antibody-mediated demyelination is not always B-cell disease. Caveats: Japan-only filing for now (global filings presumably to follow); rare disease with modest numbers; IL-6R blockade carries infection/neutropenia/lipid risk that weighs heavier when committing an adolescent to chronic therapy. Through-line: same target class, second demyelinating disease — a reminder that the right immunological node doesn't transfer just because two diseases rhyme.

Opamtistomig (LBL-024) — a PD-L1×4-1BB bispecific completes phase 2 enrollment in biliary tract cancer, reviving conditional 4-1BB costimulation for cold tumors

Sat, 01 Aug 2026 12:00:00 +0000

Leads Biolabs press release, July 30 2026 — the Chinese biotech said opamtistomig (LBL-024), a PD-L1×4-1BB bispecific antibody, finished enrolling all 70 patients in a Phase 2 first-line study in biliary tract cancer, with the full readout expected at ESMO in October. The small news peg (completed enrollment) is worth the check because of the molecule's design. One arm blocks the PD-L1 checkpoint (takes the brake off exhausted T cells); the other is an agonist of 4-1BB, a costimulatory receptor whose engagement drives T-cell proliferation, survival, and effector function — signal two layered on top of releasing the brake. The reason that second arm matters: 4-1BB agonists are a graveyard. Bristol's urelumab was potent but hit dose-limiting hepatotoxicity (systemic 4-1BB clustering causes hepatitis); Pfizer's utomilumab dodged the tox by being a weak agonist and had almost no efficacy — strong enough to work has meant strong enough to poison the liver. The field's escape route is conditional agonism: build the antibody so 4-1BB only gets crosslinked where its partner target is dense. Here the anchor is PD-L1, enriched in the tumor, so in principle the 4-1BB go-signal fires inside the tumor microenvironment and stays quiet in the liver — checkpoint release and costimulation delivered to the same place from one molecule. Editorial read for Justice (translational immunologist, Rodgers/Calibr; TCE/CAR-T/ADC/checkpoint/autoimmune beat): the data so far are a mixed bag — the most mature signal is in extrapulmonary neuroendocrine carcinoma, where monotherapy ORR across ~146 evaluable patients was ~15% with DCR just under half (a foot in the door, not a breakthrough), though the program earned FDA fast track there. What earns a look is the strategy: the company is deliberately marching the antibody into immune-cold indications where single-agent PD-L1 barely registers — biliary tract, gastric, esophageal squamous — which is exactly where you'd have to prove that conditional costimulation does real work. Brakes: completed enrollment is logistics, not efficacy; the October ESMO readout is the event. What matters there is whether the biliary tract response rate clears chemo-plus-checkpoint in first line AND whether liver enzymes stay clean at active doses — efficacy above the PD-L1-alone floor without transaminase flares would be real validation that tumor-localized 4-1BB is finally tractable. Through-line: this is the same architecture as the dual-stimulatory-receptor work (release the brake, add a spatially restricted go-signal), packaged as a plain bispecific antibody — and it sits right next to the PD-L1×VEGF bispecifics on the beat, both bets that a second function bolted onto checkpoint blockade and aimed at the tumor beats checkpoint blockade alone. The 4-1BB version has the harder safety problem, which is what makes the October data worth calendaring.

In vivo CAR-T — J&J options Sail Biomedicines in a bet worth up to $3.4B on off-the-shelf immune reset for autoimmune disease

Fri, 31 Jul 2026 12:00:00 +0000

Johnson & Johnson press release, July 29 2026 — J&J took an exclusive option to acquire Sail Biomedicines (a Flagship company building in vivo CAR-T for immune-mediated disease), structured as $785M up front (including a $465M equity investment), $140M in near-term development milestones, and $2.58B more to exercise the option — up to ~$3.4B, all pointed at immunology rather than oncology. The tell: the very same day, AbCellera and Vertex signed a separate deal to build multispecific T-cell engagers, also for autoimmune disease — two big-pharma bets, one day, both on redirecting T cells to reset the immune system. The backdrop is what makes this worth the check: the most striking autoimmune data of recent years came not from a biologic but from CD19 CAR-T borrowed from oncology — wipe out B cells in lupus, myositis, or systemic sclerosis and a meaningful fraction go into drug-free remission (immune system rebooted, autoantibodies gone). The problem is delivery: autologous CAR-T means apheresis, weeks of manufacturing, lymphodepleting chemo, and a six-figure price — impossible logistics for a non-cancer disease. Sail's bet is to make the CAR inside the body: circular RNA ("endless RNA") encoding the CAR, carried by targeted lipid nanoparticles to T cells in vivo; the cell transiently expresses the CAR, kills B cells, and — because it's RNA, not integrated DNA — expression fades on its own. No apheresis, no per-patient manufacturing, no lymphodepletion; in principle a shelf vial dosed like a biologic. Editorial read for Justice (translational immunologist, Rodgers/Calibr; TCE/CAR-T/ADC/checkpoint/autoimmune beat): the scientific thesis worth arguing is that in autoimmune disease you don't need durable engraftment to get a durable effect — you need a deep, transient B-cell sweep, after which the immune system repopulates from naive precursors and comes back tolerant. If that's true, a transient, self-limiting in vivo CAR isn't a compromise but arguably the better tool — the reset without a permanently engineered cell living in the patient forever. Brakes: this is a platform bet, not a data readout — Sail's lead autoimmune program is still preclinical/IND-enabling, with no human evidence that in vivo reprogramming matches the depth of B-cell depletion ex vivo CAR-T achieves; in vivo T-cell targeting is genuinely hard (LNP biodistribution, potency, controlling cytokine release without inpatient CAR-T scaffolding); and Flagship's Sail has had a bumpy road (merger of two struggling platforms, layoffs). Buyer context: J&J already knows CAR-T from oncology via Carvykti (Legend) and had reached into in vivo cell therapy with Kelonia before Lilly bought it — so this is buying back into a frontier it lost once, now in immunology where its commercial muscle already sits. Through-line: the next CAR-T battle isn't the target (CD19 is settled) — it's delivery, and it's being fought in autoimmune disease, not cancer; J&J and Vertex just told you on the same day that the prize goes to whoever can turn spectacular ex vivo remissions into something you can inject.

RINVOQ (upadacitinib) — first JAK inhibitor to claim complete hair regrowth wins EU approval in severe alopecia areata

Thu, 30 Jul 2026 12:00:00 +0000

AbbVie press release, July 29 2026 — the European Commission approved RINVOQ (upadacitinib), an oral once-daily selective JAK1 inhibitor, for severe alopecia areata in adults and adolescents 12 and older. Alopecia areata is a T-cell-driven autoimmune attack on the hair follicle (CD8 T cells, an interferon-gamma signature, loss of follicular immune privilege) whose sustaining cytokines signal through JAK-STAT — which is why JAK inhibition works: quiet the kinases, quiet the circuit, let the follicle recover. The approval rests on the Phase 3 UP-AA program — two replicate trials, ~1,400 patients aged 12–64. Both the 15 mg and 30 mg doses met the primary endpoint (SALT score of 20 or below at week 24, i.e. at least 80% scalp regrowth), and AbbVie's differentiation headline is that this is the first JAK inhibitor to show complete regrowth (SALT=0, a full head of hair) vs placebo at week 24, with eyebrow/eyelash improvement too. Editorial read for Justice (translational immunologist, Rodgers/Calibr; TCE/CAR-T/ADC/checkpoint/autoimmune beat): upadacitinib is roughly fourth to this market — baricitinib (Lilly), ritlecitinib (Pfizer, already with the adolescent label), and deuruxolitinib (Sun Pharma) are already approved — so its pitch is depth of response, not a new mechanism, and a placebo-controlled trial can't tell you whether SALT=0 rates beat the incumbents head-to-head. The bigger point is the safety ceiling: every drug in the class carries the JAK boxed warning (serious infections, thrombosis, malignancy, MACE) extrapolated from rheumatoid arthritis, and applying that to otherwise-healthy people — many of them teenagers — for a disfiguring-but-not-fatal condition is a genuinely different risk-benefit calculus. That ceiling is exactly why the interesting frontier is targeted JAK delivery — the JAK antibody-drug-conjugate idea (tether a JAK inhibitor to an antibody, concentrate drug at the pathology, drop systemic exposure). Through-line: JAK inhibition has become the default mechanism for severe alopecia areata; upadacitinib adds a stronger complete-regrowth claim, and for a field simultaneously chasing JAK-free options (the IL-7R and IL-15-axis antibodies covered earlier this month — bempikibart, FB102), the real prize goes to whoever gets JAK-level efficacy without the JAK-level warning label.

RP1 (vusolimogene oderparepvec) — oncolytic-plus-nivolumab melanoma combo heads into a make-or-break FDA adcom on single-arm data

Wed, 29 Jul 2026 12:00:00 +0000

STAT/BioSpace, July 28 2026 — ahead of a July 30 advisory committee, FDA briefing documents call the pivotal package for Replimune's RP1 "not interpretable," setting up a third go at approval. RP1 (vusolimogene oderparepvec) is a replication-selective, intratumorally injected oncolytic herpes simplex virus engineered to express GM-CSF and a fusogenic viral glycoprotein (GALV-GP R-), designed to lyse injected tumor cells and convert that local killing into systemic anti-tumor T-cell immunity (the abscopal thesis). It is combined with Bristol Myers Squibb's nivolumab (Opdivo, an anti-PD-1) in advanced cutaneous melanoma that has progressed on prior anti-PD-1 therapy — a genuinely underserved population. The evidence problem: the registrational data come from IGNYTE, a single-arm Phase 1/2 study (no control), reporting a confirmed response rate of ~34% in the anti-PD-1-failed cohort with a median duration of response beyond two years, ~high-40s% three-year overall survival across the cohort, and >80% among responders. FDA's briefing docs this week call the overall-survival analysis from the single-arm study "not interpretable" and say the response-assessment methodology "confounds interpretation" — the classic single-arm confound: in patients pulled off a PD-1 antibody and put back on a PD-1 antibody plus the virus, you cannot separate RP1's contribution from nivolumab's, and "responders live long" is a selection effect, not a treatment effect. The frustrating part is that the answer already exists but isn't done — IGNYTE-3, a randomized Phase 3 of the same combination vs physician's choice in melanoma progressed on both anti-PD-1 and anti-CTLA-4 — so the real dispute is accelerated approval now vs waiting for the RCT. Replimune's ethics counter (you can't randomize these patients to continued PD-1 monotherapy) is weaker precisely because the confirmatory RCT it is already running does have a comparator. Editorial read for Justice (translational immunologist, Rodgers/Calibr; TCE/CAR-T/ADC/checkpoint beat): the intratumoral-oncolytic-plus-checkpoint field lives or dies on the systemic-immunity claim, and this is the highest-profile test yet of whether regulators will accept single-arm evidence for it. Context that sharpens it: this is attempt three (complete response letters July 2025 and April 2026 over the same design/evidence concerns), and the resubmission landed right after an FDA leadership shake-up (Vinay Prasad and Marty Makary departures) with essentially no new efficacy data — so a favorable vote reads as much as a signal about where the evidentiary bar now sits as a verdict on this virus. The Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) meets July 30; the decision deadline is August 2. Watch the vote — and, more importantly, the specific objections the committee dwells on, which preview the hurdle every "inject locally, cure systemically" program will have to clear.

Sonesitatug vedotin — first Claudin 18.2 ADC to post an overall-survival win in gastric cancer, though the co-primary PFS endpoint missed

Tue, 28 Jul 2026 12:00:00 +0000

AstraZeneca press release, July 27 2026 — high-level results from the global Phase III CLARITY-Gastric01 trial show sonesitatug vedotin (Sone-Ve; formerly AZD0901 / CMG901, licensed from KYM Biosciences in March 2023) delivering a statistically significant, "highly clinically meaningful" overall-survival benefit in 2nd-and-later-line Claudin 18.2-positive advanced gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma vs investigator's choice of therapy. The asset: an anti-CLDN18.2 monoclonal antibody with a protease-cleavable linker and a monomethyl auristatin E (MMAE) tubulin-poison payload — and AstraZeneca is pointedly calling it the first pivotal win from its wholly owned ADC portfolio (not the Daiichi Sankyo/Enhertu partnership). Design and the wrinkle: dual primary endpoints were OS in the 3rd-and-later-line group and PFS by blinded central review in the full 2nd-and-later-line population. The OS co-primary hit, and a key secondary (OS across the full 2L+ population) also hit — but the PFS co-primary only showed a trend and did not reach statistical significance. That OS-positive / PFS-not-significant discordance is the story: survival extended without a formal PFS win, plausibly because benefit accrues in depth/durability of response and the post-progression tail (diluted by an early dose-selection stage), while the skeptical read is that regulators will scrutinize an open-label trial that missed a co-primary. Editorial read for Justice (translational immunologist, Rodgers/Calibr; TCE/CAR-T/ADC/checkpoint beat): the significance is modality plus biomarker. Until now CLDN18.2 was validated mainly as a naked-antibody target (zolbetuximab, working via ADCC/complement and demanding ~75% expression); Sone-Ve shows the antigen is good enough to deliver a cytotoxic payload through — and at a much lower bar, 25% expression at any intensity, which AstraZeneca estimates covers ~60% of patients vs zolbetuximab's thin slice. So the conjugate both broadens eligibility and shifts mechanism from immune recruitment to direct payload delivery (companion dx: Ventana SP455). Keep the whole CLDN18.2 board in view: AstraZeneca is also running AZD5863, a CLDN18.2×CD3 T-cell engager licensed from Harbour BioMed, in Phase I — the same antigen now hit by an ADC that's shown survival and a bispecific engager behind it, a clean case study in a target getting de-risked by one modality while your modality is earlier. Brakes: high-level PR only — no hazard ratios, medians, or confidence intervals (held for a medical meeting); "no new safety signals," which for MMAE is the reassuring-but-watch-the-neuropathy answer; and this is 2L+, with the 1st-line question in a separate Phase III (CLARITY-Gastric02, Sone-Ve + chemo ± a PD-1×TIGIT bispecific). Through-line: the first time an anti-CLDN18.2 conjugate has moved survival in gastric cancer, and it did so while widening rather than narrowing the biomarker net.

FB102 — anti-CD122 antibody anchors argenx's $2.2B acquisition of Forte Biosciences, with clinical proof-of-concept in vitiligo and celiac disease

Mon, 27 Jul 2026 12:00:00 +0000

argenx/Forte Biosciences press release, July 27 2026 — argenx (the Vyvgart maker) agreed to acquire Forte Biosciences for $77/share in cash, an all-cash tender offer valuing Forte at ~$2.2 billion (41% premium over the July 24 close; ~86% over Forte's volume-weighted average price since its July 9 positive vitiligo data). The asset is a single early-stage antibody: FB102, a first-in-class anti-CD122 monoclonal antibody. Why the target is smart: CD122 is the beta chain shared by the IL-2 and IL-15 receptors, and IL-15 is the survival cytokine for tissue-resident memory CD8 T cells and NK cells — the very cells that drive melanocyte killing in vitiligo (and relapse in place) and the intraepithelial lymphocytes that damage the gut in celiac disease. Blocking the shared beta chain starves both the autoreactive T-cell and NK-cell arms at one upstream node — argenx's "pipeline-in-a-product" pitch across IL-15-driven diseases. The angle for Justice: this is a systemic biologic playing in JAK-inhibitor territory — vitiligo's marquee approved drug is topical ruxolitinib (a JAK inhibitor), and IL-15 signals through JAK1/JAK3; FB102 hits the same pathway from the receptor side rather than the kinase, the same targeted-biologic-vs-broad-JAK contrast this show keeps returning to. Data supporting the check: positive Phase 1b vitiligo data this month (statistically significant benefit; the readout that triggered the deal), and positive Phase 1b celiac data last year with a Phase 2 celiac readout expected 2H 2026 — proof-of-concept plus catalysts, not a pivotal. Strategic read: argenx, flush with Vyvgart cash, is deploying it like big pharma — rich premium, entirely cash on hand, for an early asset that is essentially a mechanism and a hypothesis (slotting FB102 alongside efgartigimod as a new lever on pathogenic T-cell/NK activity), fitting 2026's pattern of autoimmune M&A driven by mechanistic differentiation. Skeptic's brakes: it's Phase 1b; vitiligo repigmentation is slow and durability/magnitude at scale are open; blocking IL-15/IL-2 broadly raises immune-surveillance and infection questions since those cytokines aren't only pathogenic; and celiac is a graveyard indication, so the 2H-2026 Phase 2 is the real test of whether the vitiligo signal generalizes. Through-line: money is moving toward mechanisms that sit at a shared signaling node and shut off a whole cell program, not single-cytokine or single-marker antibodies — expect more shopping around shared-chain cytokine receptors and the JAK-vs-biologic fight to keep migrating into diseases everyone assumed were small-molecule territory. Watch the celiac Phase 2: it tells you whether argenx bought a platform or a single indication.

EB103 — a CD19-redirected ARTEMIS synthetic-TCR T-cell therapy posts durable complete responses with low CRS in relapsed/refractory B-cell lymphoma, as STARLIGHT-1 opens dose-expansion

Sun, 26 Jul 2026 12:00:00 +0000

Estrella Immunopharma press release, July 24 2026 — first patient dosed in the dose-expansion phase of the Phase 1/2 STARLIGHT-1 trial of EB103 in relapsed/refractory B-cell non-Hodgkin's lymphoma, reported alongside durable complete responses from dose-escalation. The reason it matters is the receptor, not the response rate: EB103 is a CD19-redirected T-cell therapy but not a car-T. Conventional car-Ts fuse an antibody binder to an artificial signaling tail (CD3-zeta plus a 4-1BB or CD28 costimulatory domain) in one chimeric receptor — powerful, but prone to tonic always-on signaling and to dumping cytokines on high tumor burden, which is the origin of cytokine release syndrome (CRS) and ICANS neurotoxicity. Estrella's ARTEMIS platform instead wires the CD19 binder to recruit the cell's native T-cell-receptor/CD3 machinery, aiming for graded, more physiologic activation and therefore far less cytokine burst. Early signal (small): in the 9-patient dose-escalation cohort, dose level 2 produced complete responses in all evaluable patients, sustained to 6 months in patients without CNS involvement (~80% high-risk; one CNS-lymphoma patient also reached CR); no treatment-related serious adverse events reported, only low-grade CRS/neurotoxicity. Editorial read for Justice (translational immunologist, Rodgers/Calibr; TCE/CAR-T/ADC/checkpoint beat): the prize isn't a nicer safety table — it's that the car-T bottleneck in large B-cell lymphoma is the toxicity infrastructure (inpatient monitoring, tocilizumab/steroids, ICU, certified centers) that keeps it at academic hubs; a construct that keeps car-T-like efficacy while genuinely dropping the cytokine storm is one you could imagine giving outpatient, at more sites, to older/frailer patients. Skeptic's brakes: n=9, single-arm, "100% CR" in a handful is a signal not a result; 6-month durability is short versus approved autologous CD19 car-Ts with years of follow-up; Estrella is a microcap (discount the "next Arcellx" framing). The dose-expansion cohort now open at the recommended phase-2 dose is the real readout. Through-line: you may be able to decouple T-cell potency from cytokine toxicity by changing the receptor's signaling grammar (engaging the endogenous TCR complex) rather than only tweaking the binder — a design principle worth stealing if it holds. Watch the expansion N, the CRS grades at the phase-2 dose, and whether the CRs are still complete a year out.

Tec-Tal — teclistamab plus talquetamab, the first dual-antigen bispecific T-cell-engager combination, posts a Phase 3 progression-free-survival hazard ratio of 0.11 in earlier-line myeloma (MonumenTAL-6)

Sat, 25 Jul 2026 12:00:00 +0000

Johnson & Johnson topline, July 23 2026 — Phase 3 MonumenTAL-6 (NCT06208150) tests the first dual-antigen bispecific T-cell-engager combination in relapsed/refractory multiple myeloma: teclistamab (B-C-M-A×CD3) plus talquetamab (GPRC5D×CD3), the "Tec-Tal" doublet, moved into earlier lines (1–4 prior, all with prior anti-CD38 and lenalidomide). Three arms: Tec-Tal, talquetamab+pomalidomide (Tal-P), and a standard-of-care pomalidomide triplet control. The framing that matters: instead of sequencing redirectors one antigen at a time (yesterday's cevostamab logic), you hit two non-cross-resistant antigens simultaneously before the tumor escapes either. Result: Tec-Tal PFS HR 0.11 (95% CI 0.08–0.16; p<0.0001) — an 89% reduction in progression/death, the lowest HR reported in any Phase 3 bispecific RRMM trial; OS HR 0.38 (62% reduction in death). Even Tal-P cleared the bar (PFS HR 0.27). The IDMC recommended unblinding at the first interim. Editorial read for Justice (translational immunologist, Rodgers/Calibr; TCE/CAR-T/ADC/checkpoint beat): the thesis is that two proven bispecifics combined look multiplicative, not additive — and this is the brute-force, real-world rival to single-molecule trispecifics (e.g. Innovent's B-C-M-A×GPRC5D×CD3 IBI3003): don't engineer one clever trispecific, just combine two bispecifics you already have; right now the brute-force version has the Phase 3 data. Where to pump the brakes: the release gives efficacy HRs and essentially no quantitative combined safety, only "consistent with the monotherapies" — the claim to verify, because stacking two TCEs stacks CRS, infection risk (the leading cause of treatment-related death in this class), and talquetamab's GPRC5D dysgeusia/dry-mouth/skin/nail toxicities; the OS HR is a first-interim, immature number that will move. Sharpening contrast, same day: Genmab/AbbVie disclosed epcoritamab (CD3×CD20) missed OS in a US Phase 3 lymphoma study — TCE OS wins are not automatic. The field's next argument: combination-of-bispecifics vs one-molecule-trispecific. Watch the full dataset at the next major meeting — read the safety tables before believing the efficacy.

Cevostamab — FcRH5×CD3 bispecific T-cell engager posts its 324-patient Phase 1 in relapsed/refractory multiple myeloma, validating a third T-cell-redirector target after BCMA and GPRC5D (Nature Medicine, July 22 2026)

Fri, 24 Jul 2026 12:00:00 +0000

Nature Medicine, published July 22 2026 (open access) — the mature, pooled Phase 1 experience with cevostamab, Genentech/Roche's FcRH5×CD3 bispecific T-cell engager, in relapsed/refractory multiple myeloma (n=324). The framing that matters: myeloma T-cell engagers have so far hit two antigens — BCMA first (teclistamab, elranatamab) and GPRC5D second (talquetamab); cevostamab targets a third, FcRH5, expressed on essentially all myeloma cells, and the paper tests whether you can keep redirecting T cells against a fresh antigen after the first two are exhausted. Population: heavily pretreated, median 6 prior lines, 89.5% triple-class refractory, 47.5% prior BCMA-directed therapy (prior CAR-T 28.1%, ADC 17.6%, bispecific 10.8%). Recommended dose 160 mg IV every 3 weeks for 17 cycles (fixed duration), with triple step-up priming (0.3/1.2/3.6/160 mg) for CRS mitigation. Efficacy in the 160 mg cohort (n=167): overall response rate ~44.3%, VGPR-or-better 25.7%, median duration of response 10.4 months (22.7 months for VGPR+). Response was markedly deeper in BCMA-naive patients (ORR 60.6%, VGPR+ 39.4%, median DOR 19.7 months) than BCMA-exposed; median PFS 2.8 months overall (5.2 months BCMA-naive, 2.1 months BCMA-exposed). Safety: CRS 74.3% (with triple step-up 63.3%, all grade ≤2), grade ≥3 infections 15.6% (lower than BCMA-targeted comparators, where infection drives much of treatment-related mortality), grade ≥3 neutropenia 28.7%, grade 5 events 6.0% (3 treatment-related); notably absent are the GPRC5D-class toxicities (dysgeusia, skin/nail). Editorial read for Justice (translational immunologist, Rodgers/Calibr; TCE/CAR-T/ADC/checkpoint beat): don't read this as cevostamab beating teclistamab — overall PFS is short (under 3 months) and BCMA-exposed responses are shallow and brief. What it establishes is a principle: myeloma T-cell engaging is a target-sequencing problem, and FcRH5 is a legitimate, non-cross-resistant third address deployable after BCMA and GPRC5D — the cleanest clinical validation yet that resistance to one redirector need not mean resistance to the next if you change the antigen. Two real differentiators: fixed 17-cycle dosing (vs treat-to-progression BCMA/GPRC5D bispecifics), enabling a defined course and drug holiday; and a cleaner infection profile plus no GPRC5D off-tumor toxicities. Where it goes: earlier lines (where response rates are much higher) and combinations. Watch fixed-duration design and step-up-driven CRS control become the template, and FcRH5 appear as an arm in earlier-line and combination trials.

Ivonescimab — Western overall-survival hazard ratio in Phase 3 HARMONi catches up to Asia at 0.76 over three data cutoffs, de-risking the PD-1×VEGF bispecific's November 14 FDA decision in EGFR-mutant NSCLC

Thu, 23 Jul 2026 12:00:00 +0000

Summit Therapeutics press release, July 22 2026 — an updated overall-survival (OS) analysis from the global Phase 3 HARMONi study of ivonescimab (SMT112/AK112), the Akeso-originated tetravalent bispecific that blocks PD-1 and VEGF in one molecule, plus platinum chemotherapy vs placebo plus chemotherapy in EGFR-mutated, non-squamous NSCLC that has progressed on a third-generation EGFR TKI (438 patients; ~166 Western, ~272 Asian). The story is follow-up maturation resolving the class's central Western-translation doubt. At the April 2025 primary analysis PFS was a clean statistically significant win but OS missed: global HR 0.79 (95% CI 0.62-1.01; p=0.057), median OS 16.8 vs 14.0 months, and the Western subgroup HR was ~0.98 (essentially no separation) against a robust Asian benefit — fueling the worry that the survival signal was an Asia-only phenomenon that wouldn't earn a US label. The reason was immaturity: Western patients enrolled later, with only ~9.2 months of median follow-up at the primary cut vs ~32.7 months for Asian patients. Across three cutoffs the Western HR has walked in the right direction as follow-up matured — 0.98 (April 2025) -> 0.84 (September 2025, global HR 0.78, nominal p=0.0332) -> 0.76 at the June 2026 cutoff (Western follow-up now 23.2 months), identical to the overall-population HR of 0.76. No new safety signals; profile described as acceptable, manageable, consistent with prior Phase 3 data. Editorial read for Justice (translational immunologist, Rodgers/Calibr; VEGF×PD-(L)1, TCE, ADC, checkpoint beat): read this as de-risking, not a fresh positive trial. It is a descriptive, updated look at a secondary OS analysis — not a newly powered, alpha-controlled success — so the nominal p-value crossing 0.05 in September is nominal, not a pre-specified win. What changed is interpretation risk: the single most plausible bear case ("PFS wins in the West but survival doesn't follow") is much harder to argue when the Western HR has converged to 0.76 with two years of follow-up, reframing the earlier miss as a follow-up-immaturity artifact rather than "biology doesn't travel." The BLA (accepted January 2026) carries a PDUFA target action date of November 14 2026, and the data are already with the FDA. Read-through for the whole PD-1×VEGF / PD-L1×VEGF field — Summit's broader program, Merck's and Pfizer's entrants, and the CTLA-4-stacking trispecific players — since HARMONi has been the reference case skeptics point to on Western translation. Caveats: a 0.76 HR in a post-progression EGFR-mutant population is meaningful but not overwhelming; updated median OS and confidence intervals are being held for an upcoming medical meeting; and this post-TKI setting is not the front-line, checkpoint-naive market where the bigger commercial question lives.

rMeV-MG53 — an MG53-armed oncolytic measles virus drives pyroptosis, turns cold lung tumors hot, and sensitizes them to PD-L1 blockade

Wed, 22 Jul 2026 12:00:00 +0000

bioRxiv preprint 2026.07.15.738733, posted July 21, 2026, from Haichang Li's group at Ohio State (Comprehensive Cancer Center). A preclinical oncolytic-virus immunotherapy study with a novel arming payload and a clean checkpoint-combination readout. Platform: the attenuated measles virus Edmonston vaccine strain (documented safety in early-phase trials) engineered to express the tumor-suppressor MG53, also known as TRIM72 — designated rMeV-MG53. To the authors' knowledge this is the first use of MG53 as an oncolytic-virus transgene. Core biology, in non-small-cell lung cancer: (1) Killing mechanism. Arming with MG53 amplifies caspase-3-dependent apoptosis and, critically, potentiates gasdermin E (GSDME) cleavage to engage lytic pyroptosis rather than quiet apoptosis. Mechanism nailed down pharmacologically — the pan-caspase inhibitor Z-VAD-FMK rescued cells while necroptosis (Necrostatin-1) and ferroptosis (Ferrostatin-1) inhibitors did not, placing caspase-3 as the switch that flips apoptosis to pyroptosis when GSDME is present. (2) Intrinsic immunomodulation. MG53 overexpression alone (no virus) enriched TNF, NF-kappa-B, and IL-17 signaling, and rMeV-MG53 drove stronger type I interferon and pro-inflammatory cytokine induction than the unarmed control. (3) In vivo, immunocompetent syngeneic LL/2 model engineered to express human CD46 (murine receptors do not support MeV entry): intratumoral rMeV-MG53 gave the strongest tumor growth inhibition, more caspase-3/GSDME pyroptosis, selective upregulation of Cxcl10, Ifng, Il1b, and heavy CD8+ T-cell and granzyme-B+ effector infiltration. (4) Checkpoint story. That interferon-driven infiltration triggered compensatory PD-L1 upregulation (textbook adaptive immune resistance), so the payoff experiment combined rMeV-MG53 with anti-PD-L1 — anti-PD-L1 alone did almost nothing, virus alone helped, and the combination was the strongest of all groups. Editorial read for Justice (translational immunologist, Rodgers/Calibr; ADC/TCE/CAR-T/checkpoint beat): a well-controlled proof of concept for the design logic dominating the field — kill the tumor in a way that recruits T cells and unmasks it for a checkpoint drug — executed with a payload nobody had put in this seat, and with the pyroptosis mechanism pinned down rather than asserted. Caveats: preclinical; the immunocompetent readout depends on engineering the tumor line to express human CD46, so the model's delivery biology is not the patient's; no head-to-head vs the standard arming payloads GM-CSF or IL-12 (the obvious next question). A nice translational aside — naked MG53 protein has a ~1.5-hour circulating half-life, so encoding it in a replicating virus is really a delivery trick for sustained, tumor-local production. Paper link: https://www.biorxiv.org/content/10.64898/2026.07.15.738733v1

LGR5 and MET ADCs — colorectal tumors escape an LGR5-targeting ADC by turning LGR5 down and switching MET on; a reciprocally-reinforcing dual-ADC combination delays relapse and extends survival in patient-derived xenografts (NCI-funded bioRxiv preprint, posted July 20 2026)

Tue, 21 Jul 2026 12:00:00 +0000

NCI/NIH-funded preprint (corresponding author K.S.C; advisory roles at Merus and Genmab), bioRxiv 2026.07.18.739355, posted July 20 2026. Colorectal cancer ADC resistance biology plus a rational combination strategy. Target: LGR5 (leucine-rich repeat-containing G protein-coupled receptor 5), a cancer stem-like-cell marker upregulated in CRC with low normal-tissue expression — favorable ADC target profile. Core finding: an LGR5-targeting ADC (anti-LGR5 clone 8E11 conjugated to a topoisomerase-1 inhibitor payload, 8E11-CPT2) drives strong initial tumor regression but tumors recur; under either chemotherapy or the LGR5 ADC, cells reciprocally downregulate LGR5 (eroding the drug's own antigen) and upregulate/activate the MET receptor — an adaptive escape route that is antigen switching, not simple antigen loss. Rational response: the group built a MET ADC by site-specific conjugation of telisotuzumab (ABT-700, the same anti-MET antibody marketed as telisotuzumab vedotin/Emrelis in c-Met-high NSCLC) to the DNA-crosslinking pyrrolobenzodiazepine (PBD) dimer SG3199, i.e. ABT-700-SG3199. Claim: ABT-700-SG3199 was more potent and more efficacious in CRC models than the two clinical-stage MET ADCs on the identical telisotuzumab backbone — ABBV-399 (telisotuzumab vedotin, MMAE payload) and ABBV-400 (telisotuzumab-camptothecin, topo-1 payload, AbbVie's next-gen version) — a clean same-antibody, three-payload comparison in which the PBD dimer won on potency. The MET ADC in turn increased LGR5 expression (mirror image of the LGR5 ADC), so the two drugs reciprocally drive the tumor toward each other's target; the combination of 8E11-CPT2 + ABT-700-SG3199 enhanced killing in vitro and, in patient-derived xenografts, markedly delayed relapse and prolonged survival vs either single agent. Editorial read for Justice (translational immunologist, Rodgers lab Calibr — ADC/TCE/CAR-T/autoimmune-biologics beat): (1) The generalizable insight is the reciprocal antigen regulation, not the payload. Antigen loss is a familiar ADC/TCE resistance mode; this is a more actionable version — the tumor predictably pivots onto a named, druggable second receptor, so the design move is to map the compensatory antigen the first ADC drives cells toward and build the combination pre-emptively rather than chasing resistance. Cleaner rationale for rational ADC combinations than the "two active drugs, hope for additivity" logic. (2) The potency claim is the weakest link. Potency in mice is not what has killed PBD-dimer ADCs clinically — therapeutic index is. AbbVie's own program moved off MMAE toward a topo-1 payload on this exact antibody for tolerability, not potency; PBD-dimer ADCs as a class have a brutal clinical history (rovalpituzumab tesirine and others washed out on toxicity; only loncastuximab tesirine is approved). "PBD more potent than topo-1" reads the field's decision backwards; the reciprocal biology and combination logic would hold with any payload pairing, and the combination should be re-run with clinically tolerable payloads. (3) The MET backbone is clinically real — telisotuzumab vedotin was approved (2025) in c-Met-high nonsquamous NSCLC — so a telisotuzumab-based MET ADC in a CRC combination is a plausible translational path if the payload is right. Caveats: preclinical CRC cell lines + PDX only; no primary human data; no in-vivo tolerability read on the combination; PBD question hangs over the MET arm; single-lab result awaiting replication. Watch: whether the group advances the combination with a more forgiving MET payload (topo-1/Dxd-class rather than PBD); whether the reciprocal LGR5–MET regulation is confirmed in patient samples; whether the reciprocal-antigen-switching principle generalizes to other stem-cell-marker-plus-RTK pairings as a template for pre-emptive ADC combination design. Paper link: https://www.biorxiv.org/content/10.64898/2026.07.18.739355v1

AK146D1 — first-in-class TROP2×Nectin-4 bispecific ADC starts Phase 2 in combination with ivonescimab (PD-1×VEGF bispecific) in first-line advanced NSCLC (Akeso AK146D1-201, first patient dosed July 20 2026), instantiating the "IO 2.0 + ADC 2.0" two-bispecifics-no-chemo design pattern that displaces the KEYNOTE-189 chemo-plus-checkpoint standard of care

Mon, 20 Jul 2026 12:00:00 +0000

Akeso (9926.HK) announced July 20 2026 that the first patient has been dosed in AK146D1-201, a Phase 2 study of AK146D1 (internally developed TROP2 × Nectin-4 bispecific antibody-drug conjugate) in combination with ivonescimab (Akeso's PD-1 × VEGF bispecific, licensed ex-Greater-China to Summit Therapeutics) in advanced non-small cell lung cancer, with particular emphasis on the first-line setting. The regimen is a double-bispecific: bispecific ADC + bispecific IO backbone, no chemo. Bispecific ADC design rationale: TROP2 (broadly expressed epithelial antigen — sacituzumab govitecan, datopotamab deruxtecan, sac-TMT/MK-2870 target) and Nectin-4 (more restricted — enfortumab vedotin/Padcev target in urothelial + expressed in NSCLC) on one antibody with a cytotoxic payload; obligate co-engagement logic aims to concentrate delivery on tumor cells that co-express both antigens while sparing normal tissue expressing only one, widening the therapeutic window vs. single-target ADCs. Akeso frames this as "ADC 2.0" and slots AK146D1 alongside AK138D1 (also Ph2), AK157D1, and AK158D1 (bispecific ADC) as the ADC 2.0 pipeline. Combination logic: ivonescimab beat pembrolizumab head-to-head in first-line PD-L1-positive NSCLC (HARMONi-2, 2025) and is the anchor asset in Akeso's IO 2.0 portfolio; every next-generation ADC in the Akeso pipeline is being tested in combination with ivonescimab or cadonilimab (CTLA-4 × PD-1 bispecific). Field context: Kelun-Biotech OptiTROP-Lung06 (announced July 14 2026) was the first Phase 3 win for an ADC + checkpoint doublet (sac-TMT + Keytruda) over the KEYNOTE-189 chemo + checkpoint standard in PD-L1-negative first-line non-squamous NSCLC — the design bet that a topo-1 ADC payload replaces the platinum backbone in a checkpoint combination. AK146D1 + ivonescimab escalates that geometry: instead of single-target ADC + single-target checkpoint mAb, this is bispecific ADC + bispecific checkpoint — four target engagements per regimen (TROP2, Nectin-4, PD-1, VEGF), still no chemo. Editorial read for Justice: (1) Signals the first-line NSCLC battlefield structure for 2027-2028 — two bispecifics stacked, no chemo, the winning combination is ADC 2.0 + IO 2.0. (2) Bispecific ADC selectivity depends on affinity balance, whether obligate co-engagement holds at high antigen density vs. permits monovalent binding, and whether TROP2/Nectin-4 co-express on the same tumor cells or on separate subpopulations — Ph2 will start to answer, biomarker strategy (all-comers vs. dual-positive) will telegraph Akeso's own read. (3) Read-through for trispecific TCE design: the pharmacology and safety of two stacked engineered antibody modalities with four total target engagements is the leading indicator for whether a trispecific TCE + checkpoint combination composes cleanly or collapses under additive on-target-off-tumor toxicity — cheaper lesson to learn from ADC + IO first. (4) Ex-China rights question: Summit Therapeutics holds ivonescimab ex-Greater-China; if Summit picks up AK146D1 too, the pairing becomes a global platform play and Akeso becomes the design template every ADC + IO combination will benchmark against. (5) Payload chemistry not disclosed in the release — worth asking whether the AK146D1 payload is topo-1 (matching sac-TMT's cGAS-STING-priming mechanism that composes well with checkpoint) or an auristatin/maytansinoid. Caveats: no clinical data — Phase 1 tolerability sufficient to graduate to combination Ph2 but the release doesn't disclose Ph1 endpoints; Chinese-run study (Merck + Summit will need to design ex-China filings); first efficacy signal ~2027 at ASCO/WCLC/ESMO; competitive pressure from Kelun sac-TMT + Keytruda (Ph3 win in hand), Daiichi-Sankyo datopotamab-deruxtecan + Keytruda TROPION-Lung, AstraZeneca-Daiichi Enhertu combinations, and Summit's own AK112-plus-something pipeline. Watch: Ph2 endpoints registered on ChiCTR/clinicaltrials.gov; biomarker strategy (dual-positive vs. all-comers); Summit ex-China licensing decision; AK138D1 Ph2 progress as the second data point in the Akeso ADC 2.0 pipeline; whether Merck / AstraZeneca / Daiichi respond with their own bispecific ADC + checkpoint combinations.

DSR — dual stimulatory receptor (4-1BBL ectodomain × cMPL endodomain) arms TCR-T, bispecific TCE-secreting T, and CD19 chimeric-TCR cells with antigen-gated signal 2 + signal 3, delivering durable persistence and tumor control across three cell-therapy modalities without exogenous cytokine (Baylor Center for Cell and Gene Therapy preprint, posted July 17 2026)

Sun, 19 Jul 2026 12:00:00 +0000

Narula et al., Mamonkin + Watanabe labs, Baylor College of Medicine Center for Cell and Gene Therapy (Texas Children's + Houston Methodist) — bioRxiv preprint 2026.07.12.738084, posted July 17 2026. DSR (dual stimulatory receptor) is a single-gene synthetic construct: 4-1BBL ectodomain fused via a CD28 transmembrane region to the intracellular endodomain of the thrombopoietin receptor cMPL. Both halves natively homomerize, so the fusion holds as a stable multimer in a compact monomeric unit that fits into a standard lentiviral cassette alongside the antigen-recognition machinery. Mechanism. TCR-based cell therapies (TCR-T, T cell engagers, chimeric TCRs) deliver signal 1 (antigen through the TCR) but structurally lack signals 2 (costimulation) and 3 (cytokine support), producing the durability collapse routinely papered over in the clinic with exogenous IL-2, lymphodepletion, and repeat dosing. DSR's design gates both missing signals on antigen recognition. Antigen ligation transiently upregulates endogenous 4-1BB on the T cell; DSR's 4-1BBL ectodomain engages that endogenous 4-1BB in cis on the same cell surface. The in-cis engagement (a) transmits classical 4-1BB signal 2 through the endogenous receptor and (b) simultaneously activates the DSR construct's intracellular cMPL endodomain, phosphorylating STAT3 and STAT5 as a signal-3 cytokine-like input (analogous to common γ-chain cytokine signaling; cMPL is normally restricted to hematopoietic stem cells and absent from mature T cells, so this is ectopic re-purposing). Both signals require antigen; antigen withdrawal shuts them off within days — addressing the systemic-toxicity concern that limits constitutive cytokine-circuit designs (constitutive IL-7 receptor C7R, secreted IL-12). Box-1 (JAK2-binding) mutation of cMPL abrogates STAT phosphorylation, confirming cMPL-dependence rather than off-target signaling. In vitro. DSR-modified T cells expand through six rounds of repeated antigen stimulation; 4-1BBL-WT and signaling-dead ΔDSR controls collapse after three rounds. DSR cells preserve cytokine polyfunctionality (IFN-γ, TNF, IL-2, granzyme B) after four stimulations; transcriptomically they hold an effector-associated program (TBX21, EOMES, CXCR6, FGFBP2, MAF, RCAN2, SPOCK1) and stay lower on the exhaustion/terminal-differentiation program (TOX, ID3, SOX4, KLRG1). Three in vivo platforms all validated in NSG-MHC-KO xenografts without exogenous cytokine support: (1) Survivin-peptide/HLA-A2 transgenic TCR (SurvTCR) against CBG-labeled BV173 leukemia — DSR enabled sustained T cell expansion, selective enrichment of antigen-specific DSR(+) T cells in circulation, and roughly doubled median survival. (2) CD123×CD3 bispecific-TCE-secreting T cells (TCE-T) — the platform that has the most direct read-through to Justice's TCE beat — single infusion of DSR-armed TCE-T cleared MOLM-13 AML for ~90 days with durable persistence and preserved CCR7/CD27 memory phenotype and lower PD-1/TIGIT/LAG-3, while TCE-T alone or with 4-1BBL-WT/ΔDSR failed to control tumor. (3) CD19 chimeric TCR (19cTCR — scFv fused to murine TCR-α/β constant regions with stability mutations) against CBG-labeled NALM6 — DSR delivered durable tumor control over ~80 days; endogenous 4-1BB knockout abolished the DSR benefit, closing the causal loop for the 4-1BB-in-cis mechanism. Notably, DSR-armed T cells persisted at homeostatic levels in mice post-clearance (via low tonic cMPL signal) without body-weight loss or systemic-toxicity signal. Editorial read for Justice's beat (TCE + CAR-T + ADC + autoimmune biologics, Rodgers lab Calibr). (a) Directly addresses the durability limitation of every current TCE and TCR-T platform — antigen recognition works, initial kill works, cell burns out, sponsor adds exogenous IL-2 or lymphodepletion and calls it a day. DSR replaces the workaround with a mechanism-native fix. (b) The bispecific-TCE-secreting T cell experiment is the most direct trispecific/TCE read-through: TCE-T cells rely on native TCR signaling for cytotoxicity, structurally lack signals 2/3, and are the exact clinical failure mode that has kept off-the-shelf bispecific TCEs from durable in vivo control without repeat dosing. DSR converted a failing platform into a 90-day-durable one with a single infusion. (c) Antigen-gating is the safety story that has held back constitutive-cytokine designs (C7R, IL-15 sushi, secreted IL-12) — DSR's downstream signal shuts off on antigen withdrawal, giving a natural off switch that Regulatory would prefer over a constitutive circuit. (d) Vector-compact single-gene design means DSR bolts onto existing manufacturing workflows without additional cargo — feasible for clinical translation on the standard lentiviral platforms already in use for tisa-cel, axi-cel, brexu-cel-style products. (e) Modality-agnostic — three antigen-recognition strategies, three tumor models — suggests DSR extends to trispecific TCE arming, γδ-T armed platforms, iNKT, and (per 4-1BB upregulation biology) NK-cell engagers. (f) The design principle generalizes: antigen-induced endogenous receptor as the auto-trigger, hijacking the resulting engagement to deliver a second downstream signal, is a template other groups will extend beyond the specific 4-1BBL–cMPL pairing (OX40L–gp130, ICOSL–βc, TIGITL-inversion, etc.). Caveats. Preclinical mouse xenograft only, no primary human tumors, no CD4/CD8 breakdown of DSR-specific effects; small background tonic STAT signal in resting DSR T cells (attributed to spontaneous multimerization) — durability arithmetic over years in humans not answerable by mouse; no head-to-head against constitutive cMPL alone to isolate how much benefit is signal-2/signal-3 coordination versus cMPL by itself; bispecific TCE experiment used TCE-secreting T cells, not off-the-shelf antibody plus separately armed T cells (the real trispecific clinical configuration would need its own experiment); no antigen-negative tumor escape or off-target endogenous-4-1BB depletion story yet. Corresponding authors: Maksim Mamonkin, Norihiro Watanabe (Baylor CGT). Funding: Cancer Prevention and Research Institute of Texas. Watch: (a) primary-tumor / autologous-donor validation before this reaches an IND; (b) any of the Baylor CGT clinical TCE / TCR-T programs (particularly the Mamonkin bispecific engager platforms in hematologic malignancy) picking DSR up; (c) other groups extending the antigen-induced-endogenous-receptor design principle to OX40, ICOS, TIGIT geometries. Paper link: https://www.biorxiv.org/content/10.64898/2026.07.12.738084v1

KP-701 — Jasper–Kira reverse merger and $132M PIPE (July 16 2026) bring a preclinical CD79B×CD32B B-cell-silencing bispecific onto NASDAQ, alongside KP-104 (vensobafusp alfa), a Phase-2 bifunctional-complement biologic, as an autoimmune-biologics platform whose real design bet is a B-cell modality that silences rather than depletes

Sat, 18 Jul 2026 12:00:00 +0000

Jasper Therapeutics (NASDAQ: JSPR) and privately held Kira Pharmaceuticals announced July 16, 2026 a definitive all-stock reverse merger, expected to close July 20, 2026, that puts Kira's clinical + preclinical immunology pipeline into a fresh NASDAQ vehicle retaining the JSPR ticker. Pro-forma equity: pre-Jasper shareholders ~6.68%, Kira shareholders ~49.86%, PIPE investors ~43.46% (total ~653.6M common shares post-close). Concurrent $132M PIPE of non-voting convertible preferred stock (each preferred converts to 61 common, subject to beneficial-ownership limits) led by Affinity Asset Advisors + Ikarian Capital; syndicate includes Columbia Threadneedle, Sirenia, Brahma, Balyasny, SilverArc, Squadron, Nazare, Mirador Therapeutics. Combined cash funds operations through H2 2028. Continuing leadership: Jeet Mahal (President/CEO), Herb Cross (CFO) from Jasper; Wenru Song (EVP Head of R&D), Greg Keenan (CMO), Matthew Ros (COO), Patrick Crutcher (Board Chair) from Kira. Concurrent divestment: Kira's KP-301 (long-acting anti-C5a mAb) + KP-402 (small-molecule C5aR antagonist) sold to Mirador Therapeutics for $12M upfront + development/sales milestones — a small number that signals the anti-C5a market has cooled hard (avacopan owns the ANCA-vasculitis lane). Two lead assets. (1) KP-104 (vensobafusp alfa) — bifunctional biologic engaging both alternative + terminal complement pathways within a single molecule (historically disclosed as anti-C5 mAb + factor-H fragment fusion). Phase 2 in complement-inhibitor-naïve PNH reported at ASH 2023 + updated at ASH 2024: all treated patients achieved ≥2 g/dL Hgb increase transfusion-free, majority normalized Hgb + LDH, sustained ~2y follow-up. Now Phase 2/3-ready with ongoing basket trial in IgA nephropathy + C3 glomerulopathy across China + Australia; interim Stage 1 readout expected Q4 2026, updated data + interim Stage 2 Q2 2027; end-of-Phase-2 FDA meeting after; new indication announcement expected by year-end. Positions as dual-mechanism complement biologic against the crowded IgAN field: Fabhalta iptacopan (full IgAN approval Jul 17 2026 on 24-mo eGFR-slope endpoint), Vera Trutakna atacicept (approved Jul 7 2026 on BAFF/APRIL blockade), Novartis Vanrafia atrasentan (endothelin-A), Travere Filspari sparsentan (dual endothelin/angiotensin), Novartis zigakibart (anti-APRIL Ph3). (2) KP-701 — preclinical dual-acting anti-CD79B×CD32B monoclonal antibody. CD79B is the ITAM-bearing invariant signaling subunit of the B-cell receptor complex; CD32B is FcγRIIB, the only inhibitory member of the FcγR family, bearing a cytoplasmic ITIM that recruits SHP-1/SHIP to shut down BCR signaling when co-clustered with the BCR. KP-701 co-engages both receptors on the same B cell to enforce inhibitory-receptor recruitment that a natural IgG-antigen immune complex would produce — silencing rather than depleting the target B cell. CTA/IND filing planned Q1 2027; first-in-human data expected Q3 2027; first indication choice TBD but likely autoantibody-driven where target biology is well-characterized (ITP, warm AIHA, membranous nephropathy, myasthenia gravis, bullous pemphigoid are plausible starting points). First-in-class bispecific in this specific silencing geometry — CD32B engager concept traces back ~two decades (Ravetch, MacroGenics, Xencor academic work) but no clinical validation yet. Editorial read for Justice's beat (translational immunologist, Rodgers lab Calibr — CAR-T + TCE + ADC + autoimmune biologics). (1) B-cell-directed autoimmune modality landscape currently structured around depletion: CD19 CAR-T (Kyverna, Cabaletta, academic CD19 CAR-T), CD20 mAbs (rituximab, obinutuzumab), B-cell-antigen TCEs (epcoritamab, mosunetuzumab being repositioned into autoimmune by Genmab/Regeneron/Roche), BAFF/APRIL inhibitors (belimumab, Trutakna atacicept, telitacicept, ianalumab). KP-701 sits outside all of these — not depleting, not blocking a survival cytokine, but engaging an inhibitory receptor to shut off BCR signaling directly. Therapeutic profile potentially closer to a JAK-inhibitor-style signaling modulator than to any depleting modality, but with antibody specificity rather than small-molecule systemic distribution. (2) CAR-T-in-autoimmune interaction is friendly not competitive: KP-701 competes on convenience + tolerability, not depth of effect. CAR-T-induced reset + KP-701 maintenance is a plausibly interesting combination if any sponsor is set up to run it. (3) T-cell engager design read-through: bispecific antibodies engaging an inhibitory receptor rather than an activating receptor are an under-explored corner of the modality landscape — the mirror image of activating TCE design. Applies to Treg engagement, NK-cell tolerance, macrophage polarization. KP-701 not first in the geometry but first serious autoimmune-B-cell bet; Phase 1 success would validate the modality broadly. (4) JAK-alternative pressure: KP-701 is another data point in the same direction as bempikibart (IL-7Rα in AA, July 14) and AVR-001 (oral IL-23R peptide, July 15) — the oral JAK inhibitor class is being pressured by non-JAK modalities that address the same clinical problem with cleaner mechanism. JAK ADC route defends by restricting where the JAK distributes; KP-701 attacks by not being a JAK inhibitor at all. Caveats: preclinical is preclinical, no human data, first-in-class label carries first-in-class risk; ~18 mo to first-in-human data means KP-701 is a design bet + story until late 2027; KP-104 in crowded IgAN needs Q4 2026 stage-1 interim to actually deliver differentiating proteinuria numbers against Fabhalta full-approval bar; reverse-merger + PIPE is now the third autoimmune biotech capital template this month (Q32/bempikibart, Avere/AVR-001, Kira/KP-701) — consolidation pressure in 2028 will be real. Watch: (a) KP-104 IgAN/C3G Ph2 basket interim Stage 1 Q4 2026; (b) KP-104 end-of-Ph2 FDA meeting H1 2027; (c) KP-104 new indication announcement by year-end; (d) KP-701 CTA/IND filing Q1 2027 + first-in-human data Q3 2027 + first-indication choice; (e) briquilimab mast-cell update H2 2026 + pre-BLA meeting Q1 2027; (f) Mirador development of divested KP-301 + KP-402. Net: strategic transaction with unusually rich strategic content — KP-104 is a real dual-mechanism complement biologic with near-term catalyst against a very hot renal field, and KP-701 is the most interesting mechanism-of-action bet in autoimmune B-cell biology in the last 12 months — silencing pathogenic B cells through their own inhibitory receptor rather than depleting them. Press release link: https://www.globenewswire.com/news-release/2026/07/16/3328849/0/en/jasper-therapeutics-announces-merger-with-kira-pharmaceuticals.html

Sac-TMT plus KEYTRUDA — first Phase 3 win for an ADC-plus-checkpoint doublet over chemo-plus-checkpoint in first-line PD-L1-negative non-squamous NSCLC (Kelun-Biotech OptiTROP-Lung06 topline, July 14 2026), validating the design bet that a topoisomerase-1 ADC payload can substitute for the platinum backbone in a checkpoint combination

Fri, 17 Jul 2026 12:00:00 +0000

Kelun-Biotech announced July 14, 2026 that the Phase 3 OptiTROP-Lung06 study of sacituzumab tirumotecan (sac-TMT / SKB264 / MK-2870) — the Trop-2-targeting antibody-drug conjugate Merck licensed from Kelun in May 2022 for ex-Greater-China rights — in combination with pembrolizumab (Keytruda) as first-line treatment for driver-gene-negative, PD-L1-negative (TPS <1%) locally advanced or metastatic non-squamous NSCLC met its primary endpoint of progression-free survival at pre-specified interim analysis, with a positive overall survival trend and a safety profile consistent with prior sac-TMT studies. The comparator arm was the current standard-of-care KEYNOTE-189 regimen: pembrolizumab + pemetrexed + platinum. Kelun frames this as "the world's first Phase 3 clinical study of an ADC combined with an immune checkpoint inhibitor to meet its primary endpoint in the first-line treatment of driver gene-negative and PD-L1-negative non-squamous NSCLC." Scrip framed it as the first "chemo-free" combination to beat chemo + Keytruda in first-line NSCLC. No hazard ratio, no confidence interval, no exact median PFS disclosed in the release — full data expected at a fall lung-oncology congress (WCLC September 2026 or ESMO October 2026). Kelun will engage with China's Center for Drug Evaluation; Merck holds ex-Greater-China rights and is running 17 global Phase 3 studies for MK-2870 across multiple tumor types. ADC construct: humanized anti-Trop-2 monoclonal + belotecan-derivative topoisomerase-1 inhibitor payload (KL610023) + pH-sensitive cleavable linker at drug-to-antibody ratio 7.4. Historical context: PD-L1-negative (TPS <1%) non-squamous NSCLC has been the biomarker subset in which chemo + pembrolizumab has been deeply entrenched as first-line SOC since KEYNOTE-189 (2018) and in which single-agent checkpoint blockade has never had a compelling case. OptiTROP-Lung05 (published in The Lancet May 2026) already showed sac-TMT + pembro superiority to chemo + pembro in the PD-L1-positive subset; Lung06 extends the same design win into PD-L1-negative — completing coverage of the entire non-squamous NSCLC front-line population without regard to PD-L1 status. Editorial read for Justice's beat (translational immunologist, Rodgers lab Calibr — CAR-T + TCE + ADC + autoimmune biologics). (1) The chemo-free framing. Experimental arm has no pemetrexed and no platinum — it replaces the systemic-cytotoxic backbone with Trop-2-targeted delivery of a topoisomerase-1 payload. Semantically the ADC still delivers cytotoxin, but from a tolerability/patient-experience/regulatory-marketing standpoint it absolutely is chemo-free: no platinum-driven neutropenia/thrombocytopenia/nausea/neuropathy; instead ADC-driven stomatitis + cytopenias + diarrhea from Trop-2-driven distribution to normal epithelia. Real quality-of-life difference in a first-line, elderly-skewed population — and in PD-L1-negative disease specifically, dropping the platinum backbone is a major clinical win. (2) The design-precedent read. First Phase 3 win for ADC + checkpoint doublet over chemo + checkpoint doublet in a first-line solid tumor. This has been the design bet of the entire next-generation-ADC-in-lung field — datopotamab-deruxtecan + Keytruda in the TROPION-Lung suite, Enhertu + checkpoint, telisotuzumab-vedotin + checkpoint — that the payload-driven immunogenic-cell-death signal from a topo-1 ADC priming into checkpoint blockade would substitute for chemo. Until this week, thesis-only in front-line. Lung06 converts it into precedent. The mechanistic story now cite-worthy: topo-1 ADC payload → DSB-mediated tumor-cell death → cGAS-STING activation → type-I IFN → dendritic cross-presentation → T-cell priming → pembrolizumab unlocks that primed response. (3) ADC payload chemistry read-through. Validates that the topo-1 inhibitor class (belotecan derivatives here, deruxtecan on the Daiichi-Sankyo side) is the right payload class for checkpoint combinations. Auristatin- and maytansine-payload ADCs will have a harder story to tell in this design space (more direct microtubule cytotoxicity, less ICD). (4) PD-1×VEGF bispecific read-through. Raises the follow-on question of whether bispecific + ADC (dropping the checkpoint mAb in favor of the bispecific, pairing with the same Trop-2 or HER3 ADC) could take front-line lung from a doublet to a genuinely-differentiated combination. Summit/Akeso HARMONi-3 pairs ivonescimab with chemo; more interesting design in light of Lung06 may be ivonescimab + ADC without a chemo partner. (5) Trispecific TCE read-through. Shared MoA point is instructive not direct — trispecifics deliver T-cell engagement + costim + tumor recognition without cytotoxic payload, but a trispecific + ADC in a checkpoint-inflamed subset would be a genuinely-three-modality combination worth designing around a topo-1 ADC partner rather than a chemo partner. Caveats. (a) No numeric HR / CI / median PFS in the release — until fall congress readout cannot compare magnitude of benefit against the reference chemo + Keytruda from KEYNOTE-189 (HR ~0.65 for PFS). If sac-TMT + Keytruda pushes HR meaningfully below 0.5, genuine global practice change; if HR lands ~0.8, Chinese approval + footnote. (b) Safety — sac-TMT's tolerability profile includes stomatitis, neutropenia, cytopenias driving prior monotherapy dose reductions; in combination with pembrolizumab the specific safety question the full disclosure must address is pneumonitis in a Trop-2-expressing lung (irAE + ADC pulmonary-toxicity signals overlap in exactly the tissue being treated). (c) Geography — Chinese-run trial in a predominantly Chinese population; Merck is running 17 global Phase 3s for MK-2870 including western-population studies; full ex-Greater-China evidence package will not hinge on Lung06 alone. (d) Competitive pressure on Daiichi-Sankyo/AstraZeneca datopotamab-deruxtecan + Keytruda in TROPION-Lung and on AstraZeneca-Daiichi Enhertu + checkpoint lung combinations — first-mover-Phase-3 advantage now sits with sac-TMT. Watch: (a) HR + KM curves + full safety at WCLC Sep 2026 or ESMO Oct 2026; (b) OS maturation; (c) FDA/EMA regulatory strategy for ex-Greater-China filings; (d) Merck global Phase 3 readouts of MK-2870; (e) TROPION-Lung readouts from Daiichi-Sankyo side; (f) any signal on pneumonitis rate specifically. Net: first Phase 3 win for ADC + checkpoint over chemo + checkpoint in a first-line solid tumor. The chemo-free framing is marketing more than mechanism, but it does signal a design category — payload-driven immunogenic-cell-death from a topo-1 ADC substituting for the systemic-cytotoxic backbone — that every next-generation ADC + checkpoint program has been waiting to see validated at Phase 3 scale. Numbers to watch: PFS HR, OS maturation, pneumonitis + stomatitis safety-signal read. Press release link: https://www.prnewswire.com/news-releases/kelun-biotech-announces-phase-iii-study-of-sacituzumab-tirumotecan-sac-tmt-in-combination-with-pembrolizumab-as-first-line-treatment-for-pd-l1-negative-non-squamous-nsclc-met-primary-endpoint-302825316.html

KEYTRUDA — first Phase 3 PD-1 monotherapy to beat platinum doublet chemotherapy in first-line dMMR advanced or recurrent endometrial cancer (Merck KEYNOTE-C93 topline, July 15 2026), positioning pembrolizumab for a chemo-free label in the mismatch-repair-deficient subset and opening the wider question of when a biomarker-defined subgroup earns the right to drop the platinum backbone entirely

Thu, 16 Jul 2026 12:00:00 +0000

Merck announced July 15, 2026 that the Phase 3 KEYNOTE-C93 trial (NCT05173987) of Keytruda (pembrolizumab) as monotherapy versus platinum doublet chemotherapy in first-line advanced or recurrent mismatch-repair-deficient (dMMR) endometrial cancer met its primary endpoint of progression-free survival, with a "trend toward improvement" in overall survival at pre-specified interim (data not mature). Merck frames this as "the first Phase 3 trial of a PD-1 inhibitor to show improved PFS compared to platinum doublet chemotherapy when given as monotherapy in the frontline setting" — quoting principal investigator Dr. Brian Slomovitz. Trial mechanics: 299 patients randomized to Keytruda 400 mg IV Q6W for up to 18 cycles vs paclitaxel 175 mg/m² + carboplatin AUC 5-6 IV Q3W for 6 cycles; population is chemo-naive or recurrence >6 months after prior adjuvant therapy, all dMMR. PFS assessed by blinded independent central review per RECIST v1.1. Response rate, complete response rate and duration of response also described as clinically meaningful. No hazard ratio, no confidence interval, no exact median PFS disclosed in press release — expected at a fall gynecologic-oncology / ESMO congress. Safety consistent with prior Keytruda studies, no new signals. Regulatory next step: submission to FDA/global regulators for a chemo-free frontline label in the dMMR subset (~25-30% of endometrial cancer). Historical context: MSI-H/dMMR biology is the checkpoint-sensitivity paradigm (Keytruda's 2017 tissue-agnostic accelerated approval), the tissue-agnostic monotherapy label covers post-systemic-therapy progressive disease, and the current frontline standard-of-care is chemo + pembrolizumab per KEYNOTE-868/NRG-GY018 (2024) or chemo + dostarlimab per RUBY (Jemperli, GSK). In the dMMR subgroup of NRG-GY018 the addition of pembrolizumab to chemo cut PFS risk ~70% vs chemo alone — which is why the C93 question of whether the chemo backbone is doing anything at all in this biomarker subset was worth asking. C93 answers that pembrolizumab monotherapy is superior to platinum doublet as monotherapy; it does NOT answer whether pembrolizumab monotherapy is non-inferior to pembrolizumab + chemo (different trial, not run). Practical read: label lands as additional chemo-free option, practice pattern shifts toward monotherapy for chemo-averse / platinum-vulnerable patients (older, comorbid, prior pelvic radiation), combo label holds for younger fit patients. Direct competitive pressure on GSK's dostarlimab/Jemperli, which won its endometrial label with a chemo backbone via RUBY and has no equivalent chemo-free monotherapy Phase 3 to point to. Editorial read for Justice's beat (translational immunologist, Rodgers lab Calibr — CAR-T + TCE + ADC + autoimmune biologics). (1) Biomarker-defined-monotherapy paradigm: C93 establishes that when the underlying biology delivers a large enough neoantigen or immune-priming signal (dMMR = replication-error-driven neoantigens = high T-cell priming), single-agent checkpoint blockade can carry a frontline label without a cytotoxic partner. Other biomarkers plausibly in the same category: high TMB, high PD-L1 CPS in specific histologies, EBV-positive gastric. Regulatory precedent set here — 299-patient Phase 3 in a defined biomarker subgroup can carry first-line — will be cited in trial design memos for many upcoming programs. (2) PD-1×VEGF bispecific implications: ivonescimab (Summit/Akeso) is running HARMONi-2 and HARMONi-3 as combinations with platinum doublet chemotherapy. C93 does not directly threaten that thesis, but raises the question of whether a PD-1×VEGF bispecific in a checkpoint-responsive subset (MSI-H or high-TMB NSCLC, or hepatocellular where VEGF blockade already has clinical weight) could earn a chemo-free frontline label the way Keytruda just did. If yes, the bispecific class positioning shifts from replacing pembro in the chemo combo to owning the chemo-free monotherapy lane — a much larger commercial prize. (3) Trispecific TCE implications: for engagers targeting solid tumors, standard combo playbook has been engager + chemo + checkpoint. C93 is a data point that in the right biomarker subset chemo can be dropped, reducing regimen tolerability burden — especially important for TCEs with cytokine release syndrome and on-target-off-tumor concerns. Suggests biomarker-selected Ph2 designs with engager-monotherapy vs engager-plus-chemo arms may be more informative than the standard engager-plus-chemo-vs-chemo comparator. (4) CAR-T + lymphodepletion analogue (speculative): fludarabine + cyclophosphamide lymphodepletion is the platinum-analogue backbone for CAR-T. In a T-cell-inflamed subset where endogenous T cells are not competing for cytokines/space, would CAR products engraft and function without standard lymphodepletion? The C93 framing (biomarker-driven dropping of the cytotoxic backbone) ports conceptually. Caveats. (a) No numbers yet — HR, confidence intervals, median PFS curves, crossover rate on chemo arm (patients likely crossed to Keytruda at progression), OS maturity — all pending. Press-release "clinically meaningful" is doing a lot of work. (b) No monotherapy-vs-combination arm — trial designed against chemo, not against chemo + pembro; label will land as additional option not replacement. (c) OS trend not yet significant — if it fails to mature, story becomes PFS-only and practice pattern tilts back toward chemo combo. (d) Indication-specific — endometrial dMMR is among the most checkpoint-sensitive tumors known; do not directly extrapolate to pancreatic dMMR, prostate dMMR, other rare dMMR settings (colorectal is closest analogue and does behave similarly). Watch: (a) full readout at fall meeting for HR, medians, KM curves; (b) OS maturation; (c) FDA/EMA regulatory decisions on chemo-free frontline label; (d) practice-pattern surveys of gyn-onc — real question of chemo combo vs monotherapy uptake in dMMR; (e) GSK response for dostarlimab/Jemperli — head-to-head or non-inferiority framing; (f) read-across trials in dMMR CRC / dMMR gastric / EBV+ gastric of PD-1 monotherapy vs chemo. Net: small trial, big regulatory implication. Two hundred and ninety-nine patients showed pembrolizumab monotherapy beats platinum doublet in first-line dMMR endometrial cancer, positioning it for a chemo-free frontline label in a biomarker-defined subset comprising ~25-30% of endometrial cancer. The generalizable insight is the biomarker-defined-monotherapy paradigm — when on-target biology is strong enough, the chemo backbone can be dropped, creating design and commercial optionality for PD-1×VEGF bispecifics, trispecific TCEs, and next-generation checkpoint-adjacent modalities that have defaulted to running with chemo. Numbers to watch when the full readout drops: PFS hazard ratio and mature OS. Press release link: https://www.merck.com/news/keytruda-pembrolizumab-as-monotherapy-significantly-improved-progression-free-survival-pfs-in-certain-patients-with-advanced-or-recurrent-endometrial-cancer-with-mismatch-repair-deficient-d/

AVR-001 — Avere / NextCure reverse merger with Hansoh in-license and $320M PIPE brings a once-weekly oral IL-23 receptor cyclic peptide antagonist onto NASDAQ (ticker AVRX, July 14 2026), positioning a second-generation follow-on to J&J's just-approved icotrokinra with a ~100-hour half-life and Phase 1b psoriasis PASI at week 4/8 that Hansoh reports as cross-trial-comparable to the once-daily first-gen despite only 4 weeks of dosing

Wed, 15 Jul 2026 12:00:00 +0000

On July 14, 2026 NextCure (NASDAQ: NXTC) and privately-held Avere Therapeutics announced a definitive all-stock reverse merger to bring Avere public as "Avere Therapeutics, Inc." on NASDAQ under ticker AVRX. Pro-forma ownership: Avere shareholders (including new PIPE investors) ~98.79%, legacy NextCure shareholders ~1.21% plus contingent value rights entitling them to 90% of net proceeds from monetization of legacy NextCure pipeline assets over two years. Concurrent $320M private placement led by Fairmount (Akero's prior lead) and Hansoh Pharmaceutical Group, with a syndicate that includes Venrock Healthcare Capital Partners, General Atlantic, Janus Henderson, Wellington Management, Boyu Capital, Sirona Capital, T. Rowe Price, RTW Investments, Redmile, Affinity Asset Advisors, Balyasny, Wedbush Healthcare Partners and additional funds; $251M of the $320M is in convertible notes exchangeable for common stock at closing. Deal expected to close in H2 2026. Leadership team is the former Akero executive group — Andrew Cheng (CEO/President/Chairman), Kitty Yale (CDO), William White (CFO), Brett Pletcher (General Counsel) — who previously sold Akero's MASH program to Novo Nordisk for $5B. Asset: AVR-001 (Hansoh code HS-20118), a cyclic peptide IL-23 receptor antagonist engineered for oral bioavailability and ~100-hour plasma half-life supporting once-weekly oral dosing. Avere has just closed an ex-Greater-China exclusive license from Hansoh: $120M upfront, up to $2.18B in development + sales milestones, mid-single to low-double digit royalties (total headline value ~$2.3B). Clinical status: Hansoh has completed a Phase 1b in Chinese patients with moderate-to-severe plaque psoriasis and has initiated a Phase 2b in China with readout expected 2027. Phase 1b language in the release: "once-weekly AVR-001 achieved Week 4 and Week 8 PASI and PASI 75 responses comparable on a cross-trial basis to the first-generation once-daily oral inhibitor, despite only 4 weeks of dosing." The "first-generation once-daily oral inhibitor" is icotrokinra (JNJ-2113, ICOTYDE), the recently-FDA-approved oral peptide IL-23R antagonist from J&J (Phase 3 ICONIC-LEAD: 64.7% IGA 0/1 and 49.6% PASI 90 at week 16 with 16 weeks of daily dosing). No exact PASI 75 percentages, sample size, dose levels, or subject-level safety data disclosed in the release; press-release language on tolerability is "generally well tolerated with an adverse event profile supporting continued clinical development." Use of proceeds: US Phase 2b psoriasis to start early 2027 with readout H1 2028; Phase 2b ulcerative colitis initiation; preparation for Phase 3 psoriasis. Broader landscape: injectable IL-23 antibodies guselkumab (Tremfya) + risankizumab (Skyrizi) are gold-standard-of-care in plaque psoriasis; deucravacitinib (Sotyktu) is the approved oral small-molecule TYK2 allosteric inhibitor; icotrokinra is the first oral peptide IL-23R antagonist and just cleared FDA; AVR-001 is second in class with once-weekly instead of once-daily oral dosing as the differentiator. Editorial read for Justice's beat (translational immunologist, Rodgers lab Calibr — CAR-T + TCE + ADC + autoimmune biologics). (1) Modality-shift in autoimmune: cyclic peptides engineered for oral bioavailability and long half-life are now graduating from tool status into approved drugs (icotrokinra in 2026, AVR-001 as next-gen). Any autoimmune target currently dominated by injectable mAbs (IL-17, IL-13, TNF, integrins, complement factor B, possibly B-cell-directed depletion) is a target where oral cyclic-peptide competitors will get built. Same design-space as TCE/CAR-T-armoring: what modality delivers best therapeutic index for a given target. (2) JAK-alternative pressure. Yesterday's bempikibart (IL-7Rα biologic in AA) came at the oral-JAK problem by changing the target upstream; today's AVR-001 comes at it by staying at the target but changing modality (oral peptide vs oral small-molecule JAK). Both directly pressure the JAK ADC thesis — the ceiling for oral small molecules in autoimmune is being raised by non-JAK oral alternatives with cleaner mechanism and (likely) cleaner safety. The ADC route needs to differentiate on onset, depth, or oncology-precedent safety. (3) Chinese asset flow with strategic-equity twist. Hansoh (also the source of the B7-H3 ADC HS-20093/Ris-Rez licensed to GSK, positive artemis-008 Phase 3 SCLC readout July 2026) is now not just a licensor but a lead PIPE investor in the US vehicle developing their asset. Expect more cross-Pacific in-license + Chinese-pharma-strategic-equity patterns. (4) Reverse-merger + PIPE as capital vehicle. NextCure — was standalone immune-onc biotech running LAIR-2 mAb program — becomes public shell for the Hansoh asset; Avere hits NASDAQ pre-Phase-2b with $300M+ cash. This capital-formation template (reverse-merge stalled mid-cap biotech + in-license Chinese asset + syndicate PIPE at closing) is now the fastest route to a public autoimmune company at Phase 2b scale. (5) IL-23 pathway durability: the axis works across psoriasis, PsA, Crohn's, UC — Tremfya + Skyrizi have already validated broad IBD applicability. AVR-001's planned Phase 2b UC ambition is a real read on whether oral peptides at the IL-23R can reach gut tissue at concentrations that reproduce injectable-mAb efficacy — that's a non-trivial pharmacological question given IL-23 is produced in the gut and target engagement in inflamed intestinal tissue may differ from skin. Caveats to hold. Phase 1b data are not disclosed at level required to independently reproduce the icotrokinra-comparability claim; cross-trial comparisons across ethnic populations, different investigators, different baselines are the softest kind of comparator argument in dermatology. US Phase 2b will not start until early 2027; the intervening catalyst is Hansoh's Chinese Phase 2b readout in 2027 — if that underperforms icotrokinra's Phase 2b, the story compresses hard. Ulcerative colitis remains speculative — no Phase 1b UC data disclosed. Hansoh's dual role as licensor + strategic PIPE investor creates governance/pricing questions that S-1 and 10-K filings will need to address. Watch: (a) full Chinese Phase 1b readout at fall dermatology congress (EADV, AAD) — dose levels, sample size, PASI 75 percentages, safety database; (b) Chinese Phase 2b readout 2027; (c) US Phase 2b start (early 2027) and readout (H1 2028); (d) UC program dose-escalation and biomarker work; (e) any indication expansion to psoriatic arthritis or Crohn's; (f) Hansoh pipeline behind AVR-001 (their ADC and biologic pipeline is deep and expect additional licensing to Avere or others). Net: this is a strategic transaction more than a clinical readout, but it is a well-structured transaction that places a genuine second-generation oral IL-23R peptide antagonist into a fresh public company with $300M+ cash, Chinese-pharma strategic-equity backing, and a differentiated once-weekly dosing pitch against a first-generation drug that only just cleared approval. Signals where autoimmune biologics are structurally headed — modality-shift into oral peptides at established targets, cross-Pacific asset flow with Chinese-pharma equity participation, reverse-merger vehicles for Phase 2b-ready public companies. Scientific verdict on whether the ~100-hour half-life + once-weekly oral dosing delivers clinical differentiation from icotrokinra in a head-to-head will not arrive before 2028; the strategic pattern is worth understanding today. Press release link: https://www.globenewswire.com/news-release/2026/07/14/3326655/0/en/nextcure-and-avere-therapeutics-announce-merger-to-advance-once-weekly-oral-il-23-therapy.html

Bempikibart — anti-IL-7Rα antibody Phase 2a hit in severe alopecia areata including JAK-experienced patients (Q32 Bio SIGNAL-AA Part B, 36-week topline, July 13 2026), positioning an upstream IL-7 + TSLP-blocking biologic as mechanistically differentiated from the oral JAK class (Litfulo, Leqselvi, Olumiant) with an off-drug durability signal the JAK inhibitors do not have

Tue, 14 Jul 2026 12:00:00 +0000

Q32 Bio (NASDAQ: QTTB) announced on July 13, 2026 positive 36-week topline results from Part B of the Phase 2a SIGNAL-AA trial (NCT06018428) of bempikibart (formerly ADX-914) in severe and very severe alopecia areata. 33 patients enrolled (ITT), 25 in the mITT population, baseline SALT 50-100 (mean baseline ~77), episode duration up to 4 years, all severe/very severe by baseline SALT; 36.4% (12/33) had prior oral JAK inhibitor exposure. Regimen: bempikibart 200mg SC weekly x 4 doses (loading), then 200mg SC every 2 weeks through week 36; no placebo comparator in Part B. Efficacy at week 36: mean 35.3% SALT reduction (mITT); SALT-20 responder rate 40.0% mITT (10/25) vs 30.3% ITT (10/33); SALT-30 and SALT-50 responder rates each 44.0% mITT (11/25) vs 33.3% ITT (11/33). Severe subgroup (76% of patients): 37.8% mean SALT reduction; very severe subgroup (24%): 27.4%. Analyst going-in bar was 15-30% SALT-20 — readout comfortably beat expectations. Comparators: Litfulo (ritlecitinib) ALLEGRO week-24 SALT-20 ~23% in severe; Leqselvi (deuruxolitinib) THRIVE-AA week-24 SALT-20 33-38%; bempikibart week-36 mITT 40% is competitive-to-modestly-better. Safety (n=33): 0 SAE, 0 Grade ≥3 AE, 0 discontinuations for safety, no new signals. Injection site reactions 36.3% of patients (4% per-dose), all mild, resolved spontaneously (majority within 1 day). Favorable PK/PD; negligible anti-drug antibodies. Off-drug follow-up through week 52 (16 weeks post-last-dose): the company reports maintenance or deepening of response in multiple patients, including one who achieved SALT=0 (complete regrowth) at week 44 after dosing stopped. Full week-52 curve across the full cohort not yet public; JAK-experienced subgroup response rate not broken out (both to be presented at a future medical conference). Q32 plans a registration-directed Phase 3 program in severe and very severe alopecia areata in 1H 2027. Molecule and mechanism (load-bearing): bempikibart is a fully human anti-IL-7 receptor alpha (IL-7Rα, CD127) monoclonal antibody that blocks signaling through both cytokine receptor complexes that use this alpha chain — the IL-7R (with common gamma chain) and the TSLP-R (with TSLP receptor chain). IL-7 through IL-7R is the master survival/homeostasis signal for peripheral memory and effector T cells (proliferation, long-term tissue persistence); TSLP through the same alpha chain is the epithelial-alarm cytokine that primes type-2 and inflammatory responses at barrier surfaces. Critical selectivity feature: IL-7Rα is expressed at low levels on regulatory T cells (which use IL-2R as their dominant survival signal) and at high levels on pathogenic effector/memory T cells. Blocking IL-7Rα therefore preferentially starves autoreactive T cells of survival input while relatively sparing the Treg compartment — a bias toward self-tolerance rather than global immunosuppression. Compare with the currently approved oral JAK class (baricitinib/Olumiant, ritlecitinib/Litfulo, deuruxolitinib/Leqselvi): downstream small-molecule signaling inhibitors that block JAK-STAT for many cytokines at once (IL-7, IL-15, IL-21, IFNγ), delivered systemically, class black-box warning covers serious infection, MACE, malignancy, thrombosis. Bempikibart is a subcutaneous biologic hitting a single upstream receptor complex with (in principle) Treg sparing — different safety-efficacy tradeoff, potentially very different long-term safety envelope. Editorial read for Justice's beat (translational immunologist, Rodgers lab Calibr — CAR-T + TCE + ADC + autoimmune biologics). (1) Design-pattern hit on autoimmune biologics that go upstream rather than at terminal cytokines (anti-TNF, anti-IL-6, anti-IL-17, anti-IL-23) or at downstream signaling (JAKs). IL-7Rα blockade is one of the few pharmacologically clean ways to bias against pathogenic memory T cell persistence, generalizable across T-cell-driven autoimmune indications — myasthenia gravis, vitiligo, atopic dermatitis (already tested and failed — see 3 below), lupus, primary Sjögren's, celiac. (2) JAK-alternative narrative directly pressures the JAK ADC thesis. Both approaches — the JAK ADC (restrict where the JAK inhibitor goes) and the upstream-cytokine-receptor biologic (change the target so systemic exposure is tolerable) — are responses to the same observation that oral JAK inhibitors are too toxic for many chronic autoimmune indications. The biologic-based alternatives are getting real clinical PoC; the ADC route now needs to show something a subcutaneous biologic cannot deliver (faster onset, deeper suppression, or oncology-precedent safety story). (3) Platform proof point beyond AA: bempikibart is licensed from AstraZeneca (as ADX-914); Q32 took it into atopic dermatitis in 2025 and that Phase 2 failed — stock plunged, company restructured aggressively around alopecia. Today's readout retroactively suggests the eczema fail was more about indication biology (TSLP-driven barrier disease with heavy environmental-trigger component) than about the mechanism failing. Framing to carry: IL-7Rα blockade appears to work in indications driven by pathogenic T cell persistence in target tissue, less well in indications driven by ongoing environmental provocation of barrier surfaces. (4) Treg-sparing selectivity story extends to TCE design in autoimmune. A bispecific engager that reads IL-7Rα expression as part of its target-cell logic would in principle preferentially engage pathogenic effector cells over Tregs. Most autoimmune TCEs under development are anchored on lineage/state markers (CD19, BCMA); IL-7Rα as an autoimmune-TCE target has been under-explored and bempikibart's translational readout strengthens the case for engager-side work on the same receptor. (5) Off-drug durability is the diagnostic to watch. If patients maintain response through week 52 and into a full year off drug, this is genuinely different from JAK class (which relapse within weeks of stopping). If the tail falls apart between week 52 and week 78, bempikibart converges onto a "chronic maintenance biologic" positioning competing with JAKs on safety but not durability. Phase 3 will need to build in a formal off-drug follow-up arm to make the durability claim rigorously. (6) Safety: acute-toxicity profile is now a clean subcutaneous biologic with ISRs, no more, across the pooled Part A + B database. The unresolved intermediate-term question is chronic IL-7 blockade's impact on T-cell repertoire maintenance and infection risk — slowly-developing peripheral T-cell contraction is the theoretical concern that Phase 3 will need to answer. Caveats to hold: 33 patients, no placebo comparator in Part B (Part A had one but was underpowered), single-arm expansion, JAK-experienced subgroup response rate not disclosed, prior atopic dermatitis Ph2 failure means the platform has produced a negative readout (survivorship bias in reading today's number). SALT-20 is a hair-count endpoint that does not track eyebrow/eyelash involvement or the autoimmune process in other tissues. Landscape context: alopecia areata systemic therapy pipeline now includes IL-7Rα (bempikibart, Q32), OX40L (rocatinlimab, Amgen; amlitelimab, Sanofi/Kymab — both primarily in atopic dermatitis but with dermatologic-autoimmune read-across), JAK1/2 (Olumiant), JAK3+TEC (Litfulo), JAK1/2 (Leqselvi), plus early-stage IL-2 muteins and OX40 inhibitors. Q32 is first-mover on IL-7Rα in alopecia areata with a positive Phase 2 signal in severe/very severe patients including JAK-experienced. Watch: (a) medical-meeting presentation (likely fall 2026 AAD or ACR-adjacent dermatology) for JAK-experienced subgroup response rate breakdown and full week-52 durability curve; (b) Phase 3 registration-directed program initiation 1H 2027 — trial design (comparator: placebo? active? off-drug follow-up arm?); (c) indication-expansion signal — will Q32 (or a partner) take IL-7Rα into myasthenia gravis, lupus, or T-cell-driven autoimmune settings; (d) competitor readouts on the same axis (there is no other IL-7Rα antibody at meaningful clinical stage in autoimmune currently); (e) any Q32 commercial partnership signal (cash runway is real). Net: this is a real Phase 2a hit for the first IL-7Rα antibody to make it to a positive readout in severe alopecia areata, at effect sizes competitive with the oral JAK class, with a differentiated safety profile appropriate for a subcutaneous biologic, and — most importantly — an early off-drug durability signal that suggests genuine immune reset rather than continuous signal suppression. If Phase 3 confirms in 2027-2028, bempikibart becomes the second wave in AA after the JAK class, and IL-7Rα graduates from platform target to validated autoimmune mechanism with real read-across to other T-cell-driven indications. The JAK-experienced subgroup response rate and the week-52 durability curve are the two numbers that will determine whether this is a JAK-alternative or a genuine step change. Press release link: https://www.prnewswire.com/news-releases/q32-bio-announces-positive-36-week-topline-results-from-part-b-of-the-signal-aa-clinical-trial-of-bempikibart-in-alopecia-areata-302823403.html

PD-1-directed CAR-T for rheumatoid arthritis — Amit lab (Weizmann) preprint uses PDCD1 as a disease-state antigen to hit synovial disease-associated T cells, with an NR4A2-driven CAR-responsive biosensor to restrict activity to inflamed synovium and a soluble TNFRII armoring cassette that dampens local inflammation and drives a tissue-reparative myeloid state (bioRxiv, posted July 12, 2026)

Mon, 13 Jul 2026 12:00:00 +0000

Preclinical bioRxiv preprint posted July 12, 2026 from Ido Amit's Systems Immunology group at the Weizmann Institute (with rheumatology co-authors from Hadassah Medical Center and Rambam / Technion): a PD-1-directed CAR-T cell for rheumatoid arthritis. Single-cell multi-omics of human RA synovium and mouse arthritis models identified PDCD1 as a selective marker of synovial disease-associated T cells. The authors built a CAR-T targeting PD-1 as an antigen (not the checkpoint pathway) to selectively eliminate the pathogenic synovial T cell subset while sparing systemic PD-1-transient-positive activated T cells; the CAR-T potently eliminated the synovial disease-associated cells in vitro and in vivo and produced marked attenuation of synovitis in mouse RA models (specific arthritis models, effect sizes, and safety data not extractable — abstract-only at the time of recording; the bioRxiv HTML body has not rendered yet, ~24-36h after posting). Two design layers on top of the basic CAR-T: (1) NR4A2-driven CAR-responsive biosensor — NR4A2 (Nur77-related orphan nuclear receptor) is upregulated in T cells in response to strong/chronic TCR signaling and serves as a transcriptional proxy for chronic antigen exposure in the target tissue. The design uses NR4A2 activity to license CAR activity, restricting killing to the inflamed synovium where the T cell has already been chronically stimulated by antigen, adding a tissue-context filter on top of the antigen-recognition filter. Direct synthetic-biology heritage: Wendell Lim group synNotch circuits, now deployed as production-grade CAR engineering. (2) sTNFRII armoring cassette — engineered secretion of soluble TNF receptor II decoy for TNF-alpha in the local joint microenvironment. Does two things simultaneously: provides ongoing anti-inflammatory tone (the same pharmacology Enbrel/etanercept has provided for RA for 25 years, delivered locally instead of systemically), and counteracts the IFN + TNF response the CAR-T itself induces on tumor-cell killing. Also drives a tissue-reparative myeloid state — joint macrophages shift toward repair rather than inflammatory phenotype in response to the modified cytokine environment. Editorial read for Justice's beat (translational immunologist, Rodgers lab Calibr — CAR-T + TCE + ADC + autoimmune biologics): (1) The autoimmune CAR-T wave to date has been almost entirely a B-cell-depletion story (anti-CD19 in SLE, MG, SSc — Schett-and-followers) — this preprint opens a T-cell-directed lane for diseases where the T cell compartment is doing the driving. RA is the canonical example; the synovial T cell subset that infiltrates the joint and organizes ectopic lymphoid architecture is transcriptionally distinct from circulating T cells, and depleting them non-selectively has never been viable because global immunosuppression is intolerable. The claim is that PD-1-selectivity on that pathogenic subset makes anti-PD-1 CAR-T tractable. (2) Target-selection generalization — everyone in oncology thinks of PD-1 as a checkpoint blocked with an antibody to release T cells. Amit's group treats PD-1 as a tumor-associated-antigen-analog for autoimmune disease — a disease-state marker selectively expressed on the pathogenic cell subset in the affected tissue, that the CAR can be pointed at. This is the same mental model shift as anti-CD19 in lupus — targeting a lineage/state marker, not signaling biology. Any surface molecule enriched on the disease-associated cell in the affected tissue is a candidate CAR target — regardless of signaling role. Generalizes to MS, T1D, primary Sjögren's, autoimmune myocarditis. (3) NR4A2 biosensor is the answer to the tissue-selectivity constraint the field has been circling on for two years — most autoimmune-relevant markers are not tissue-exclusive at the protein level, so you need logic gating. This is one of the first production-grade papers deploying it as CAR engineering rather than as a synthetic-biology proof-of-concept. (4) sTNFRII armoring establishes a template — combining a killing-modality CAR-T with local biologic-secretion cassette is going to become standard practice. sTNFRII in RA, potentially IL-10 in IBD, IL-2 mutein for tolerogenic contexts. Every engineered-T-cell company with a broad autoimmune platform now needs an opinion on which armoring cargo fits which indication. (5) Bispecific/TCE analog is worth benchmarking as a shorter-development-cycle version of the same target hypothesis — a PD-1 x CD3 T-cell engager pointed at the same PD-1-high synovial T cells could deliver similar biology without the CAR-T manufacturing chain. (6) Caveats — preclinical, one paper, mouse arthritis models (CIA and K/BxN presumed but not confirmed off abstract), effect sizes and toxicity data not disclosed. PD-1 is transiently upregulated on essentially any activated T cell — the quantitative case for synovium-selectivity depends on the biosensor plus the antigen filter working in concert. Off-target killing of activated PD-1-positive T cells in secondary lymphoid organs is exactly the safety question when the full paper renders. Watch: (a) full-body HTML/PDF rendering in next 24-48h for effect sizes, safety data, and the specific mouse models used; (b) peer-reviewed follow-up publication; (c) other groups reporting disease-associated-T-cell-marker CAR-T approaches in other autoimmune indications over next 12 months; (d) any startup formation around this concept — Amit-lab spinouts historically fast. Net: well-conceived preclinical CAR-T design for a disease that has been off the CAR-T table because it is T-cell-driven and needs tissue-selective targeting. Uses a T cell surface marker (PD-1) as a disease-state antigen rather than a checkpoint, adds an NR4A2 synovium-restriction biosensor, and armors with sTNFRII that both dampens inflammation and shifts local myeloid cells toward tissue repair. Opens a T-cell-directed lane in autoimmune CAR-T alongside the existing B-cell-depletion wave. Design template — disease-state antigen + tissue-context filter + therapeutic-armor cassette — generalizes across engineered T-cell products in autoimmune disease. Preprint link: https://www.biorxiv.org/content/10.64898/2026.07.09.737520v1

Padcev + Keytruda — head-to-head Phase 3 win over neoadjuvant cisplatin chemotherapy in perioperative muscle-invasive bladder cancer (EV-304 / KEYNOTE-B15) delivers the first US FDA approval of a platinum-free perioperative regimen for MIBC regardless of cisplatin eligibility, on 47% event-free-survival and 35% overall-survival risk reductions and a 55.8% versus 32.5% pathologic complete response

Sun, 12 Jul 2026 12:00:00 +0000

The US FDA approved perioperative enfortumab vedotin (Padcev, Nectin-4-directed ADC with an MMAE microtubule-disrupting payload and cleavable linker) plus pembrolizumab (Keytruda, anti-PD-1) as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer (MIBC) regardless of cisplatin eligibility on Friday July 10, 2026, jointly announced by Merck, Pfizer, and Astellas. This is the first-ever platinum-free perioperative regimen approved for the full MIBC population in the US. Supporting trial: EV-304 / KEYNOTE-B15 (NCT04700124), an 808-patient global, open-label, randomized Phase 3 in cisplatin-ELIGIBLE MIBC — the harder efficacy bar, because the control arm is not surgery alone (as in EV-303/KEYNOTE-905, the cisplatin-INELIGIBLE trial covered on June 27) but neoadjuvant gemcitabine + cisplatin, the perioperative standard of care since the mid-1990s. Design: 1:1 randomization. Experimental arm = 4 cycles neoadjuvant Padcev + Keytruda, cystectomy, 5 adjuvant Padcev + Keytruda cycles plus 8 additional Keytruda monotherapy cycles (9 EV doses, 17 pembro doses total across the perioperative window). Control = 4 cycles neoadjuvant gem-cis, cystectomy, no adjuvant systemic. Primary endpoint EFS; key secondaries OS and pCR. Data. Event-free survival: HR 0.53 (95% CI 0.41–0.70), p<0.0001 — 47% reduction; median EFS not reached vs 48.5 months for cis chemo; 2-year EFS 79.4% vs 66.2%. Overall survival: HR 0.65 (95% CI 0.48–0.89), p=0.0029 — 35% mortality reduction; both OS medians not reached; 2-year OS 86.9% vs 81.3%. Pathologic complete response: 55.8% vs 32.5% (23.4-point absolute delta, 95% CI 16.7–29.8, p<0.0001). Compared with the June 27 episode on EV-303/KEYNOTE-905 (cisplatin-INELIGIBLE vs surgery alone: EFS HR 0.40, OS HR 0.50, pCR 57.1% vs 8.6%), EV-304 delivers smaller absolute effect sizes because the comparator is active gold-standard cis chemotherapy, but the combined US label using both trials read together displaces cisplatin as the first-line perioperative systemic option for the full MIBC population. Molecule biology (load-bearing): Padcev = Nectin-4-targeting monoclonal + MMAE microtubule-disrupting warhead via cleavable linker, with strong bystander effect from cleaved free auristatin into antigen-negative neighboring tumor cells. Nectin-4 is broadly overexpressed in urothelial cancer and comparatively spared in normal tissue — the therapeutic-window handle. Keytruda adds PD-1 blockade in a setting where the ADC is actively lysing tumor cells and releasing antigens into a checkpoint-permissive microenvironment; the perioperative window (primary tumor intact, antigen load maximal) is the design regime where the synergy is theoretically strongest. Editorial read for Justice's beat (translational immunologist, Rodgers lab Calibr — CAR-T + TCE + ADC + autoimmune biologics): (1) Target biology validated in the hardest-comparator perioperative test in solid tumors to date; ADC + PD-1 combination now formally beats an aggressive active platinum comparator in curative-intent disease, not just surgery alone. (2) Design template — every ADC developer running or planning a perioperative program now has EV-304 as the reference dataset for trial architecture (9 ADC + 17 PD-1 doses across neoadjuvant and adjuvant, tail PD-1 monotherapy after the ADC stops). Datopotamab deruxtecan into early-stage NSCLC, sacituzumab govitecan into early-stage TNBC, the HER3 DXd programs, the CLDN18.2 ADCs — all will be judged against the shape of the EV-304 curve. (3) Design lesson generalizes to TCE + checkpoint perioperative combinations — any pharmacology that produces immunogenic tumor cell death in the setting of an intact primary tumor is a candidate; the EV-304 numbers are what TCE-plus-checkpoint perioperative reads will now be expected to at least approach. (4) Toxicity discount is real — grade ≥3 TEAEs 75.7% (combo) vs 67.2% (cis chemo), Padcev auristatin profile (skin reactions, peripheral neuropathy, diarrhea) stacked on Keytruda irAE profile. Grade ≥3 pneumonitis ~7% in the studied population — meaningful signal for a curative-intent regimen. Community urology practice discontinuation rates and on-treatment mortality signal in older patients are worth tracking over the next 12–18 months of real-world data. (5) Cross-tumor watch — datopotamab-plus-pembrolizumab in early-stage NSCLC is the next big ADC + PD-1 perioperative read (2026-2027), which will test whether the EV-304 pattern (checkpoint synergy strongest in curative-intent with intact primary tumor) generalizes to other tumor types and other ADC payload classes (TOP1i vs auristatin). Landscape. Perioperative MIBC standard of care is now Padcev + Keytruda, full stop. EV-304 was first presented at ASCO GU February 2026; the EMA validated the corresponding type II variation earlier and full EU approval on the cisplatin-eligible population is expected to follow. Prior Padcev + Keytruda first-line advanced/metastatic urothelial approval (EV-302) already established the combination in the metastatic setting; EV-303 (June 27 episode) established the perioperative approval in the cisplatin-ineligible population; EV-304 (today) closes the loop for cisplatin-eligible patients. Net: the ADC + IO perioperative playbook is now the reference template across solid tumors, cisplatin is displaced from first-line perioperative MIBC in the US, and the field's big open question shifts from "does ADC + checkpoint synergy work in curative-intent" to "which ADC target + which warhead + which earlier setting is next." Press release link: https://www.merck.com/news/keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-reduced-risk-of-event-free-survival-events-by-47-and-risk-of-death-by-35-for-cisplatin-eligible-patients-with-muscle-invasive/

Ris-Rez (risvutatug rezetecan, HS-20093) — first-ever positive Phase 3 overall survival readout for a B7-H3-targeted ADC in any tumor type, in advanced/relapsed small-cell lung cancer vs topotecan (Hansoh Pharma ARTEMIS-008, announced by GSK-licensor July 10, 2026; global ex-China EMBOLD-SCLC-301 pivotal readout expected 2027)

Sat, 11 Jul 2026 12:00:00 +0000

Hansoh Pharma (Jiangsu Hansoh Pharmaceutical Group) announced on July 10, 2026 that its pivotal ARTEMIS-008 Phase 3 trial of risvutatug rezetecan (Ris-Rez, formerly HS-20093) in Chinese patients with advanced or relapsed small-cell lung cancer met its primary endpoint of overall survival, delivering a statistically significant and clinically meaningful improvement versus topotecan (second-line standard of care). Progression-free survival showed consistent benefit; safety profile was in line with prior Ris-Rez data with no new signals identified. Effect size (OS/PFS hazard ratios, medians) and the ORR/DoR/safety table were not disclosed in the announcement — expected at a medical meeting later in 2026 (likely WCLC or ESMO Asia). Trial: pivotal Phase 3, randomized, 1:1 vs topotecan, in Chinese SCLC patients failed on prior platinum. Sample size not disclosed. Molecule (load-bearing): Ris-Rez is a fully human anti-B7-H3 monoclonal antibody conjugated via a tumor-microenvironment-responsive tetrapeptide-based cleavable linker to a topoisomerase-1 inhibitor payload (HS-9265, an exatecan derivative). Architecturally the same family as Daiichi Sankyo's DXd platform (humanized antibody + tetrapeptide cleavable linker + exatecan-class TOP1i) that gave the field trastuzumab deruxtecan (HER2), datopotamab deruxtecan (TROP2), and ifinatamab deruxtecan (B7-H3, i-DXd/DS-7300) — same chassis, different antibody. Significance (load-bearing frame): first-ever positive Phase 3 OS readout for a B7-H3-targeted ADC in ANY tumor type. Provides the B7-H3 target class its first pivotal proof of concept, and simultaneously provides SCLC — a disease that has been an ADC graveyard since rovalpituzumab tesirine (DLL3-PBD, Stemcentrx) failed in TAHOE + MERU — its first modern ADC win. Deal context: GSK licensed ex-China rights to Ris-Rez in late 2023 for ~$1.7B up front + ~$1.5B in milestones (widely questioned as too expensive at the time for a preclinical-heavy China-originated asset) and is running the global Phase 3 EMBOLD-SCLC-301 in relapsed extensive-stage SCLC, pivotal data expected 2027. Broader Ris-Rez program spans lung, prostate, osteosarcoma, head and neck, esophageal squamous cell, colorectal (multiple Phase 3 in China; multiple Phase 1-2 proof-of-concept globally). Prior data anchor: ARTEMIS-001 Phase 1 in relapsed SCLC (published Cancer Cell 2026; presented at WCLC 2024) showed encouraging ORR and DCR consistent with a class-competitive TOP1i-ADC. Editorial read for Justice's beat (translational immunologist, Rodgers lab Calibr — CAR-T + TCE + ADC + autoimmune biologics): (1) B7-H3 is one of the two or three most crowded ADC targets on the planet (see July 6 Novartis-Myricx NMTi ADC deal — both lead assets are on B7-H3 or HER2) AND is an active target for CAR-T (glioblastoma, pediatric solid tumors), T-cell engagers, and radioconjugates. A pivotal OS win on the same target with a completely different modality is the strongest form of target-level de-risking there is — it tells you the antigen is genuinely tumor-restricted enough to give a therapeutic window at the level of complete tumor kill. If you are building any B7-H3-directed cell therapy or bispecific, your target hypothesis just got the strongest possible external validation. (2) The TOP1i/DXd payload class is now formally validated on B7-H3 in a pivotal setting — but the cross-resistance liabilities we flagged in the July 6 NMTi episode still apply. Every TOP1i-ADC on every target will eventually converge onto the same escape mechanisms (TOP1 downregulation, MDR1 efflux, DDR upregulation). The field's payload-diversification imperative is unchanged. (3) SCLC as an ADC-addressable disease: the rovalpituzumab tesirine failure defined SCLC as an ADC graveyard for a decade. Ris-Rez reopens it. Read this against DLL3-targeted approaches (Amgen tarlatamab BiTE, DLL3 CAR-T programs, DLL3 radioligand) — the SCLC landscape just got a new benchmark comparator to compete against. (4) Sequencing note for the field: with cemiplimab / atezolizumab / durvalumab now integrated into first-line SCLC (IMpower133, CASPIAN), and Ris-Rez likely to enter 2L, the interesting design question becomes ADC → PD-L1 rechallenge or ADC + PD-L1 combination — a mechanistic story since TOP1i-driven DNA damage should prime cGAS/STING and repolarize the tumor microenvironment (see our July 8 THIO-101 episode on 6-thio-2'-deoxyguanosine → cGAS/STING → PD-1 sensitization). Expect Hansoh + GSK to run Ris-Rez + PD-L1 combination cohorts. (5) Antibody-backbone-effect experiment: Daiichi/Merck's i-DXd (DS-7300, ifinatamab deruxtecan) is still the class-leading global asset on B7-H3, with strong IDeate-01 Phase 2 data and global Phase 3 in progress. Ris-Rez has beaten i-DXd to the first Phase 3 OS readout. Once both Phase 3s are on the table (Ris-Rez China 2026 + i-DXd IDeate-01/-05 global 2027-2028), the field gets its first clean apples-to-apples read on how much antibody backbone matters within a DXd-style TOP1i-ADC (same target, same payload class, different antibody engineering). That result will shape antibody-side design choices in this class for the next several years. Next diagnostic: (a) Ris-Rez ARTEMIS-008 detailed OS/PFS effect size disclosure at WCLC / ESMO Asia 2026; (b) Hansoh Ris-Rez NMPA filing in China; (c) i-DXd IDeate-01 registrational Phase 3 SCLC readout (Daiichi/Merck); (d) GSK EMBOLD-SCLC-301 global Phase 3 ex-China readout 2027; (e) Ris-Rez cross-indication readouts in prostate cancer, osteosarcoma, NSCLC; (f) any B7-H3 CAR-T pivotal signal; (g) any Ris-Rez + checkpoint combination cohort disclosure. Net: first Phase 3 OS win for a B7-H3 ADC, in a disease that has been an ADC graveyard, using a payload class we already know a lot about, from a licensor that GSK paid dearly for. Yesterday's readout retroactively vindicates the 2023 deal. Watch the effect-size disclosure at the fall meeting, the pooled safety profile, and the Daiichi-Merck response — because the second Phase 3 on this target is going to define the class as much as the first one did. Press release link: https://www.gsk.com/en-gb/media/press-releases/gsk-s-licensor-hansoh-pharma-announces-positive-phase-iii-results-for-ris-rez-in-china-patient-population/

FT819 — off-the-shelf, iPSC-derived, TRAC-integrated 1XX anti-CD19 CAR-T with complete TCR knockout, given outpatient without fludarabine (and in one case with NO lymphoconditioning at all), produced clinically meaningful improvement — rCRISS≥25 in 4/4 evaluable patients at 3 months, one at rCRISS 100 — in moderate-to-severe treatment-resistant systemic sclerosis, with zero CRS/ICANS/GvHD/hypogammaglobulinemia and 3/5 patients dosed as outpatient or discharged in <24h; Fate Therapeutics FT819-102 Phase 1 basket update, presented ISSCR Montreal July 9, 2026

Fri, 10 Jul 2026 12:00:00 +0000

Fate Therapeutics presented emerging data on July 9, 2026 at the International Society for Stem Cell Research (ISSCR) meeting in Montreal from FT819-102 (NCT06308978), a Phase 1 single-arm basket study of FT819 — an off-the-shelf, iPSC-derived, anti-CD19 CAR-T — in four B-cell-driven autoimmune diseases (ANCA-associated vasculitis, systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathies). 30 total patients dosed across baskets at 21 sites (16 US, 5 ex-US). Data cut June 12, 2026; systemic sclerosis (SSc) cohort of 5 patients (4 evaluable at cut, plus 1 dosed after cut) is the focus of the ISSCR readout. Molecule design (load-bearing): clonal iPSC master cell bank → single-step multiplex gene edit → uniform, on-demand product. (1) 1XX CAR19 — novel CAR construct from Sadelain/MSKCC (van der Stegen et al., Nat. Biomed. Eng. 2022) with CD28 costimulatory domain and modified CD3ζ signaling tail with attenuated ITAM strength to reduce activation-induced exhaustion. (2) TRAC-targeted CAR insertion — CAR transgene inserted into the T-cell receptor alpha constant locus, using the endogenous TCR promoter for physiologic CAR expression. (3) TCR null — complete bi-allelic disruption of TRAC ablates surface TCR expression, eliminating GvHD risk in the allogeneic setting. Trial design (design-critical): two dose levels (DL1 = 3.6×10^8, DL2 = 9×10^8 viable cells) and TWO conditioning regimens — Regimen A: cyclophosphamide OR bendamustine conditioning (no fludarabine); Regimen B: NO lymphoconditioning, patients continue maintenance immunosuppressive (MMF/MPA, AZA, or MTX) until D-5 then stop. SSc inclusion required ACR/EULAR 2013 SSc criteria + failure or intolerance to ≥2 prior immunosuppressives for ≥3 months. Notable: 2 of the evaluable SSc patients had disease duration >5 years (A3: 9.6y, A4: 8.7y) — a population most CAR-T-in-autoimmune trials specifically exclude because established fibrosis is presumed less reversible. Baseline mRSS 18-34, all female, ages 28-51. Efficacy at 3M (n=4 evaluable): all 4 hit rCRISS-25 or higher; 1 patient (A1) hit rCRISS 100 at 3M and rCRISS 75 sustained at 6M. mRSS changes at 3M: A1 22→15 (also 15 at 6M); A2 32→23; A3 18→10; B1 (no lymphoconditioning) 34→30. Clinician Global Assessment down in all 4; Patient Global Assessment down in 3 of 4; HAQ-DI down in 3 of 4; FVC% predicted preserved or improved. Deep B-cell depletion in peripheral blood in the conditioned patients (below LLOQ through M1 for A1/A3, deeper depletion in A1 through M6); nasopharyngeal adenoid tissue B-cell depletion also demonstrated — CAR-T reaching lymphoid compartments, not just circulating B cells. B-cell recovery started by M1 in some patients. Safety (n=4): 0 CRS, 0 ICANS, 0 GvHD, 0 hypogammaglobulinemia, 0 DLTs, 0 deaths. 2/4 (50%) had a grade ≥3 AE — both were in the same patient (1 migraine, 1 immune thrombocytopenia/ITP), who separately had a suspected inflammatory myopathy overlap flare and was started on MMF around M6. 3 of 5 SSc patients dosed as outpatient or discharged in ≤24h. Prior lupus data (3 patients, ASGCT May 2026): 2/3 achieved lupus low-disease activity state (LLDAS), no CRS/ICANS/GvHD. Editorial read for Justice's beat (translational immunologist, Rodgers lab Calibr — CAR-T + TCE + ADC + autoimmune biologics). (1) The load-bearing scientific claim is that CD19-driven immune reset in autoimmune disease may not need fludarabine — or, in the extreme, any lymphoconditioning at all — if the CAR-T is potent enough. If Regimen B holds, CAR-T-in-autoimmune goes from specialty hospital procedure to community rheumatology infusion clinic — the difference between boutique salvage therapy and a real second-line replacement for rituximab + MMF. (2) Depth of response is not yet at autologous-CAR-T levels. Erlangen's autologous CD19 CAR-T scleroderma cases and Cabaletta's CABA-201 are producing double-digit mRSS drops and essentially normalized skin at 12-24M. Fate's 3M numbers are meaningful but modest by comparison (7-9 point mRSS drop conditioned, 4 points no-lymphoconditioning). Whether they deepen with time or plateau is the open question. (3) Regimen B (no lymphoconditioning) is the design-critical arm; smaller signal expected, but convergence on conditioned-arm response over 6-12M would reshape the modality. (4) The ITP + IIM overlap flare in a CAR-T-treated scleroderma patient is a signal to watch across the basket. (5) Persistence in a lymphoreplete host — B cells started returning by M1 in some — is the open mechanistic question; the field needs to know whether the immune reset that happens during the depletion window is durable. (6) Design lesson generalizes: if immune-engagement pharmacology is strong enough, the pre-conditioning story softens across TCE / bispecific / trispecific B-cell-directed modalities — direct relevance to platform-side work at Calibr. Landscape context. Autologous CD19 CAR-T for autoimmune: Kyverna KYV-101 (SLE, myositis, SSc, MS, MG), Cabaletta CABA-201 (SLE, myositis, SSc, MG, pemphigus vulgaris), Cartesian Descartes-08 (mRNA BCMA CAR-T in MG), plus academic Erlangen data (Schett group). Off-the-shelf competitors: Fate FT819 (this), Adicet ADI-001 (γδ CD20 CAR-T), Artiva AlloNK, Century Cyto-NK, Caribou CB-010. Fate is the first mover on iPSC-derived off-the-shelf CD19 CAR-T in autoimmune with published clinical data. Watch. B-cell recovery kinetics at 6M/12M in Regimen B — single most informative FT819 datapoint of the next 12 months. Any partnership signal on FT819 in autoimmune (Fate has ongoing Ono Pharmaceutical collab referenced in forward-looking statements). ACR Convergence November 2026 for data update. Regulatory alignment on a registrational path for SSc or SLE. Peer-reviewed publication of combined basket safety + efficacy dataset. Any competitor no-conditioning readout. Net: FT819 is the cleanest current signal that off-the-shelf CD19 CAR-T can produce measurable clinical activity in treatment-resistant systemic sclerosis without fludarabine and — in at least one case — without any lymphoconditioning, with a safety profile compatible with outpatient administration. Depth vs autologous is the open question; accessibility upside is the point. Presentation link: https://www.fatetherapeutics.com/wp-content/uploads/2026/07/ISSCR-_SSC_July-8-2026-Final_clean.pdf ; Fierce Biotech coverage: https://www.fiercebiotech.com/biotech/fates-shelf-car-t-cell-therapy-shows-early-promise-treatment-resistant-autoimmune-disease

Ateganosine (6-thio-2'-deoxyguanosine, THIO) sequenced with cemiplimab — 90.5% disease control (19/21) in checkpoint- and chemo-refractory 3L NSCLC, on a telomerase → cGAS/STING → CD8 cross-priming → PD-1 re-sensitization mechanism (MAIA THIO-101 Part C expansion, reported July 8, 2026)

Thu, 09 Jul 2026 12:00:00 +0000

MAIA Biotechnology (NYSE American: MAIA) reported initial efficacy from the Part C expansion cohort of the Phase 2 THIO-101 trial on July 8, 2026: 90.5% disease control rate (19/21 efficacy-evaluable) in third-line NSCLC patients who had progressed on prior immunotherapy, prior chemotherapy, and prior docetaxel. Regimen: ateganosine (also known as THIO, 6-thio-2'-deoxyguanosine) followed by cemiplimab (Regeneron/Sanofi Libtayo, PD-1 mAb) in 21-day cycles. MAIA cites 25-35% historical DCR for standard-of-care chemotherapy in the same setting (a low-end benchmark; real-world docetaxel monotherapy DCR is closer to 40-50%). Prior Parts A + B in 3L NSCLC ran at 88% DCR — the Part C readout is within-program consistent. Objective response rate, depth-of-response distribution (SD vs PR vs CR), duration of response, PFS, OS, and a formal safety AE table were NOT disclosed in the July 8 release. Mechanism (load-bearing): ateganosine is a nucleotide analog selectively recognized and incorporated by telomerase into cancer-cell telomeres — telomerase is active in the great majority of cancer cells and effectively silent in adult somatic tissues outside a few stem-cell compartments, giving the analog a cancer-cell-intrinsic selectivity handle. Once incorporated, the 6-thio modification uncaps the telomere; broken telomeric fragments spill into the cytosol as micronuclei; cGAS (cyclic GMP-AMP synthase) senses them as aberrant double-stranded DNA; STING activation drives type-I IFN from tumor cells and infiltrating dendritic cells; DCs cross-prime tumor-specific CD8 T cells; PD-1 blockade with cemiplimab then unleashes the primed T-cell response. The clinical sequence (ateganosine first, cemiplimab after) is not a hedge — it's the design; simultaneous or reverse-order dosing would break the mechanism. Published mechanistic anchor: Nandakumar et al., Cancer Cell 2020, "Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity." Editorial read for Justice's beat (translational immunologist, Rodgers lab Calibr — CAR-T + TCE + ADC + autoimmune biologics): (1) Cleanest current example of a small-molecule immunogenic-cell-death agent designed as a pre-conditioning arm upstream of a PD-1 antibody rather than in parallel — the design lesson generalizes to any cancer-selective DNA-damaging modality that reliably fires STING, and directly informs sequencing strategy for TCE/CAR-T/ADC-driven immune engagement in previously immune-cold or checkpoint-refractory patients. (2) Telomerase-selective delivery is the elegant part — every tumor cell has telomerase running; no normal adult tissue does at meaningful levels. Closest thing the field has to a universal cancer-cell-intrinsic selectivity handle for innate immune priming. (3) Caveats to hold: DCR is a soft endpoint that counts stable disease alongside actual responses; MAIA has not disclosed ORR, depth, or duration; n=21; historical benchmark is on the low end of real-world docetaxel. (4) MAIA is a nanocap on NYSE American; single-arm open-label expansion; safety table not disclosed — expect some late-emerging on-STING-agonist toxicity signals given the innate-immune-activation mechanism. Next diagnostic. Pivotal Phase 3 THIO-104: 300-patient 1:1 randomization vs investigator's choice of chemotherapy in the same 3L NSCLC checkpoint-and-chemo-refractory population; overall survival primary endpoint; first patient dosed December 2025; sites active in US/Europe/Asia; first interim likely 2027. Also watch for: (a) formal Part C ORR + duration + safety table disclosure at AACR/ESMO/WCLC 2026, (b) any peer-reviewed publication of Parts A+B+C combined, (c) MAIA financing runway through Phase 3 readout, (d) any large-pharma partnership signal on ateganosine specifically or the telomerase-into-STING axis more broadly. Net: encouraging within-program signal with a mechanistically coherent story, but disease control rate alone is not enough — ORR, duration, and the Phase 3 THIO-104 confirmatory readout are what will determine whether this becomes a real second act for the cGAS/STING checkpoint-sensitization thesis or another small-biotech signal that does not survive randomization. Worth tracking. Release link: https://www.globenewswire.com/news-release/2026/07/08/3324207/0/en/MAIA-Biotechnology-Reports-Strong-Initial-Efficacy-Data-in-Third-Line-Non-Small-Cell-Lung-Cancer-from-Phase-2-THIO-101-Part-C-Expansion-Trial.html

TRUTAKNA (atacicept-vymj) — first dual BAFF+APRIL inhibitor FDA-approved (accelerated) for IgA nephropathy, on 42% placebo-adjusted proteinuria reduction and 68% Gd-IgA1 biomarker suppression from ORIGIN 3 (Vera Therapeutics, announced July 7, 2026)

Wed, 08 Jul 2026 12:00:00 +0000

Vera Therapeutics (Nasdaq: VERA) received FDA accelerated approval on July 7, 2026 for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk for disease progression. TRUTAKNA is the first and only BAFF+APRIL dual inhibitor approved for IgAN, dosed 150 mg SC once weekly via at-home autoinjector. Molecule: soluble recombinant fusion protein containing the human TACI (transmembrane activator and CAML interactor) receptor extracellular domain fused to human IgG1 Fc; TACI is the natural high-affinity receptor for both BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand). Circulating TACI-Fc pulls both cytokines out of solution, starving the pathogenic B-cell + plasmablast + long-lived plasma cell compartment that produces the disease-driving autoantigen galactose-deficient IgA1 (Gd-IgA1) and its autoantibodies. Pivotal data. ORIGIN 3 (NCT04716231) prespecified 36-week interim analysis in first 203 randomized patients: 46% reduction in UPCR from baseline, 42% placebo-adjusted (p<0.0001) — the accelerated-approval endpoint. Secondary observational: 68% reduction in Gd-IgA1 — the pathogenic B-cell-derived autoantigen itself. Efficacy consistent across prespecified subgroups (age, sex, race, region, baseline proteinuria, baseline eGFR, baseline SGLT2i use). Safety across full 428-patient ORIGIN 3 dataset: infections 32% vs 28% placebo (upper respiratory tract 12% vs 9%), local-administration reactions 30% vs 5% (injection site reaction 19% vs 2%), no serious/opportunistic infections, NO hypogammaglobulinemia observed. Confirmatory eGFR analysis pulled forward to Q3 2026; supplemental BLA for full approval targeted Q4 2026. Competitive landscape. Fifth IgAN drug approved in about two years and the fourth mechanism: (1) Calliditas Tarpeyo (delayed-release oral budesonide targeting Peyer's patch B cells, Dec 2023, NefIgArd); (2) Travere Filspari / sparsentan (dual endothelin+angiotensin blocker, Sep 2024, PROTECT); (3) Novartis Fabhalta / iptacopan (Factor B complement inhibitor, Mar 2025, APPLAUSE-IgAN); (4) Otsuka Voyxact / sibeprenlimab (APRIL-only mAb, accel Nov 2025, VISIONARY — 50% placebo-adjusted proteinuria reduction); (5) TRUTAKNA (dual BAFF+APRIL). The class-defining empirical question in IgAN is now BAFF+APRIL vs APRIL-only. No head-to-head, but the Gd-IgA1 pharmacodynamic biomarker signal (68% reduction) is the differentiator Vera's commercial team will lead with. Direct mechanism-class competitor is Vertex's povetacicept (also TACI-Fc dual BAFF+APRIL fusion, Alpine Immune acquisition April 2024 for $4.9B; monthly SC dosing vs TRUTAKNA weekly; Phase 3 RUBY-3 in IgAN, readouts likely 2027-2028) — Vera has a 12-24 month first-mover window on the dual claim. Editorial read for Justice's beat (translational immunologist, Rodgers lab Calibr — CAR-T + TCE + ADC + autoimmune biologics): (1) Mechanism-repurposing story — atacicept was originally developed by Merck-Serono in the 2000s, failed a systemic lupus trial around 2010; Vera acquired, matched mechanism (dual BAFF+APRIL against plasmablast/plasma cell axis) to the disease (IgAN, where B-cell autoantigen production is the central driver rather than a comorbid feature), ran the pivotal, shipped it. Validated regulatory precedent for biology-first indication mapping — the AI-native platform pitch (Xaira, Iambic, Isomorphic Labs) that mechanism-disease pairing systematically applied surfaces recoverable failed molecules. (2) Class-mechanism differentiation is empirical: BAFF-plus-APRIL vs APRIL-only will decide the IgAN market split. Cross-trial numbers on proteinuria are very close (42% TRUTAKNA vs 50% Voyxact placebo-adjusted); the Gd-IgA1 biomarker gap (68% TRUTAKNA) is the mechanistic signal that dual blockade hits the plasmablast/plasma cell compartment harder at the disease-driving cell population — commercial story but scientifically load-bearing. (3) Safety story to watch: 36-week data shows NO hypogammaglobulinemia and no serious/opportunistic infections. Multi-year exposure data on dual BAFF+APRIL blockade is not yet in — plasma cell depletion over years may drop total IgG and open serious-infection risk that 36 weeks did not surface. This is the class-wide long-term signal to track. (4) B-cell autoimmune indication expansion — every disease where pathogenic B cells + plasmablasts + plasma cells drive autoantibody production is now a live dual-BAFF-APRIL indication. Vera has TRUTAKNA in Phase 3 lupus nephritis (ORION program), readouts expected 2028. Vertex-Alpine has povetacicept in Phase 3 systemic lupus. Both are pursuing myasthenia gravis, Sjögren's syndrome, membranous nephropathy. This is the class-expansion axis that matters for the autoimmune biologic pipeline over the next 3-5 years. (5) Delivery format — weekly SC autoinjector at home is competitive with monthly SC (Vertex povetacicept, Otsuka Voyxact moving to at-home) but not superior on convenience; the differentiation lever is mechanism + biomarker, not dosing frequency. Financial context. VERA closed +7% on approval news; Wolfe Research upgraded to Outperform with $88 PT; LifeSci Capital reiterated Buy at $90; BofA Buy at $66; consensus 12-month target ~$78. Analyst consensus TRUTAKNA peak sales $1.5-2.5B against ~40-60K US patients with progressive high-risk IgAN on maximal RAS inhibition (of ~160K total US IgAN diagnosed). Voyxact list price ~$300K/patient-year; Fabhalta $225K; Tarpeyo $120K. TRUTAKNA pricing not yet disclosed but likely $250-350K/patient-year range consistent with specialty-nephrology biologic class. TRU SUPPORT patient support program launched simultaneously with approval. Next diagnostic. ORIGIN 3 eGFR confirmatory analysis Q3 2026 (converts accelerated to full approval, confirms disease-modifying benefit on kidney function not just proteinuria surrogate). TRUTAKNA pricing + payer coverage 2-4 weeks. Vertex povetacicept RUBY-3 IgAN Phase 3 readout 2027-2028. Vera ORION lupus nephritis Phase 3 readout 2028. Longer-term serious-infection + hypogammaglobulinemia surveillance data. Any Vera acquisition offer inside 12-18 months if launch curve confirms $2B peak trajectory. Net: first dual-BAFF-APRIL inhibitor is FDA-approved for IgAN as of yesterday. The disease-specific competitive fight with APRIL-only Voyxact is the near-term commercial event; the mechanism-class fight with Vertex-Alpine's monthly povetacicept is the 2027-2028 event. The bigger read is that dual-BAFF-APRIL blockade of the pathogenic B-cell axis is now a regulator-approved mechanism, opening indication expansion across the entire plasmablast/plasma cell autoimmune universe — lupus nephritis, SLE, myasthenia gravis, Sjögren's, membranous nephropathy. Approval link: https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-receives-fda-accelerated-approval-trutaknatm

NMTi ADC payload class — Novartis pays $1.1B upfront + up to $400M in milestones for Myricx Bio's B7-H3 and HER2 preclinical ADCs, betting on N-myristoyltransferase inhibitors as a payload category orthogonal to DXd/exatecan and MMAE/MMAF (announced July 6, 2026)

Tue, 07 Jul 2026 12:00:00 +0000

Novartis to acquire Myricx Bio for $1.1B upfront + up to $400M in milestones (total up to $1.5B), announced 01:00 ET Monday July 6, 2026; expected close H2 2026. Novartis release: "Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients." Myricx Bio is a UK-based, preclinical-stage biotech spun out of Imperial College London + Francis Crick Institute in 2019 (founders: Ed Tate — the leading academic in NMT drug discovery for two decades — Roberto Solari, Andrew Bell); £90M / ~$114M series A led by Novo Holdings + Abingworth in mid-2024 with Eli Lilly participating alongside British Business Bank, Cancer Research Horizons; seed backing from Brandon Capital + Sofinnova. What Novartis is buying. Two lead ADC assets targeting B7-H3 and HER2 — both remain preclinical — plus, more importantly, an entirely new class of ADC payload: N-myristoyltransferase inhibitors (NMTi). Payload biology. NMT1/NMT2 catalyze co-translational addition of a 14-carbon myristoyl lipid to the N-terminus of ~150 human proteins, which anchors many of them to membrane compartments; substrates include Src-family kinases, ARF GTPases, and multiple pro-survival + mitochondrial proteins. Blocking NMT strips this modification and mis-localizes the affected substrates — a targeted-therapy-style mechanism, upstream of the resistance machinery that normally attacks cytotoxic payloads (TOPO-1 downregulation, MDR1 efflux, DDR upregulation). Preclinical claim (load-bearing scientific claim in this deal, per Novartis release + Myricx pipeline page): efficacy across multiple cancer cell lines, complete tumor regression in in-vivo solid-tumor models poorly responsive to standard payload classes, and explicit activity in TOPO-1-resistant models. Fiona Marshall (President, Novartis Biomedical Research): "ADCs have become an important part of cancer treatment, but there remains a clear need for new payload mechanisms to overcome resistance and expand their impact for patients." Strategic framing. This is Novartis buying a payload category, not two preclinical assets. $1.1B up front for a preclinical HER2 + B7-H3 pair only makes sense as a bet on NMTi as a platform applicable across many future targets — explicit analogy to how Novartis positioned radioligand therapy after Endocyte. If validated clinically, NMTi becomes the third viable ADC payload class alongside topoisomerase-1 inhibitors (DXd, exatecan derivatives — Enhertu, Datroway, Trodelvy, and most of the phase 1-2 pipeline) and microtubule-binding auristatins (MMAE/MMAF — Padcev, sigvotatug vedotin, Adcetris). Editorial read for Justice's beat (translational immunologist, Rodgers lab Calibr — CAR-T + TCE + ADC + autoimmune biologics): (1) Payload monoculture is a real strategic problem: HER2, TROP2, HER3, B7-H3, Nectin-4, and other targets all get DXd-class ADCs in parallel, and their emerging resistance mechanisms are shared. Every ADC developer now has to ask whether their next-generation asset should carry a payload orthogonal to their current one. (2) Ed Tate's 20+ years of NMT drug-discovery groundwork means this is a fundamental-biology-anchored payload, not a platform-hop asset assemblage — the mechanistic claims are more likely to hold up when the field kicks the tires. (3) Preclinical translation risk is real: NMT inhibitors as free small molecules have a long clinical history and none have made it past early phase without narrow index or off-target problems; the pitch is that ADC-mediated delivery solves this, but the safety window is not free. (4) Cross-resistance claims in TOPO-1-resistant models are a category of preclinical statement that has repeatedly not translated in patient studies — this deserves rigorous cross-resistance work in phase 1 dose-escalation with prior-DXd cohorts. (5) Both lead assets are on maximally crowded targets — HER2 has trastuzumab deruxtecan owning it plus multiple bispecific ADCs incoming (Sidewinder, Duality-Adcentrx, others); B7-H3 has ifinatamab deruxtecan and several phase-3-adjacent programs. Differentiation must come from the payload, not the antibody target. (6) Novartis has been aggressive on oncology dealmaking through 2026 — Antares Therapeutics ($105M upfront), Pikavation Therapeutics (~$2B in breast cancer) — this is a payload-platform play consistent with a strategy of owning multiple modality categories. What to watch next: IND-enabling packages + first-in-human trial designs for the B7-H3 and HER2 NMTi-ADCs; whether Novartis extends the NMTi payload onto radioligand or T-cell-engager backbones (Novartis has both); whether other ADC platform buyers respond with novel-payload deals in Q3-Q4 2026; peer-reviewed NMTi payload preclinical data disclosure at AACR / SITC / ESMO. Net: small-ish deal by 2026 standards, but the first meaningful validation in years of a fundamentally new ADC payload class — a targeted-therapy-style mechanism delivered inside an ADC, potentially orthogonal to deruxtecan and auristatin cross-resistance. If it validates clinically, it reshapes ADC payload diversification across the entire pipeline. Deal link: https://www.novartis.com/news/media-releases/novartis-agrees-acquire-myricx-bio-advancing-next-generation-antibody-drug-conjugate-innovation-novel-nmti-payload-expanding-options-cancer-patients

GPC3 CAR-T for post-liver-transplant recurrent HCC — FKBP1A + TRAC double CRISPR knockout resists tacrolimus, sirolimus, and everolimus while cyclosporine remains as an off-switch (bioRxiv preprint, posted July 5, 2026)

Mon, 06 Jul 2026 12:00:00 +0000

Kocheise L, Bacil G, Bhimalli P, Benmebarek M-R, Li D, Huang P, Ma C, Muralidaran V, Hernandez-Felix J, Bugliarelli JR, Chari R, Bauer K, Myojin Y, Firdaus S, Zhu XB, Morris C, Korangy F, Kroemer A, Ho M, Greten TF (senior, corresponding; NCI Center for Cancer Research, Thoracic and GI Malignancies Branch; funded by NCI intramural + DFG), "Engineering CAR T Cells for Hepatocellular Carcinoma Recurrence after Liver Transplantation," bioRxiv 10.64898/2026.06.30.735569v1, posted July 5, 2026. Preprint; not peer-reviewed. Full-text HTML rendered by bioRxiv within 24h; body read via r.jina.ai proxy. Central problem: HCC is a top indication for liver transplantation, and ~20% of transplanted HCC patients recur; when they do, they are on lifelong tacrolimus (or sirolimus/everolimus) to protect the graft, and every current CAR-T candidate walks straight into tacrolimus-mediated calcineurin/NFAT shutdown of T-cell activation. Standard-of-care for recurrence is TKIs and not much else. The Greten lab's fix is a two-cut CRISPR edit on a Glypican-3 (GPC3) CAR-T backbone. Cut 1: FKBP1A (encoding FKBP12, the immunophilin adapter that tacrolimus, sirolimus, and everolimus ALL bind before forming the ternary complex that blocks calcineurin or mTOR) — knockout the adapter, drug is still in the patient at therapeutic troughs and still protecting the graft, but cannot touch the engineered T cell. Cyclosporine still works on the edited cells (binds cyclophilin, not FKBP12), so tacrolimus→cyclosporine swap gives a pharmacologic off-switch for CRS or rejection episodes. Cut 2: TRAC — eliminates endogenous TCR to reduce alloreactivity against the transplanted liver. Standard allogeneic move but essential in the transplant setting. Results. Wild-type GPC3 CAR-T is suppressed by tacrolimus in vitro (cytokine production + cytotoxicity both drop); FKBP1A/TRAC double-KO CAR-T retains full function under tacrolimus, and shows in-vivo antitumor activity in a Hep G2 xenograft with mice on tacrolimus. TRAC-KO alone knocks xenoreactivity in a GvHD model. Manufacturing feasibility leg: functional double-KO CAR-T generated from PBMCs of actual liver transplant recipients drawn 30 days post-transplant. Selection strategy is worth flagging — everolimus in media kills residual FKBP1A+ cells, CD3-based MACS depletion strips residual TCR+ cells, and the combined selection pushes double-KO enrichment above 98% with viability intact. Scalable protocol, not a bench trick. Editorial read for Justice's beat (translational immunologist, Rodgers lab Calibr — CAR-T + TCE + ADC + autoimmune). (1) First published CAR-T design that solves the drug-drug-interaction problem with standard-of-care solid-organ-transplant immunosuppression via genetic resistance rather than a suicide switch or drug-holiday approach. Opens post-transplant recurrent cancers as a distinct addressable segment for cell therapy — HCC first, then kidney/heart/lung transplant recurrent cancers where tacrolimus + sirolimus + everolimus regimens are ubiquitous. (2) FKBP1A knockout is one guide + one small edit; a straightforward add to existing allogeneic CAR platforms without extending manufacturing timelines. Portable module. (3) Same FKBP1A-resistance logic ports to bispecific/trispecific TCE programs run through an ex-vivo redirected-T-cell manufacturing route (edit patient T cells, activate with the TCE, infuse) — worth watching for solid-tumor TCE indications overlapping the transplant recurrence populations. (4) Selection strategy (mTOR-inhibitor + CD3-MACS) is a reusable double-KO enrichment template for any allogeneic cell therapy needing two knockouts at once. Caveats. Preprint, xenograft-stage, single group, GPC3 CAR construct only. Xenoreactivity control is a GvHD model, not full-repertoire alloreactivity in humanized-mouse setting. Selection reliance on everolimus is a manufacturing consumable exposure that will need process-safety data. Not clear yet whether long-term persistence of the double-KO CAR-T under chronic tacrolimus dosing recapitulates function or drifts. Cyclosporine off-switch demonstrated but timing/dose to achieve reliable in-vivo shutdown not established. Next diagnostic. IND-enabling package + first-in-human trial design out of the NCI intramural program (Greten group has run prior GPC3 CAR-T trials at NIH). Extension of the FKBP1A-KO module to kidney-transplant renal cell carcinoma recurrence and heart-transplant post-transplant lymphoproliferative disorder. Any spin-out or licensing signal from NCI tech transfer around the double-KO CAR-T platform. Peer-review venue and timeline. Net: an elegant one-edit solution to a specific but severe translational deadlock in post-transplant cellular oncology, with an obvious platform-portability story into the broader immunosuppressed-patient CAR-T and TCE space. Paper link: https://www.biorxiv.org/content/10.64898/2026.06.30.735569v1

CIITA / tumor-cell MHC class II — a Helicobacter-community-driven antigen-presentation axis converts microsatellite-stable colorectal cancer to PD-1 + CTLA-4 checkpoint-responsive in mouse orthotopic AKPS + human MSS PDOs (bioRxiv preprint, posted July 4, 2026)

Sun, 05 Jul 2026 12:00:00 +0000

Chung C, Ozcelik E, Zhang J, ... Rogava M, Beyaz S (senior, corresponding; Cold Spring Harbor Laboratory + collaborators at MIT Fox lab microbiome + Univ. Pittsburgh Hand lab), "Microbial induction of MHC-II expression in colon cancer cells overcomes immunotherapy resistance and limits metastasis," bioRxiv 2026.06.30.735621 (posted July 4, 2026). Preprint; not peer-reviewed. Full-body HTML not yet rendered by bioRxiv 24h post-submission; summary based on abstract + Jina-proxied PDF synopsis with quantitative results (complete rejection rates, species names, model panel). Central claim: a specific Helicobacter-containing gut microbiome induces the master class-II transcription factor CIITA in colon cancer epithelial cells themselves, driving cancer-cell-intrinsic MHC class II surface expression that is both necessary and sufficient to sensitize immune-refractory MSS CRC to combined PD-1 + CTLA-4 blockade. Mouse pipeline: four orthotopic CRC models — MC38/BL6 (MSI-H-like syngeneic), CT26/BALB, and endoscopy-guided orthotopic AKP + AKPS organoids (Apc-null / Kras-mutant / Trp53-null / +Smad4-null in AKPS; AKPS is the aggressive metastatic MSS model that is the right mouse setting for checkpoint-refractory human MSS CRC). Protective community: H. typhlonius + H. mastomyrinus (whole-flora transfer > single-species colonization; three other Helicobacter species — H. bilis, H. pullorum, H. hepaticus — do nothing). CIITA loss-of-function in AKPS organoid: MHC-II ablated (MHC-I preserved) → microbiome protection collapses (larger tumors, more mets, less CD3+ infiltration, worse survival) — proves the effect is class-II-specific, not generic antigen presentation. CIITA gain-of-function (overexpression): reduces tumors + metastasis even in Helicobacter-negative animals but does not fully phenocopy Helicobacter+ survival — tumor MHC-II is necessary but not solely sufficient for the full microbiome benefit. Checkpoint combination result (the money slide): complete tumor rejection under anti-PD-1 + anti-CTLA-4 is 10% in H- controls, 30% in H+ + ICB, and 71% in CIITA-OE + ICB — a seven-fold ICB-response lift from a single transcription factor turned on in the tumor cell. Human MSS PDO experiment: CIITA overexpression in patient-derived MSS CRC organoids drives more autologous PBMC / CD4+ T cell colocalization + more organoid apoptosis in 3D co-culture — mouse story translates in a dish with human cells. Two important open questions the authors explicitly flag: (1) identity of the peptides presented by tumor MHC class II — microbial mimics vs. shared self-antigens vs. tumor neoantigens; TCR reconstruction + MHC-II immunopeptidomics required; (2) exact signaling pathway from Helicobacter to CIITA — direct microbial signaling on epithelium vs. classical IFN-gamma-through-myeloid-intermediary CIITA induction. If IFN-gamma-mediated, small-molecule / biologic tumor-MHC-II inducers become drug-developable without reshaping gut flora. Editorial read for Justice's beat (translational immunologist, Rodgers lab Calibr — CAR-T + TCE + ADC + autoimmune biologics): (1) MSS CRC is ~80-85% of colorectal cancer and is essentially checkpoint-blank since Keytruda's MSI-H approval; the AKPS system + a 7x ICB rejection lift is the cleanest MSS-sensitization mechanism to hit bioRxiv this year. (2) Three translational arms all now visible: (a) live biotherapeutic — reconstituted protective Helicobacter community as pre-treatment (Seres / Vedanta / Finch LBP playbook, with a specific bacterial signature and a defined mechanism instead of a black-box FMT); (b) small-molecule or biologic CIITA inducer / tumor-cell-targeted MHC-II induction construct — the more elegant, more drug-developable arm; (c) companion diagnostic — biopsy tumor MHC-II expression in MSS CRC to enrich checkpoint responders. (3) Read-through for the trispecific / CD3-TCE program space: tumor MHC-II engagement is the CD4-help lever that the TCE field has largely designed away in favor of CD8-heavy MHC-I / CD3 architectures. A tumor-side MHC-II component in a solid-tumor TCE is a design axis worth revisiting. (4) Convergent with recent melanoma correlative work showing cancer-cell MHC-II expression predicts ICB response — this paper gives that signal a causal + druggable microbiome + CIITA anchor. Caveats: preprint, mouse-dominant, single group, human data ex vivo (PDO not patient), upstream signaling unresolved, AKPS is one MSS model. What I would watch: replication in a second independent orthotopic MSS CRC model, IFN-gamma-vs-microbe pathway dissection, journal placement (Nature / Cell / Immunity plausible), any IP filing or spinout from Beyaz group or CSHL tech transfer, and any oncology-microbiome company (Seres, Vedanta, 4D Pharma-adjacent) picking up the CIITA / MHC-II induction thesis. Net: strongest mechanistic anchor for MSS-CRC checkpoint sensitization to appear in 2026 to date, with a druggable target (CIITA / tumor-intrinsic MHC class II) that is a step upstream of the microbiome itself. Paper link: https://www.biorxiv.org/content/10.64898/2026.06.30.735621v1

DPP9 / IL-18 — first genetic risk factor for checkpoint inhibitor pneumonitis and a druggable therapy hypothesis (bioRxiv preprint, posted July 3, 2026)

Sat, 04 Jul 2026 12:00:00 +0000

Brewer JR, Han A, Nassar AH, ... Choueiri TK, Gusev A, Flavell RA (senior, corresponding; Yale + Dana-Farber), "DPP9-mediated inflammasome repression protects against checkpoint inhibitor lung toxicity," bioRxiv 2026.06.30.735609, posted 2026-07-03. Preprint, not peer-reviewed. Discovery: DPP9 is the first genome-wide susceptibility gene ever described for checkpoint inhibitor pneumonitis (CIP) — the top cause of immune-checkpoint-inhibitor mortality (case fatality ~10%), for which no genetic risk factors had been established. Clinical anchor: clinico-genomics cohort of 4,397 ICI-treated patients; DPP9 locus signal is pneumonitis-specific, not the pan-irAE grab-bag. Mechanism: DPP9 is a cytosolic serine peptidase that proteolytically represses the CARD8 inflammasome in monocytes. Reduced DPP9 activity releases CARD8, activates caspase-1, and drives IL-18 secretion. In human monocyte biochemistry the pathway sits upstream of the pulmonary event, and plasma IL-18 is elevated in patients before CIP onset — candidate predictive biomarker running ahead of clinical diagnosis. Mouse causality leg: myeloid-restricted Dpp8/Dpp9 knockout recapitulates the pulmonary histopathology and immunology of human CIP — granuloma formation, IFNγ-producing T cells, expansion of monocyte-derived macrophages. Every phenotype collapses on IL-18 neutralization. Therapeutic hypothesis: IL-18 blockade is druggable — recombinant IL-18 binding protein tadekinig alfa is already in humans in NLRC4 and related inflammasomopathies; anti-IL-18 antibodies exist; CARD8 small-molecule inhibitors are moving toward the clinic in other inflammasomopathy indications. Any of those, layered on the ICI backbone or triggered by a rising plasma-IL-18 signal, becomes mechanistically rational rather than empirical. Compare to current SoC for high-grade CIP: steroids, more steroids, and eventually the checkpoint blocker that saved the tumor is discontinued and the tumor comes back. Editorial read for Justice (translational immunologist, Rodgers lab Calibr, cancer immunotherapy + TCE + CAR-T + ADC + autoimmune). (1) The class-wide translational significance is that as immunotherapy stacks get more powerful — trispecific TCEs, ADC payloads with cytokine-releasing linkers, armored CAR-Ts, IL-15 fusions — the toxicity ceiling starts to bind harder than the efficacy ceiling. This paper is the cleanest example in 2026 of an irAE mechanism closed all the way from a human GWAS locus to a druggable target in a single preprint. (2) Continuity with the same-lab humanized-mouse DPP9-deficiency / CARD8-pyroptosis pancytopenia paper (Xiao, Brewer, Flavell — bioRxiv July 1, 2026, covered on Scripps Biomed Brief 2026-07-01) — Yale is systematically building the case that the CARD8-IL-18 branch of the inflammasome family is the branch that produces marketed drugs in the next five years. Third Flavell-lab CARD8 paper in a fortnight. (3) Trial design read-through. First clinical readout most likely NOT prophylactic IL-18 blockade in every ICI patient — the number needed to treat is unfavorable. Right design is IL-18-guided rescue: plasma IL-18 rising on treatment triggers pre-emptive IL-18 blockade in the highest-risk (DPP9 low-function-variant + IL-18-elevated) subgroup, and you measure pneumonitis avoidance + preserved tumor response. That is a 200-300 patient adaptive trial that is fundable next year. (4) Autoimmune read-through. DPP9 loss-of-function is a full-body inflammasomopathy in humans (Hatipoglu syndrome). Same axis explains why IL-18 blockade has been pursued in NLRC4, Still's / MAS, and adult-onset periodic fever syndromes. If the CIP hypothesis reads out, the drug-class capital case for CARD8-inflammasome inhibitors + IL-18 blockers gets an oncology-adjacent expansion — a strategically valuable label to have next to an autoimmune label. Caveats. Preprint, not yet peer-reviewed. 4,397 patients is a good discovery cohort but not an independent replication. DPP9 sits in a broadly inflammation-pleiotropic locus — fine-mapping to a single causal variant will decide whether this becomes a clinical screen. Myeloid Dpp8/Dpp9 double knockout is a stronger perturbation than the human common-variant effect size — argues for causality but not effect-size calibration. Next diagnostic. Independent replication cohort (Choueiri and Gusev sit on multiple ICI-treated genomics cohorts). Rising plasma IL-18 quantitative dynamics before CIP onset — hazard ratio and lead time. Journal placement of the peer-reviewed version. Whether a company (Ciedon, mentioned in COI on senior author) picks up the CARD8-IL-18 combo hypothesis as a formal oncology-support asset. Net: first genome-wide anchor for the top-mortality checkpoint-inhibitor irAE, closed all the way to a druggable target that already has clinical-stage tools. Best translational immunology paper of the week. Paper link: https://www.biorxiv.org/content/10.64898/2026.06.30.735609v1

viroVbot — a computationally-screened Piry-virus envelope plus layered safety switches for redosable in-vivo CAR-T across BCMA/CD19 myeloma and Claudin-18.2 gastric cancer (bioRxiv preprint, posted July 1, 2026)

Fri, 03 Jul 2026 12:00:00 +0000

Alam R, Kumar S, Shukla R, ... Ahmad T (senior, corresponding; Jamia Millia Islamia + Institute of Genomics and Integrative Biology, New Delhi), "Safe Redosable Low-Immunogenic In Vivo CAR-T Therapy for B Cell Malignancies and Solid Tumors," bioRxiv 2026.06.30.735484, posted 2026-07-01. Preprint, not peer-reviewed; body HTML not yet rendered by bioRxiv 48h post-submission — summary based on the detailed abstract; full-text controls unread. Platform: viroVbot — a next-generation in-vivo CAR-T system built by inverting the standard envelope-design order of operations. Rather than start from a high-tropism envelope (VSV-G) and route around its immunogenicity + off-target liabilities, the authors start from a computational immunogenicity screen and only then engineer tropism back in. Design pipeline. (1) Envelope screen — computational immunogenicity prediction (CIMMEX) applied to 22,562 glycoprotein sequences → 641 vesiculovirus homologs → Piry virus glycoprotein (PIRYV) selected as the winning candidate. Piry is a rare South-American vesiculovirus with near-zero human seroprevalence and predicted lower MHC-I + MHC-II epitope density than VSV-G; in vitro Piry drives less T cell activation than VSV-G controls. (2) Receptor-binding-deficient PIRYV (ePIRYVᴿᴮᴰ) engineered to abolish native tropism, then displayed with CD3 + CD7 single-domain antibodies for T cell-selective transduction. Same retargeting concept as Umoja / Interius / Capstan / Orbital but layered on a starting envelope selected for immune-invisibility rather than potency. (3) Three orthogonal safety layers stacked on top: (a) engineered CAR-TRAP producer cells that eliminate residual B-cell transduction; (b) machine-learning-optimized T-cell-specific promoters restricting CAR expression to lymphocytes (silent in hepatocytes, macrophages, other bystanders even if vector uptake occurs); (c) additional modifications suppressing hepatocyte expression + reducing phagocytic uptake. Efficacy claims (humanized xenografts): (i) viroVbot3 generates potent BCMA/CD19 dual-specific CAR-T responses against multiple myeloma — dual-antigen construct plausibly addresses BCMA-escape from monospecific BCMA CAR programs; (ii) same platform generates functional Claudin-18.2-targeting CAR-T against gastric cancer — the solid-tumor extension is the real translational hook because in-vivo delivery bypasses the ex-vivo manufacturing / TME infiltration bottleneck that has strangled solid-tumor autologous CAR programs; (iii) sequential redosing demonstrated with alternative envelopes — the first in-vivo CAR-T proposal to frame the redosing problem as an envelope-library problem (many envelopes with same CD3/CD7 retargeting apparatus, cycle through them as ADAs develop) rather than an ADA-suppression problem; (iv) minimal off-target organ biodistribution, CAR expression restricted to T lymphocytes. Editorial read for Justice's beat (translational immunologist, Rodgers lab Calibr, CAR-T + TCE + ADC + autoimmune). (1) In-vivo CAR-T is currently the hottest translational cell-therapy space (Umoja UB-VV111 lymphoma dosing, Interius INT2104 P1 dosing, Capstan CPTX2309 in-vivo CD19 CAR platform, Orbital OB-101 in-vivo T cell delivery, plus Century, Odyssey, Precigen platforms). All of them fight two structural walls: envelope immunogenicity (limits redosing) + off-target transduction (safety). viroVbot claims to solve both at once by starting upstream at envelope selection with a computational-immunogenicity-first filter. (2) The redosing framing shift is the conceptually new piece — envelope-library rather than single-molecule immunogenicity. If it holds up on peer review, this is a template rather than a product; competitors adopt the same portfolio approach and the field's redosing constraint softens materially. (3) Solid-tumor Claudin-18.2 CAR-T in vivo, if reproducible, is a genuinely new tool — ex-vivo Claudin-18.2 CAR-T (Legend / CARsgen zolbetuximab-adjacent CT041) has posted response signals but manufacturing + persistence + TME infiltration make it uneconomical outside China. In-vivo delivery routes around all three. Caveats. Preprint; not peer-reviewed; single group. Humanized xenograft, not patient. Whether redosing experiments were done in the same animal or in parallel cohorts is not readable from the abstract. Machine-learning-optimized T-cell-specific promoter claim requires seeing the actual promoter panel + leakiness data — promoter engineering has burned this field before. Low-Piry-seroprevalence claim rests on prior South-American serosurveys not powered for global generalizability; a non-trivial fraction of humans with pre-existing anti-Piry immunity would limit the immune-invisibility argument. Solid-tumor Claudin-18.2 data must be evaluated on effect size + persistence + tumor microenvironment infiltration — abstract-level "potent responses" is not the same as durable regression. Next diagnostic. Body HTML render on bioRxiv within 24-48h — quantitative controls on the immunogenicity screen, redosing kinetics + ADA titers, TIL infiltration + persistence data in the Claudin-18.2 gastric cancer model. Peer-review venue and speed. Any follow-on IP filings or company spin-out from the Ahmad / Ramalingam groups. Net: first in-vivo CAR-T proposal that treats envelope immunogenicity as a computational-design variable rather than a downstream problem, and that treats redosing as a portfolio-of-envelopes problem rather than a per-molecule ADA-suppression problem. Template-level thesis if the numbers hold up. Paper link: https://www.biorxiv.org/content/10.64898/2026.06.30.735484v1

Tregzi — Orca Bio's Treg-enriched allograft becomes the first regulatory T cell therapy FDA-approved in the U.S., cutting chronic GvHD-free survival at 1 year from 38% to 78% in the Precision-T Phase 3 across AML, ALL, MDS, and mixed-phenotype acute leukemia at a WAC of $428K (FDA approval July 1, 2026)

Thu, 02 Jul 2026 12:00:00 +0000

FDA approved Orca Bio's Tregzi (formerly Orca-T) on Tuesday, July 1, 2026, for prevention of graft-versus-host disease in adults undergoing matched-donor allogeneic HSCT for AML, ALL, MDS, and mixed-phenotype acute leukemia. First-ever FDA approval of a regulatory T cell (Treg) therapy — genuine field-defining first in cellular immunotherapy. What Tregzi actually is: NOT genetically engineered T cells, NOT a CAR construct, NOT a bispecific, NOT off-the-shelf allogeneic — Tregzi is a compositionally defined allograft. Orca isolates three components separately from matched-donor mobilized peripheral blood — CD34+ HSPCs (engrafts marrow), natural regulatory T cells (Tregs), and conventional effector T cells (Tconv) — then reconstitutes them in defined ratio before infusion. Tregs = ~1% of T cell pool in standard graft, so the enrichment is significant; infused product is Treg-dominant on controlled Tconv background sitting on full CD34 dose. CEO Nate Fernhoff's framing (near-decade of BLA review including formal extension): "the art of what we do is to remove the cells that you don't want ... it's all about the things that you're removing to leave behind the thing of art." No cells engineered, no lymphodepleting chemo added to standard conditioning, therapeutic effect entirely a function of shipped composition. Manufacturing constraint: Tregs cannot be cryopreserved without losing suppressive function → 72-hour vein-to-vein window (donor apheresis → cell sort at Sacramento CA or newly announced Princeton NJ facility → ship fresh → infuse). Same fresh-product problem that constrained early CAR-T before Novartis cryo-Kymriah — Orca eats it because cryo compromises biology. Precision-T Phase 3 (n=187, AML+ALL+MDS+MPAL) randomized Tregzi vs unmanipulated matched-donor allograft with SoC GvHD prophylaxis (tacrolimus+MTX). Primary composite endpoint: chronic-GvHD-free relapse-free survival at 1 year — Tregzi 78% vs control 38.4% — largest reported randomized delta on chronic-GvHD-free survival in any allo-HSCT trial in the modern era. Secondary OS 94% vs 83% at 1 year (not powered for OS superiority — Orca framing "extremely important hypothesis-generating endpoint" = code for Phase 4 OS-powered confirmatory). Safety: oral/GI inflammation, diarrhea, rash, viral infections — consistent with conditioning + transplant setting expectations, no new-signal from Treg composition. Pricing: $428,000 WAC one-time. Launch: orders in coming weeks. Competitive framing: SoC alternative = post-transplant cyclophosphamide (PTCy), which became default over last decade because cheap + off-the-shelf + works across matched+mismatched. Tregzi has to justify $428K + 72-hr fresh supply chain against generic small molecule transplanters already comfortable with. Precision-T did NOT run head-to-head vs PTCy (comparator was tacrolimus+MTX) — KOL debate to come. Composite delta large enough it should hold up, but community wants that data eventually. Editorial read for Justice's beat (translational immunologist, Rodgers lab Calibr, cancer immunotherapy + TCE + CAR-T + ADC + autoimmune biologics). (1) Regulatory precedent for the Treg cell therapy class. Field has been promising 20 years — polyclonal Tregs in T1D, CAR-Tregs in transplant tolerance, engineered Foxp3 stability constructs (Sonoma, Abata, Quell, CARThera, GentiBio) — until this week, nothing in class had crossed randomized FDA-approvable pivotal bar. Now one has, and it is the LEAST engineered version — just cell isolation with tight release specs + rigorous compositional-analysis assay. Next-gen CAR-Tregs + engineered-stability constructs now have first-in-class approval to point at when asking agency for accelerated pathways. FDA has been forced to build review infrastructure for Treg product, portable to more sophisticated engineered constructs behind Orca. (2) Autoimmune expansion — the bigger commercial story. Fernhoff explicit on earnings call + launch materials: evaluating conditioning-reduced regimens for autoimmune indications; sister program Orca-Q (further sculpted Tconv against disparate haploidentical donors) framed as the tool. If Orca extends Treg-enriched cell therapy from transplant setting into refractory autoimmune (lupus, myositis, SSc — same population CD19 CAR-T-in-autoimmune companies + CD19×CD3 TCEs are attacking, e.g. Metis-Boulevard MTS-128 covered Wed, Cullinan CD19×CD3 SLE signal earlier June 2026) — competing directly against pathogenic-lymphocyte-depletion thesis with mechanism that suppresses rather than eliminates. Opposite arrow: Tregs damp autoreactive response; CD19 CAR-T deletes autoreactive compartment. Both plausible, mechanistic bets different enough both funded + tested. (3) Relevance to Rodgers lab beat. If TCE + CAR-T franchise = offensive weapon for autoimmune, Treg cell therapy = credible flanking maneuver with FDA precedent depletion approaches don't yet have outside oncology labels. Orca compositional-precision manufacturing template portable to any allogeneic engineered T cell product — watch whether they release release-spec tech to TCE/CAR-T community or hold as competitive moat. Deep-response-with-clean-safety Precision-T profile (78% vs 38% cGvHD-free, 94% vs 83% OS, no new safety signals) will pressure CAR-T-in-autoimmune field to match not just efficacy but tolerability of Tregs. Genuine bar-raise for the class. Net: Tregzi = first-in-class regulatory event in cellular immunotherapy, NOT incremental line addition. Validates precision-composition allografts as modality distinct from engineered cell therapy. Gives Treg field its first randomized pivotal win. Orca autoimmune expansion signal → Treg competitive set shifts from scientific curiosity to real commercial vector inside next 12-18 months, competing directly against depletion-based approaches Calibr autoimmune team is watching. Approval of the summer for cellular immunotherapy. Paper link: https://medcitynews.com/2026/07/orca-bio-treg-cell-therapy-tregzi-blood-cancer-leukemia-graft-versus-host-disease-gvhd/

MTS-128 — Metis TechBio out-licenses a preclinical AI-designed trispecific T cell engager for autoimmune disease to Deerfield-backed Boulevard Bio for $20M upfront and up to $1.6B in milestones (HKEX filing June 30, 2026)

Wed, 01 Jul 2026 12:00:00 +0000

Metis TechBio Co., Ltd. (HKEX: 7666), a Hong Kong-listed China-based AI-native drug design company, announced June 30, 2026 (HKEX voluntary announcement, filed 2026-06-30) an exclusive global license agreement with Boulevard Bio, Inc. — a US-based Deerfield Management-backed asset vehicle — granting Boulevard the global rights to develop, manufacture, and commercialize MTS-128, a proprietary trispecific T cell engager. Terms: $20M upfront + up to $1.6B in development, regulatory, and commercial milestone payments + tiered sales royalties. Asset profile: MTS-128 is a preclinical trispecific TCE independently developed on Metis' NanoForge platform, specifically the AiProtein engine (AI-driven protein-and-antibody design). Target antigens and clinical indication are undisclosed in the HKEX filing; Metis' own pipeline page classifies MTS-128 under Immunology → Autoimmune (Biologics, PCC stage) alongside two sibling assets MTS-109 and MTS-118. Fierce Biotech (June 30) independently confirms the autoimmune indication per Metis' website. This makes MTS-128 the second highest-value preclinical trispecific TCE deal on record and the first out-licensing of any asset from Metis' AiProtein engine — 47 days after Metis' May 13, 2026 Hong Kong IPO ($269M raised, marketed as the "world's first listed AI drug delivery company"). Metis was co-founded 2020 by Dr. Hongming Chen (US NAE member, ex-CSO Kala Pharmaceuticals) with MIT scientists Dr. Tsai-Ta Lai (chairman/CEO) and Dr. Wenshou Wang (COO); the NanoForge platform integrates four solution engines — AiLNP (lipid-nanoparticle design), AiRNA (mRNA sequence design), AiProtein (protein-and-antibody design), AiTEM (small-molecule formulation) — and Metis claims the world's largest proprietary LNP lipid library (>10M lipids). Boulevard Bio is Deerfield-incubated, low-profile — not yet listed on the Deerfield portfolio page. No other Boulevard programs disclosed. Metis' own framing: "Compared with traditional bispecific TCEs, trispecific TCEs can simultaneously modulate more biological mechanisms, offering unique potential advantages in enhancing target cell killing efficiency, increasing therapeutic window, improving selectivity and safety profiles." Editorial read for Justice's beat (trispecific TCE + autoimmune biologics). (1) Class positioning. CD19 CAR-T off-label experience in refractory lupus (Erlangen cases 2022+) established the "kill the autoreactive B cell compartment" thesis as a mechanism-level reset of pathogenic autoreactivity that anti-CD20 mAbs (rituximab, obinutuzumab) do not reliably deliver. T cell engagers are the off-the-shelf, no-lymphodepletion, no-manufacturing version of that thesis. Cullinan Therapeutics reported clinical signal for its own CD19×CD3 bispecific TCE in SLE earlier in June 2026 — the reference case Fierce anchors this deal to. Class is now bispecific, single B-cell antigen, deep pan-B-cell depletion. (2) Mechanistic bet on trispecific for autoimmune. A trispecific with two lymphocyte-antigen arms + CD3 forms an AND-gate on the target cell — synapses productively only when both antigens are co-expressed. Applied to autoimmune, this is dual-antigen gating for pathogenic-subset selectivity: carve off autoreactive plasmablasts / auto-antigen-reactive memory B cells / Tfh cells while sparing the polyclonal compartment supporting normal humoral immunity. Selectivity is the design frontier where trispecific structural sophistication has plausible clinical value over bispecific pan-depletion, and autoimmune is where the selectivity premium is highest because you are targeting patient's own cells at prolonged exposure. Metis' safety-profile-and-therapeutic-window language is consistent with this mechanistic argument. (3) Structural / market read. Boulevard is a Deerfield asset vehicle — same pattern as Talawar Therapeutics (Khanda IL-13×IL-18 for AD, JATT II SPAC merger June 29 — covered) and Beeline Medicines (BMS-carveout autoimmune assets, Series B extension June 30 — same-day headline). Platform sells preclinical asset at 9-figure milestone value into purpose-built vehicle; vehicle carries development through P2 on outside capital; pharma / specialist buyer is the exit. That $1.6B milestones on a preclinical trispecific TCE with undisclosed targets, no data, autoimmune indication has cleared Deerfield's vehicle-underwriting standard is a market-structure signal that autoimmune TCE class conviction is running well ahead of the current clinical data package. Deal comparables: Astellas × Vir Biotechnology $1.7B masked prostate TCE (mid-June 2026). Caveats. (a) Trispecific TCEs have no clinical proof of concept in any indication yet — class is preclinical or very early P1. (b) Target antigens + format geometry + CD3 affinity band undisclosed → cannot yet evaluate design decisions. (c) AI-designed ≠ AI-de-risked; higher upfront physical-property design bar is the pitch, clinic is the test. Next catalysts. Boulevard Bio target disclosures at post-JPM 2027 or scientific meetings; second AiProtein-engine or AiLNP-engine Metis deal within 12 months; Cullinan or peer autoimmune-TCE clinical updates. Net: on-beat trispecific TCE for autoimmune biologics — the deal of the week in the trispecific + autoimmune intersection. Paper link: https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000679.pdf

Droplet single-cell CRISPR screen of per-cell T cell killing — RPTOR/mTORC1 emerges as a brake across blinatumomab, CAR-T, and 1G4 TCR settings; transient rapamycin during ex vivo expansion improves adoptive transfer (Geiger lab, bioRxiv June 29, 2026)

Tue, 30 Jun 2026 12:00:00 +0000

Roger Geiger lab (IRB Bellinzona / ETH Zürich, bioRxiv 2026.06.23.734054 posted June 29, 2026) reports a droplet microfluidic single-cell CRISPR screening platform that turns CD8 T cell-mediated target killing into a pooled screening phenotype with kinetic resolution, and uses it to identify RPTOR/mTORC1 as an unexpected negative regulator of per-cell killing across bispecific T cell engager, CAR-T, and TCR-T settings. Method: primary human CD8 T cells co-encapsulated with CD19+ JeKo-1 lymphoma cells and the CD19×CD3 bispecific blinatumomab in picoliter water-in-oil droplets with SYTOX Green; 90-min incubation; conversion to double emulsions for conventional flow cytometry; sort dead-target vs live-target droplets; recover sgRNAs from each fraction. ~20M droplets/screen, ~15% T-cell-plus-target pairs, ~25% killing within the 90-min window = ~750,000 informative single-T-cell encounters per donor per screen. Library = 4,462 sgRNAs / 791 genes covering TCR signaling, differentiation, trafficking; ≥5 donors per batch. Hits recapitulate canonical positive regulators of cytotoxicity (CD3D, CD247, LCK, ZAP70, LAT, LCP2/SLP-76, VAV1, ITK, CD28, PIK3CD, ORAI1, GZMB, UNC13D, RAB27A, VAMP8, ITGB2, TLN1, WAS, EOMES, NFKB1, SH2D1A/SAP) and canonical negative regulators (PTEN, RASA2, SOCS1, FOXO1, IKZF2/Helios). Two unexpected hits: AFAP1L2 (signaling adapter previously linked to dysfunctional TILs) and RPTOR (Raptor, defining mTORC1 component). RHEB knockout phenocopies RPTOR knockout — confirms the effect is mTORC1-output-dependent rather than mTORC1-independent Raptor function. RPTOR-KO signaling state: ↓phospho-p70-S6K (Thr389), ↑phospho-AKT (Ser473, consistent with release of canonical S6K→IRS-1 negative feedback on PI3K-AKT), ↓CD62L/SELL, ↑LAG3, ↑PD-1, ↑CD25, ↑CD69 — more differentiated effector-like surface phenotype despite reduced anabolism. Quantitative proteomics on resting cells (n=12 RPTOR-KO from 4 donors / n=24 NTC from 8 donors): ~65% Raptor depletion (~3,800 → ~1,300 copies/cell), unchanged Rictor/mTORC2, *reduced* perforin and granzyme B abundance and IFN-γ secretion (faster killing not via increased granule load), collapsed anabolic programs (ASNS, GLUL, CTH amino-acid biosynthesis; FASN, ACACA, HMGCS1, FADS1, FADS2, SCD lipogenesis). Targeted metabolomics: pile-up of amino acids and glycolytic intermediates consistent with reduced anabolic utilization. Generalization: NY-ESO-1 1G4 TCR-transduced primary T cells with RPTOR or AFAP1L2 KO accelerate killing of Huh7 spheroids and A375 melanoma cells — confirms phenotype is not blinatumomab- or JeKo-1-specific and spans CD3 bispecific engagement, CAR-T recognition, and engineered TCR settings. Translational hook: permanent RPTOR or RHEB knockouts do NOT improve tumor control in vivo (NSG / A375) because proliferation defect catches up; transient low-dose rapamycin during 8-day ex vivo expansion of 1G4-TCR-T cells reproduces the rapid-killing state and DOES improve tumor control and survival after adoptive transfer. So the clinical lever is a media additive during the expansion window, not a permanent edit — fits cleanly into existing CAR-T/TCR-T manufacturing. Conceptual reframe: cytotoxic execution and anabolic fitness are dissociable T cell programs; mTORC1 is the dial. Caveats: 90-min killing window with 8-h bulk orthogonal validation, not durable tumor-control biology in vitro; in vivo data is one tumor model in immunodeficient mice; rapamycin/mTOR modulation in adoptive cell therapy has 20-year literature (Pearce, Powell, Restifo) — what's new is the per-cell killing kinetics angle and the screen that surfaced it. Translational implication for trispecific TCE/ADC+TCE work: the question of how to dial up per-cell killing kinetics during the encounter window without burning T cell persistence budget is the same question across all of these modalities. Paper link: https://www.biorxiv.org/content/10.64898/2026.06.23.734054v1

TALA-125 — IL-13 × IL-18 bispecific for atopic dermatitis emerges from Khanda Therapeutics in a $285M JATT II SPAC merger; pair-two-orthogonal-validated-pathways thesis tested against Dupixent's monotherapy efficacy ceiling, with Apollo Therapeutics' camoteskimab Phase 2a CHAMELEON readout as the IL-18 anchor

Mon, 29 Jun 2026 12:00:00 +0000

Talawar Therapeutics and JATT II Acquisition Corp (Nasdaq: JATT) announced a definitive business combination agreement June 29, 2026 — combined company to trade as Talawar Therapeutics on Nasdaq under ticker TLWR; expected close 2H 2026. Total proceeds at closing ~$285M: $60M from JATT II trust + $225M concurrent oversubscribed PIPE at $10/share, led by founding investor Access Biotechnology with Bain Capital Life Sciences, Deep Track Capital, RA Capital Management, Janus Henderson Investors, Vianti Capital, Farallon Capital Management. Cash runway funds TALA-125 through Phase 2b POC readout 2H 2028. Leadership: CEO Marc Schegerin (ex-COO/CFO Morphic Therapeutic, ex-CFO ArQule); CMO Fabio Nunes (ex-VP Dermatology & Respiratory Clinical Development, J&J); Board Chair Dan Becker (MD Access Biotechnology); Praveen Tipirneni (former CEO Caldera, Morphic) joining board. Lead asset TALA-125 is an anti-IL-13 × anti-IL-18 bispecific antibody for atopic dermatitis, IND clearance / clinical entry targeted Q1 2027, interim Phase 1 data Q4 2027, Phase 2b POC readout 2H 2028. Two undisclosed discovery-stage programs (TALA-307, TALA-711) in other I&I indications behind it. Khanda Therapeutics is the biotech company-builder umbrella; Talawar is Khanda's first company. Khanda thesis: unite two orthogonal, clinically validated pathways into a single bispecific molecule to break the monotherapy efficacy ceiling that has constrained I&I biologics for a decade. Mechanism: IL-13 is the canonical Type-2 driver in AD, validated by Dupixent/dupilumab (IL-4Rα), Adbry/tralokinumab (anti-IL-13), Ebglyss/lebrikizumab (anti-IL-13) — Dupixent ~40% EASI-75 at week 16, IL-13 monoclonals high 40s, majority of moderate-to-severe AD patients never reach a clean clinical response on Type-2 monotherapy. IL-18 is the orthogonal arm: IL-1-family cytokine released as inactive precursor primarily from keratinocytes (and Langerhans cells), activated by NLRP1 inflammasome cleavage in response to S. aureus colonization on lesional skin; once secreted, IL-18 sensitizes memory Th2 cells via IL-9-driven IL-18R upregulation and drives more IL-13 secretion (upstream alarmin amplification of the same downstream effector); also independently activates Th1, Th17, Th22 channels orthogonal to the IL-4/IL-13 axis. IL-18 clinical validation in AD: Apollo Therapeutics' camoteskimab (anti-IL-18 monoclonal, antibody-recycling engineered, Q3-month dosing) — CHAMELEON Phase 2a, n=62, hit EASI primary endpoint at week 16 (Sep 2025), efficacy preserved in patients who had failed prior anti-IL-13 / anti-IL-4Rα biologics — the proof point that IL-18 blockade captures a non-Type-2 slice of AD biology Dupixent-refractory patients still carry. Aletekitug (second anti-IL-18 mAb) replicates the signal independently — Phase 2 data published Allergy 2026. So IL-13 monotherapy is approved + IL-18 monotherapy is Phase 2-validated in AD; TALA-125 is the integrated combination in one molecule. Competitive context: bispecific AD architecture has a graveyard. Sanofi lunsekimig (TSLP × IL-13 nanobody) — VELVET Phase 2b in AD missed primary (Apr 2026), same molecule hit asthma + CRSwNP Phase 2 primary endpoints simultaneously, suggesting TSLP × IL-13 is partly redundant in AD because TSLP sits upstream of IL-13 in the same Type-2 cascade (limited orthogonality). Keymed CM512 (TSLP × IL-13) — Phase 1b 50% vs 7% EASI-75 at week 6 (small n). Innovent IBI3002 (IL-4Rα × TSLP) — Phase 2 ongoing. IL-13 × IL-18 is mechanistically distinct from TSLP-pairings because IL-18 is alarmin on a non-Type-2 amplifier track — if the Khanda thesis is that orthogonality drives ceiling-breaking, the lunsekimig miss is actually data in favor of the IL-18 choice over the TSLP choice. Caveats: TALA-125 is preclinical (no human data); bispecific format not disclosed (IgG-like? KIH? scFv tandem? nanobody?); PK reconciliation non-trivial (IL-13 mAbs dose Q2-4w, camoteskimab engineered for Q3-month interval — bispecific gets one half-life and which target's pharmacology dominates matters); AD bispecific space already burned lunsekimig + J&J icotrokinra + multiple TSLP failures, so picking the wrong two arms is the established failure mode. Bigger architectural lesson portable to oncology TCE/ADC work: Khanda model is "preselect bispecific format, find the orthogonal target pair" — converse strategy from the Padcev + Keytruda (ADC + checkpoint), teclistamab + daratumumab (BCMA bispecific + CD38 mAb), mRNA-2808 (multiplexed mRNA trispecific) precedent, which start from a clinical combination signal and engineer down. Both strategies converge on the same bispecific-as-combination thesis being financed at preclinical-stage capitalization ($285M for a pre-IND molecule) across both I&I and oncology in 2026, with similar investor syndicates. Diagnostic readouts: TALA-125 Phase 1 interim Q4 2027 (first integrated IL-13 × IL-18 PK/PD in human); Phase 2b POC 2H 2028 (does integrated bispecific replicate sum of camoteskimab + IL-13-mAb monotherapy signals). Net: bispecific architecture is now financeable at preclinical scale in autoimmune; the IL-13 × IL-18 target pair is technically defensible because both arms have Phase 2 monotherapy validation in AD; the Khanda company-builder model is worth tracking as the I&I-side template for what AbCellera/Jazz, Janux, conditional-TCE houses are doing in oncology TCEs.

Teclistamab + daratumumab — BCMA T-cell engager + CD38 monoclonal earns CHMP positive opinion for second-line myeloma on MajesTEC-3 PFS HR 0.17, 87% MRD-negativity at 10^-6 in complete responders, and CRS that never broke grade two

Sun, 28 Jun 2026 12:00:00 +0000

EMA CHMP issued a positive opinion on June 26, 2026 recommending approval of teclistamab (Tecvayli) in combination with subcutaneous daratumumab for relapsed/refractory multiple myeloma in patients with ≥1 prior line of therapy — EU regulatory closure on the same indication FDA approved March 5, 2026, both off the MajesTEC-3 readout first presented at ASH 2025. MajesTEC-3 (NCT05083169): Phase 3, randomized, open-label, n=587 (291 teclistamab + dara SC vs 296 investigator's choice of DPd or DVd — daratumumab + dex + pomalidomide or bortezomib), in RRMM with 1–3 prior lines including a PI and an IMiD. Dosing: teclistamab step-up (0.06/0.3 mg/kg) → 1.5 mg/kg SC weekly cycles 1–2 → 3 mg/kg q2w cycles 3–6 → 3 mg/kg q4w cycle 7+; daratumumab SC 1800 mg weekly cycles 1–2 → q2w 3–6 → q4w thereafter. Primary endpoint PFS: HR 0.17 (95% CI 0.12–0.23; p<0.0001) — 83% reduction in risk of progression/death; median PFS not reached vs 18.1 months control; 3-year PFS 83.4% vs 29.7%. OS: HR 0.46 (95% CI 0.32–0.65; p<0.0001) — 54% reduction in mortality; 3-year OS 83.3% vs 65.0%. ORR 89.0% vs 75.3%; ≥CR 81.8% vs 32.1% (OR 9.56); MRD negativity at 10^-5 by NGS 58.4% vs 17.1% (evaluable 89.3% vs 63.0%); MRD- at 10^-6 in ≥CR responders 87.5% vs 41.8% — deepest MRD readout from any Phase 3 myeloma trial. Safety: CRS 60.1% combination arm, all Grade 1/2, zero Grade ≥3 CRS; ICANS 1.1% (rare); Grade 3/4 infections 54.1% vs 43.4% (the trade-off — BCMA bispecific + CD38 mAb both deplete normal humoral immunity); Grade 3/4 TEAEs 95.1% vs 96.6% (comparable); treatment discontinuations from AEs 4.6% vs 5.5% (combination better tolerated than the standard triplet). Pharmacology intuition: daratumumab does not just kill plasma cells via complement/ADCC — it also depletes CD38-high regulatory T cells, MDSCs, and a subset of immunosuppressive myeloid cells, conditioning the bone-marrow microenvironment so that subsequent teclistamab-mediated T-cell redirection lands on a cleared-up effector compartment. Stacks three mechanisms: CD38-directed tumor killing, immune-microenvironment conditioning by Treg/MDSC depletion, T-cell redirection by the BCMA × CD3 bispecific. Synergy shows up in both depth-of-response (87% MRD-neg at 10^-6 in CR responders) and safety profile — no Grade ≥3 CRS plausibly reflects that overactivation-prone Tregs/MDSCs are thinned by daratumumab before the bispecific arrives. The technical lesson worth pulling forward: pair the T-cell engager with an upstream immune-modulator that conditions the microenvironment and you appear to get both efficacy and safety wins from the same combination move. Architecture portability: same template (TCE + CD38 mAb in 2L) reproduces in MonumenTAL-3 (talquetamab, GPRC5D × CD3 — covered June 15) with directionally similar PFS / depth-of-response / tolerability; cevostamab (FcRH5) Phase 3 combo with daratumumab is next; trispecific TCEs (Moderna mRNA-2808, AbCellera/Jazz protein platforms) sit in the next-generation pipeline behind this combination architecture. Template should be portable to CD20 bispecifics in lymphoma + rituximab/obinutuzumab, CD30 bispecifics in Hodgkin disease, and CD19×CD20×CD3 trispecifics where the open question is whether redirection should be paired with CD38 or CD20 depletion. Caveats: MajesTEC-3 enrolled 1–3 prior lines (mostly 1st/2nd relapse) — 1L induction trials (MajesTEC-7 and analogs) running quadruplet bispecific + dara + IMiD/PI vs VRd / dara-VRd are the next regulatory frontier; community-practice infection management (54% Grade 3/4 infections) needs institutional support for antimicrobial prophylaxis; cost structure of running two biologics on continuing monthly therapy non-trivial; FDA label uses daratumumab-hyaluronidase formulation, CHMP recommendation specifies SC daratumumab — both consistent (bispecific is the active ingredient) but the SC pairing is part of why the combination tolerability is what it is. Net: new bar for 2L+ myeloma — combination architecture (BCMA bispecific + CD38 mAb in subcutaneous formulation) defines the template for moving T-cell engagers out of late-line into induction-adjacent windows across heme malignancies. Pharma development implication: single-agent era of BCMA bispecifics is closing; the combination era, with the right immune-modulating partner, is where the next decade of myeloma and other heme TCE therapy gets built.

Padcev + Keytruda — perioperative Nectin-4 ADC + PD-1 wins EU approval in cisplatin-ineligible muscle-invasive bladder cancer; first PD-1 inhibitor plus ADC ever authorized in a curative-intent setting, with a 57% pathologic complete response rate and an EFS HR of 0.40

Sat, 27 Jun 2026 12:00:00 +0000

European Commission, June 24, 2026, approved perioperative pembrolizumab (Keytruda) plus enfortumab vedotin (Padcev) in cisplatin-ineligible patients with resectable muscle-invasive bladder cancer (MIBC) — the first PD-1 inhibitor + antibody-drug conjugate regimen authorized anywhere in a curative-intent perioperative setting. Approval follows positive CHMP recommendation (May 2026) and US FDA approval (Nov 2025). Supporting data: KEYNOTE-905 / EV-303, Phase 3, n=595, three-arm randomized in cisplatin-ineligible/decliner resectable MIBC. Arm A: 3 cycles neoadjuvant pembrolizumab → cystectomy → 14 cycles adjuvant pembrolizumab. Arm B: cystectomy alone (control). Arm C (combination, approved): 3 cycles neoadjuvant pembrolizumab + enfortumab vedotin → cystectomy → 6 cycles adjuvant combination + 8 additional cycles pembrolizumab monotherapy (9 EV doses + 17 pembro doses total). Primary endpoint event-free survival (EFS), Arm C vs Arm B: HR 0.40 (95% CI 0.28–0.57), p<0.0001 — 60% reduction in EFS events. Median EFS not reached (combination) vs 15.7 months (surgery alone). Overall survival, Arm C vs Arm B: HR 0.50 (95% CI 0.33–0.74), p=0.0002 — 50% reduction in mortality. Median OS not reached vs 41.7 months. Pathological complete response (pCR): 57.1% (95% CI 49.3–64.6) combination vs 8.6% (95% CI 4.9–13.8) surgery alone, p<0.0001 — a 48-point spread, the cleanest ADC + checkpoint pCR signal in any solid tumor in any line. Mechanism: Nectin-4-targeting monoclonal coupled to MMAE (monomethyl auristatin-E, antimitotic tubulin disruptor) via cleavable linker, with bystander kill from cleaved free auristatin; ADC-induced tumor cell death releases antigen into a TME the PD-1 blockade is simultaneously unmasking; perioperative window maximizes antigen load (intact primary tumor still present) and lets cytotoxic priming + checkpoint release operate in parallel before cystectomy removes the antigen source. Adjacent context: cisplatin-ineligible MIBC ~50% of muscle-invasive patients (renal impairment, cardiac comorbidity, performance status); prior standard was surgery alone with no neoadjuvant systemic option. Safety: in neoadjuvant phase combination arm (n=167 with assessable toxicity), serious adverse reactions 27%, fatal events 1.2%, permanent discontinuation due to adverse reactions 15%; common treatment-related events: pruritus, alopecia, diarrhea, fatigue, anemia (EV profile) stacked on pembrolizumab irAEs. Cisplatin-eligible MIBC indication still pending: EV-304 / KEYNOTE-B15 trial, EMA Type II variation validated March 23, 2026 — head-to-head against neoadjuvant cisplatin chemotherapy is the real efficacy bar. Net for the broader ADC + checkpoint design space: this is the reference data set for moving ADC + PD-1 combinations from metastatic into curative-intent. The 48-point pCR delta and 50% OS reduction are large enough that the question shifts from whether ADC + ICI synergy is real to which tumor antigen, which warhead, and which earlier setting — datopotamab deruxtecan in NSCLC, sacituzumab govitecan in TNBC, HER3 D-X-d programs, CEACAM5 conjugates, Claudin-18.2 ADCs all looking at this readout as the proof point.

mRNA-2808 — Moderna's mRNA-encoded multiplexed T-cell engager (BCMA + GPRC5D + FcRH5) posts first clinical signal in R/R multiple myeloma; sister TCE mRNA-2151 advances into ovarian and in vivo CAR-T mRNA-6007 joins the autoimmune horizon

Fri, 26 Jun 2026 12:00:00 +0000

Moderna Science Day, June 25, 2026 — disclosed an early encouraging clinical signal for mRNA-2808 in the Phase 1/2 study (NCT07116616, opened Sept 2025) in relapsed/refractory multiple myeloma. mRNA-2808 is the first multiplexed T-cell engager in the clinic that hits three validated MM targets in a single medicine: an IV lipid nanoparticle delivers three separate mRNA transcripts encoding three CD3 bispecifics (BCMA×CD3, GPRC5D×CD3, FcRH5×CD3); patient cells translate the messages and secrete the three engagers in vivo. Architectural intuition: the design moves the combinatorial complexity out of the protein (where trispecific antibody engineering compromises affinity/manufacturability around three tumor-binding domains + CD3) and into the formulation (relative mRNA ratios are titratable). Pharmacokinetics are mRNA-vaccine kinetics applied to a cytotoxic effector — ongoing secretion from a single LNP infusion, replacing protein-engager continuous-infusion regimens. Trial design enrolls patients with prior BCMA, GPRC5D, or FcRH5 exposure — i.e., the post-sequential-bispecific population where the trispecific thesis would matter most. No patient counts, ORR, depth-of-response, or CRS profile disclosed; the load-bearing question for the modality is whether mRNA-driven gradual onset of three simultaneous CD3-engager exposures softens the dose-limiting CRS that protein TCE step-function dosing produces. Sister program advancement: mRNA-2151 (multiplexed TCE for ovarian cancer, same architecture, targets not yet public) is being pushed into early development on the back of the 2808 signal — first non-hematologic test of mRNA-encoded multispecific TCE. Adjacent autoimmune-side disclosure: mRNA-6007 (Horizon 3, FIH targeted by end of 2027) is Moderna's first in vivo CAR-T — multiplexed mRNA encoding two CARs delivered via T-cell-targeted LNP, intended for deep B-cell depletion in SLE and other B-cell-mediated autoimmune disease; competes with Capstan/AstraZeneca (CPTX-2309/CTX-1131), Lilly/Kelonia, and EsoBiotec/AstraZeneca in vivo CAR-T autoimmune programs. The multiplexing logic — encode more than one effector to dodge antigen-loss resistance — is consistent across the oncology and autoimmune arms of the platform. Caveats: no quantitative clinical data released (data-light Science Day disclosure); CRS profile of mRNA-encoded multispecific TCE is the open clinical question; durability of in vivo translation, anti-LNP / anti-payload immunogenicity, and re-dosing kinetics remain to be established in human; competitive context for the BCMA/GPRC5D/FcRH5 myeloma slot is teclistamab + talquetamab + cevostamab (sequential), CAR-T (ide-cel/cilta-cel), and emerging dual-target CAR-T programs. Net: first clinical-grade evidence that mRNA-encoded multispecific T-cell engagers are a real modality, with implications for the trispecific TCE design space (AbCellera/Jazz, Janux conditional formats, protein trispecifics) — engineering constraints are entirely different and the cocktail-of-encoded-bispecifics architecture is now an open competitor to protein trispecifics. Phase 1 readout at the next medical meeting is the diagnostic event for the modality.

B7-H3 × 4-1BB bispecific — Southampton architecture study sets the design rules for tumor-localized costim bispecifics: receptor-side bivalency is the dominant determinant, 4-1BB beats the rest of the TNFRSF, and the principles are conserved in human T cells

Thu, 25 Jun 2026 12:00:00 +0000

Al-Shamkhani / Cragg / Beers preprint out of the University of Southampton (Widdess et al.; bioRxiv 10.64898/2026.06.19.732642 v1, posted June 24, 2026) is the rigorous architectural answer to two open questions in the costim T-cell-engager design space the field has converged on as the next-gen replacement for two-arm CD3 + tumor-antigen TCEs: what valency on which arm matters most, and which TNFRSF member is the best signal-2 receptor to point at. Setup: uniform-scaffold bispecific antibody panel using B7-H3 as the tumor-associated antigen, varying (a) format — 2x2 (dual-bivalent), 2x1 (TNFRSF-bivalent, tumor-monovalent), 1x1 (fully monovalent) — and (b) TNFRSF target across multiple family members. Format result: 2x2 is maximally active; 1x1 is least active; the asymmetric 2x1 retains substantial activity — which identifies costim receptor bivalency (NOT tumor-antigen bivalency) as the dominant determinant of efficacy. Mechanistic intuition: TNFRSF members signal through trimerization / higher-order clustering, monovalent engagement under-crosslinks the receptor; bivalency on the T-cell side recovers signaling even when tumor engagement is monovalent. Implication for trispecific costim TCEs (e.g., the AbCellera/Jazz architecture covered June 19): the costim arm has to be at least bivalent on the receptor side even when CD3 and tumor arms stay monovalent. Receptor result: across TNFRSF members, 4-1BB drives the strongest CD8 cytotoxic differentiation and anti-tumor response — hierarchy is conserved in human T cells and reproduced by the natural cognate ligand, so it's receptor-intrinsic signaling biology, not antibody affinity / epitope artifact. Resolves a long-running debate about whether costim receptor choice is a coin flip in practice (it isn't — 4-1BB first). Mechanistic controls: activity requires tumor-antigen-positive cells (genuine tumor localization, not systemic 4-1BB agonism); 4-1BB signaling must be T-cell-intrinsic (bona fide signal-2 on the T cell). Caveats: abstract-only (preprint < 36h old, body figures not yet rendered on bioRxiv) — quantitative magnitudes of 2x2-vs-1x1 differential, 4-1BB-vs-OX40 gap, and in vivo survival are in the figures and the take should be recalibrated when the full body lands; mouse-and-human-cell biology, not clinical; B7-H3 as the only tumor antigen tested (deliberate but worth flagging — architecture portable to other antigens at the same valency rules); senior authors disclose Talix Therapeutics and F-star consulting (commercial programs downstream); receptor hierarchy was established without the systemic-inflammation context that limited urelumab — this is the design-rules layer underneath the molecule-by-molecule clinical story. Closest clinical comparators: AstraZeneca, Pieris, F-star, Inhibrx 4-1BB-targeting tumor-localized bispecifics; read-across is at the design-principles level. Net: the architecture-rules paper the costim TCE space has been waiting for — receptor-side bivalency is the load-bearing constraint (not tumor-side), and 4-1BB sits on top of the TNFRSF hierarchy conserved across species and engagement modality. Should sit at the front of the next protein-engineering review on costim multispecifics.

CD8-iTreg CAR — Blazar–Dustin bifunctional regulatory–cytolytic CD19 CAR T cell outperforms conventional CAR19-CTL in Nalm-6 xenografts and suppresses xenogeneic GVHD without inflammation via Granzyme-K supramolecular attack particles, reframing the CRS dilemma for autoimmune CAR-T

Wed, 24 Jun 2026 12:00:00 +0000

Blazar (Minnesota) + Dustin (Oxford) + Kean (Boston Children's) + Cantor (Dana-Farber) preprint (Larson et al.; bioRxiv 10.64898/2026.06.18.731665 v1, posted June 23, 2026) shows that human CD8+CD25neg PBMCs can be differentiated into a bifunctional CD8-iTreg population that is simultaneously regulatory and cytolytic — a combination the field has largely abandoned in favor of CD4-iTreg programs because previous CD8-iTreg recipes lost either phenotype stability or killing capacity. Differentiation: anti-CD3-epsilon mAb-loaded artificial APCs + IL-2 + TGF-beta + rapamycin. Phenotype (spectral flow + scRNA-seq): stable, highly proliferative; canonical Treg markers (FoxP3, HELIOS, CD25, CD39, CTLA-4, CCR4, IL-10) with tissue-residency CD103+; downregulated pro-inflammatory cytokines; suppressive activity comparable to CD4-iTregs. Cytolytic program: elevated Granzyme-K and Thrombospondin-4 (Tsp-4); perforin + multiple granzymes packaged into Tsp-4+ supramolecular attack particles (SMAPs) — a Dustin-lab delivery modality distinct from conventional CTL degranulation, with GzmK doing double duty as both cytotoxic and immunosuppressive effector. The load-bearing translation: CAR19-transduced CD8-iTreg cells (CAR19+CD8-iTreg) were not equivalent to CAR19-CTLs in a Nalm-6 human leukemia xenograft — they were SUPERIOR, with greater tumor burden reduction and prolonged survival, AND lower pro-inflammatory cytokine production. The conventional prediction would be that the regulatory program dampens anti-tumor activity; what appears to happen is that SMAP-packaged GzmK does the killing through a delivery vehicle that doesn't require full inflammatory CTL degranulation. The second key in vivo experiment: in a xenogeneic GVHD model with residual human leukemia, CAR19+CD8-iTreg suppressed GVHD lethality AND controlled tumor growth, without increasing systemic inflammation — exactly the combination the autoimmune CAR-T field (Kyverna KYV-101, Cabaletta CABA-201, Cartesian Descartes-08, academic Erlangen/Stanford/NIH programs) has been chasing as CRS gates clinical expansion into lupus, myositis, scleroderma, NMO. Caveats: xenograft mouse data, not autologous human; abstract-only (preprint < 36h old, body figures not yet rendered) so quantitative effect sizes for CAR19-iTreg vs CAR19-CTL aren't available; CD8-iTreg phenotype stability without supporting cytokines and over months not fully addressed; manufacturing (anti-CD3 aAPC + 4-cytokine differentiation) more complex than standard CD3/CD28 bead activation and needs industrialization; translation likely requires the same allogeneic/gene-editing platform work the conventional autoimmune CAR-T programs are already running. Mechanistic portability: a TCE construct that biases T-cell engagement toward SMAP release rather than free degranulation could in principle import the same toxicity dampening into a more deployable modality. Net: sharp paper rehabilitating CD8-iTreg as a CAR-T substrate, with a SMAP-mediated killing mechanism that explains how the bifunctional phenotype works and predicts the lower inflammatory output observed in vivo — one of the more consequential preprints of the month for the CAR-T / TCE / autoimmune biologics intersection.

CD8-iTreg CAR — Blazar–Dustin bifunctional regulatory–cytolytic CD19 CAR T cell outperforms conventional CAR19-CTL in Nalm-6 xenografts and suppresses xenogeneic GVHD without inflammation via Granzyme-K supramolecular attack particles, reframing the CRS dilemma for autoimmune CAR-T

Wed, 24 Jun 2026 12:00:00 +0000

CD8-iTreg CAR — Blazar–Dustin bifunctional regulatory–cytolytic CD19 CAR T cell outperforms conventional CAR19-CTL in Nalm-6 xenografts and suppresses xenogeneic GVHD without inflammation via Granzyme-K supramolecular attack particles, reframing the CRS dilemma for autoimmune CAR-T

Wed, 24 Jun 2026 12:00:00 +0000

Sigvotatug vedotin — integrin-beta-6 ADC misses Phase 3 overall survival in non-squamous NSCLC, but two-thirds-of-trial second-line subset signal and a Pfizer pivot to first-line pembrolizumab and PD-1×VEGF bispecific combinations keep the asset alive

Tue, 23 Jun 2026 12:00:00 +0000

Pfizer announced topline Phase 3 results on June 22, 2026 for sigvotatug vedotin (PF-08046047; SV) in the SigVie-002 trial (NCT06012435, n=703, open-label, randomized vs docetaxel) in previously treated, locally advanced or metastatic non-squamous NSCLC. SV is a first-in-class integrin beta-6 (IB6/ITGB6)–directed antibody-drug conjugate with the MMAE (vedotin) tubulin-disrupting payload — same payload class as brentuximab and enfortumab, inherited via the Seagen platform. IB6 is an adhesion integrin overexpressed in non-squamous NSCLC, HNSCC, gastric, CRC, and cervical cancers; the Phase 1 SGNB6A-001 monotherapy ORR in NSCLC was 19% confirmed (modest but real). Headline: SV did NOT demonstrate a statistically significant overall survival benefit vs docetaxel in the overall population. HRs and medians not disclosed pending congress presentation. The interesting result: in the ~two-thirds of patients who had received only one prior line of systemic therapy (true second-line), Pfizer reports a stronger OS + PFS trend, with outside commentary framing the 2L slice as showing a clinically meaningful survival benefit (no HR disclosed). Mechanistic intuition for the line-of-therapy split — and the load-bearing point — MMAE is a tubulin disruptor and docetaxel is a tubulin stabilizer; once patients have failed a taxane, the residual tumor is enriched for cells that survive tubulin perturbation broadly, and stacking an MMAE ADC on top in 3L+ collapses the payload window. The 2L cohort is taxane-naive (post-checkpoint blockade only) and is where the payload has a real biological window — same lesson the Trop-2 ADCs (sacituzumab, datopotamab) have been learning in the same setting. Pfizer's salvage plan, which is exactly where Justice's interests intersect: (1) Phase 3 in 1L NSCLC PD-L1 TPS ≥50% with pembrolizumab — vedotin-mediated immunogenic cell death rationale for ADC + checkpoint combination; (2) Phase 1/2 combining SV with PF-08634404 (Pfizer's PD-1×VEGF bispecific, acquired from 3SBio in 2025 for up to $6B; SSGJ-707; tetravalent format) in earlier-stage lung and across IB6-expressing tumors — the exact ADC + PD-1×VEGF stack the Akeso/Summit ivonescimab thesis has been making the case for, with the chemo slot replaced by a targeted payload. Caveats: actual HRs and medians not yet released (2L "trend" could mean HR 0.75 with wide CI or 0.6 with clean separation); FDA increasingly skeptical of line-of-therapy subgroup-driven labels (post-enfortumab/Trop-2 refinements suggest a fresh 2L-only Phase 3 is the registration path); combination programs still Phase 1/2 with a compromised monotherapy bar to clear; trial was unselected by IB6 expression and a biomarker-stratified re-cut on existing tissue should be run if not already. Net: headline Phase 3 failure on registration terms, but the operational read is a payload-mechanism trap that recommends moving up a line plus the combinations that anchor Pfizer's PD-1×VEGF + ADC narrative — the exact intersection of Justice's ADC and VEGF×PD-L1 pillars. Watch the congress presentation for the 2L HR and the early SV + PF-08634404 combination data.

Decitabine + entinostat — sequential epigenetic priming surfaces a shared cancer-testis antigen panel across mutationally distinct sarcomas, turns whole-cell vaccination + checkpoint blockade into a synergistic combination, and converges in human sarcoma cell lines

Mon, 22 Jun 2026 12:00:00 +0000

Johns Hopkins preprint (Recho et al., corresponding Brian H. Ladle; bioRxiv 2026.06.18.733244 v1, posted June 21, 2026) argues that the antigen-poverty problem in low-mutation pediatric sarcomas is pharmacologically reversible: a sequential combination of decitabine (DNA methyltransferase inhibitor) + entinostat (HDAC inhibitor) de-silences epigenetically suppressed genes — including cancer-testis (CT) antigens — and upregulates MHC class I, restoring both the antigen repertoire and antigen presentation simultaneously. Vehicle: a GM-CSF-secreting irradiated whole-cell vaccine made from epigenetically treated KRAS-mutant murine sarcoma cells (KP Sarc model). Validation cascade: T cell immunity against matched tumor challenge directed specifically at the epigenetically upregulated antigens (antigen-specificity established, not a non-specific effect); T cell-dependent (depletion ablates response); potentiated by ICB on top (vaccine + checkpoint blockade are synergistic, not redundant — the clinically relevant regimen prediction); confers immunologic memory. The load-bearing finding for translational use is the cross-tumor sharing: epigenetically upregulated antigens are shared between KP Sarc and a second murine sarcoma model (M-3-9M) with distinct mutational drivers, and vaccination against one provides cross-protection against the other — implying a relatively conserved CT antigen panel emerges across mutationally heterogeneous sarcomas under the same priming regimen. Human bridging: decitabine + entinostat applied to human sarcoma cell lines produced concordant gene-expression changes, shared antigen targets, and increased MHC class I — mouse-to-human convergence on the most consequential finding. Translational read for TCE/CAR-T/ADC platform planning: the conceptual move is target nomination by pharmacological induction. Cell-therapy targets in sarcoma have historically been bounded by native expression (GD2 on osteosarcoma, HER2 variable, B7-H3, CD56 in rhabdo); the CT antigen menu (NY-ESO-1, MAGE-A4, KK-LC-1) has been small + expression-heterogeneous + intracellular (TCR-T niche, not CAR-T/TCE). This paper's implication is that you can pharmacologically force expression of a shared CT antigen panel across sarcoma subtypes, then deploy off-the-shelf TCR-T, TCR-mimic antibody, or HLA-restricted TCE against the induced antigens after priming — a regimen design where the priming step is two FDA-approved drugs. Caveats: abstract-only (preprint < 24h old, body HTML not yet rendered) — specific antigens in the shared panel not named, would want to know whether any are surface-tractable for classical CAR-T/TCE; mouse + human cell line, no human in vivo; chronic-tolerability of decitabine + entinostat in pediatric patients not established; whole-cell GM-CSF vaccine modality operationally heavy and patient-specific (best as proof-of-mechanism, with off-the-shelf cell therapy or TCE as the deployable downstream); two co-authors at Nkarta + Merck (declared unrelated). Net: sharp conceptual contribution — pharmacologically induce a shared antigen repertoire across mutationally heterogeneous tumors and you've solved the target-nomination problem for cell therapies in low-mutation cancers; specific antigens on the shared panel will determine whether this reaches Phase 1 within two years or stays a model curiosity.

ChAdOx1/MVA — heterologous viral-vector prime-boost drives brain CD8 TRM and controls ICB-refractory murine glioblastoma, reframing checkpoint failure as a priming bottleneck rather than an effector problem

Sun, 21 Jun 2026 12:00:00 +0000

NCI Center for Cancer Research + Ludwig Institute Oxford preprint (Steffke et al., corresponding Masaki Terabe; bioRxiv 2026.06.18.733241, posted June 20, 2026) argues that the dominant failure mode of checkpoint blockade in glioblastoma is upstream of effector exhaustion: T cells are never primed in sufficient magnitude against tumor antigen in the first place. Test: a strong heterologous prime-boost vaccine — ChAdOx1 simian adenovirus (same backbone as Oxford-AstraZeneca COVID) prime, MVA poxvirus boost — delivered systemically against the SB28 orthotopic murine glioblastoma model, which is checkpoint-refractory in mice (matching human GBM's clinical refractoriness). Vaccination targeted two antigens: P1A (known mouse tumor antigen) and Gpr149 (newly identified glioblastoma-associated antigen). Results: therapeutic efficacy against SB28; robust infiltration of antigen-specific CD8+ T cells into tumor-challenged brains, the majority CD103+CD69+ tissue-resident memory (TRM)-like, polyfunctional and durable in animals maintaining tumor control; tissue-specific immunological memory established. The mechanistic kicker — adding ICB on top of the vaccine gave no additional benefit, consistent with the priming-is-the-bottleneck hypothesis (if effectors were rate-limiting, anti-PD-1 should extract more activity). The sufficiency experiment — intracranial adoptive transfer of brain TRM-like cells into naive recipients protected against subsequent orthotopic tumor challenge. Translational signal: ChAdOx1/MVA is a clinical-grade vector pair (existing cancer-vaccine programs in HBV-driven HCC and prostate cancer); priming-not-effector logic flips the standard "layer everything onto checkpoint blockade" combination ordering for cold tumors; the Gpr149 antigen, if its human ortholog is expressed in glioblastoma tissue, becomes a potential target nomination for CAR-T or T cell engagers. Caveats: mouse data only; abstract-only (preprint < 24h old, body HTML not yet rendered by bioRxiv) — no methods, dosing intervals, T cell magnitudes, or survival curves available; ChAdOx1/MVA viral-vector cancer-vaccine IP encumbered (Van den Eynde + Leung listed inventors); Gpr149 human-tissue expression unverified in this preprint. Net: sharp hypothesis, right adversary model, gold-standard adoptive-transfer sufficiency proof, clinical-grade platform — track when the full body lands.

PROPHET-Ab — 160-arm bispecific antibody library separates which developability liabilities inherit from the parents and which require building the bispecific

Sat, 20 Jun 2026 12:00:00 +0000

Ginkgo Bioworks group preprint (bioRxiv, posted June 15, 2026, indexed June 19–20) measures inheritance of developability properties from parental monoclonals to bispecific antibodies at a scale large enough to convert "everyone knows" intuitions into quantitative selection rules. Library: 160 bispecifics derived from 65 parental arms, all on a uniform knobs-into-holes CrossMab IgG1 scaffold, characterized across 10 assays on the PROPHET-Ab high-throughput biophysics platform (Ginkgo's commercial platform; authors disclose Ginkgo employment and funding). Three inheritance classes fall out, each with platform-engineering implications. Class 1 — clean inheritance: hydrophobicity and surface charge come straight through (Spearman ρ ≈ 0.85–0.95), so triage these at the parental level before pairing; avoid pairing two arms both high on the HIC × HAC plane (a parental biophysical ceiling). Class 2 — partial inheritance: self-association and polyreactivity inherit at ρ ≈ 0.60–0.88 with mechanistically interpretable outliers driven by Fv-Fv charge complementarity — pair Fv regions of the same charge sign (not opposite) to suppress emergent self-association, then re-validate in formulation buffer (ionic strength changes the picture). Class 3 — does not inherit: thermostability is poorly predicted from parents (ρ < 0.4), so it has to be measured on the bispecific itself, no shortcut. Practical impact for a TCE / ADC / trispecific platform: upstream filtering of parental arms on hydrophobicity + charge plus Fv charge-sign partner design can substantially shrink the bispecific-stage workload before construction, while thermostability budgets need to assume bispecific-level testing. Caveats: scaffold is fixed (knobs-into-holes CrossMab IgG1); other formats (DVD-Ig, BiTE, tandem scFv, appended-Fab) may inherit differently and the authors explicitly flag per-format re-validation. Ginkgo is the platform vendor and the benchmark is in-house — sound experimental design, but a second-site replication on a different scaffold is the right confirmation before betting clinical programs on the rules.

AbCellera CD3+costim TCE platform — Jazz pays $56M upfront for trispecific multispecifics targeting GI solid tumors, latest deal underwriting the industry pivot from two-arm BiTEs to costim-armed three-arm formats

Fri, 19 Jun 2026 12:00:00 +0000

Jazz Pharmaceuticals and AbCellera announced on Tuesday, June 17, 2026 a preclinical research collaboration, option, and license agreement to discover next-generation T cell engaging multispecific antibodies aimed at gastrointestinal cancers and other solid tumors. Economics: $56M upfront for the first two discovery programs, $28M more on initiation of a third program (contractually within 12 months), up to ~$792M per program in option fees + development/regulatory/commercial milestones, plus mid-single to low double-digit tiered royalties; potential for two additional mutually-agreed programs. Jazz holds exclusive per-program options to develop and commercialize; AbCellera runs discovery and early-stage research. The asset isn't a molecule — it's a platform with four named components: (1) proprietary panels of CD3-binding antibodies (multiple affinity/epitope flavors tunable for tissue context), (2) costimulatory targeting arms, (3) multispecific protein engineering technology, (4) a high-throughput functional assay suite reading T-cell function rather than binding. The architecture being bought is the substance of the story: first-generation TCEs (blinatumomab-style CD3 + tumor antigen, two arms) have worked in heme but systematically stalled in solid tumors on antigen heterogeneity, on-target off-tumor toxicity, and CD3-driven T cell exhaustion. The field's consensus bet for the past two years has been that a third arm — a costimulatory engager like CD28 or 4-1BB, ideally conditional on dual-antigen binding so signal 1 and signal 2 arrive together only on tumor cells — is what unlocks durable activity inside cold solid-tumor stroma. AbCellera is explicitly selling that architecture as a discovery engine; every program out of this collaboration is a trispecific by default. Target/program identities undisclosed (standard for preclinical platform deals), but the GI focus (pancreatic, gastric, CRC — graveyards for two-arm bispecific TCEs and conventional checkpoint inhibitors) is exactly where the trispecific thesis should pay off if it's right. Strategic read for Jazz: their oncology business (Rylaze in ALL, Zepzelca in SCLC) is rare-disease-adjacent, so this is either a strategic widening into volume oncology or a platform bet that costim-armed trispecifics will become reusable across rare-disease oncology later — probably both. Strategic read for the field: this is the third or fourth major deal in 12 months underwriting CD3 + tumor antigen + costim — joining Sanofi/Synaffix/Inhibrx, Pfizer's post-Seagen trispecific expansion, Cullinan, IGM-style multispecifics — and no serious new TCE startup pitched a two-arm format in 2026. Caveats: no molecules exist yet, first development candidates years out, first INDs further still; the field's rate-limiter is not architecture but whether the costim arm can be made conditional enough to avoid TGN1412-style systemic CD28 activation; the $792M/program biobuck is the standard inflated headline (Jazz's real capital at risk is $56M upfront + discovery costs). Net: deal-flow consensus has converged on costim-armed trispecific TCEs as the default next-gen architecture, and discovery engines for that architecture — not single molecules — are now the assets being acquired. Watch for AbCellera's first CD3 panel disclosures and first costim target reveal.

LRRC15 — first cryo-EM structure of the cancer-associated fibroblast ADC target shows samrotamab vedotin binds the lateral surface, leaving the concave face open for next-gen ADCs and de novo minibinders

Thu, 18 Jun 2026 12:00:00 +0000

Walter and Eliza Hall Institute preprint (Shakeel lab, posted to bioRxiv on June 18, 2026) reports the first high-resolution structure of LRRC15 — the leucine-rich-repeat cancer-associated fibroblast antigen that's been a stromal ADC target since AbbVie advanced samrotamab vedotin (ABBV-085) into Phase 1 in sarcoma a half-decade ago and then quietly shelved the program. LRRC15 is heavily upregulated on TGF-β-induced stromal fibroblasts wrapping desmoplastic tumors (pancreatic, breast, head-and-neck), correlates with therapy resistance, and the therapeutic thesis is: deliver cytotoxic payload to the stroma, kill the fibroblast, collapse the stromal barrier, let immune cells or co-administered drugs through. The Shakeel team used hydrogen-deuterium exchange mass spec to roughly localize the samrotamab epitope, then cryo-EM of the LRRC15–samrotamab complex at 2.6 Å resolution — the first publication-grade structure of this target. Three findings: (1) LRRC15 is an extended open-arc solenoid of leucine-rich repeats with a concave inner surface and convex outer surface, both exposed; (2) samrotamab binds laterally on the side of the arc in the C-terminal membrane-proximal LRRs — it does not engage the canonical concave ligand-binding face, which provides a structural rationale for why antibody occupancy may leave signalling-competent surfaces intact (and retrospectively rhymes with samrotamab's middling Phase 1 efficacy); (3) the authors computationally designed de novo minibinders against the concave face — multiple hits at nanomolar affinity, validated in binding assays. The translational signal for Justice's group is not "samrotamab was the wrong molecule" but "LRRC15 has a structurally distinct second surface that nobody has touched": a next-generation LRRC15-directed therapeutic (ADC, TCE, multispecific bridging stroma to a tumor antigen) built on a concave-face binder would have a non-overlapping epitope, no IP collision with the samrotamab estate, and a plausible mechanistic story for higher potency by occupying a geometrically central surface rather than a peripheral one. The minibinder scaffold is also the right size for a stromal target — penetrates desmoplastic tissue better than full IgGs, fast clearance for radioligand/imaging, amenable to multispecific formats. A trispecific TCE bridging tumor antigen × CD3 × concave-face LRRC15 would simultaneously activate T cells and tether them to the desmoplastic stroma — a structural argument the field hasn't had access to until this paper. Caveats: apo binary complex only (no in-cell TGF-β-induced co-receptor context); minibinders are in-vitro nanomolar hits, not validated therapeutics (no cell killing, PK, or efficacy); the underlying biology of whether engaging LRRC15 on CAFs translates to durable tumor regression remains where AbbVie left it. Net: a structural-biology paper that resets the design space for an ADC target the field had nearly given up on; expect the next round of LRRC15 programs to target the concave surface and use small-scaffold binders.

CTIM-76 — CLDN6×CD3 bispecific T cell engager posts 29% ORR with grade-1-only CRS in heavily pretreated platinum-resistant ovarian cancer, putting an off-the-shelf TCE within reach of BNT211 CAR-T efficacy on a much milder safety footprint

Wed, 17 Jun 2026 12:00:00 +0000

Context Therapeutics (CNTX) reported the first efficacy readout for CTIM-76, a CLDN6×CD3 bispecific T cell engager, in a Phase 1a dose-escalation in platinum-resistant ovarian, testicular, and endometrial cancers (announced June 15, 2026; May 29 data cut). 21 patients enrolled (PROC n=14, testicular n=4, endometrial n=3) across weekly doses 22.5–560 µg; the 560 µg dose exceeded target exposure and was abandoned, with active doses defined as 140–280 µg QW. At active doses in PROC, 7 efficacy-evaluable patients delivered ORR 29% (2 confirmed partial responses), DCR 57%, with 3 patients past the 6-month mark on treatment. Safety: CRS in 1/9 patients at active dose, grade 1; no ICANS, no DLTs; AEs mostly grade 1–2, reversible, clustered around first/second dose. FDA Fast Track in PROC. Patient context matters: median 7 prior lines, 89% prior ADC (most having already exhausted mirvetuximab folate-receptor-alpha ADC), 100% prior anti-VEGF, 78% prior DNA-repair agent (PARPs), 55% prior checkpoint inhibitor. Mirvetuximab in earlier-line PROC runs ~31% ORR — so 29% on a post-mirvetuximab denominator is the same number on a sicker population, evidence of activity past ADC failure (the real translational question for new ovarian agents). The bigger story: CLDN6 (fetal/germ-cell antigen re-expressed in ovarian/testicular/endometrial/NSCLC) has been the hottest "embryonic-antigen" solid-tumor IO target, with BioNTech's BNT211 (autologous CLDN6 CAR-T + CARVac mRNA boost) delivering low-30% ORRs but with full CAR-T operational stack (leukapheresis, lymphodepletion, manufacturing, hospitalization, meaningful CRS). CTIM-76 goes after the same target with an off-the-shelf TCE — no cell collection, no conditioning, no manufacturing — and the safety asymmetry is exactly what it should be (G1 CRS in one of nine, zero ICANS, zero DLT). If those numbers hold through expansion, CTIM-76 delivers cell-therapy-grade efficacy on an outpatient antibody footprint — same shape as the bispecific-vs-CAR-T story playing out in B-cell malignancies, now extending into a solid tumor where CAR-T has had a much harder time. Caveats: 7 evaluable PROC at active doses is thin; open-label single-arm dose-escalation; no CLDN6 IHC selection (expansion could dilute with CLDN6-low patients); 3-patient durability signal is encouraging but tiny; Context is a microcap with Phase 1b financing risk into 2027. Next inflection: Q3W dosing schedule in 2H 2026 — if Q3W holds efficacy and safety, the asset shifts from "interesting solid-tumor TCE" to "outpatient injection schedule competitive with ADC standard of care."

LB2501 — Legend Biotech's in vivo CD19/CD20 CAR-T hits 100% ORR and 83% CR with no ICANS at top dose in r/r B-NHL, first clean clinical proof-of-concept that a single IV vector infusion can replace ex vivo manufacturing and lymphodepletion conditioning

Tue, 16 Jun 2026 12:00:00 +0000

Legend Biotech's LB2501 — a CD19/CD20 dual-targeting in vivo CAR-T built on the TaVec lentiviral vector platform engineered to selectively transduce endogenous T cells after a single IV infusion — read out its Phase 1 NCT07002112 data in a late-breaking oral session at EHA 2026 in Stockholm on Saturday June 14. 12 patients with r/r B-cell NHL across two dose levels (data cutoff April 1, 2026). DL1 (n=6): 50% ORR, 33% CR. DL2 (n=6): 100% ORR (6/6), 83.3% CR (5/6), all responses ongoing at median 2.2-month follow-up. CAR-T cells detected in peripheral blood up to 116 days. Safety: no DLTs, no SAEs, no deaths, zero ICANS across all 12 patients; CRS 66.7% all G1–2 (median 4.5 days, no steroids, 4/12 received tocilizumab); IRRs 75% all G1–2 (median resolution 18.6 hours); G≥3 cytopenias limited to lymphocyte and neutrophil decreases (notable because no lymphodepleting chemo was given — cytopenias are CAR-T-expansion-driven, not conditioning-driven). The translational read: the two operational barriers throttling CAR-T from earlier-line use are ex vivo manufacturing (cost, vein-to-vein delay, failures) and fludarabine-cyclophosphamide conditioning (excludes elderly + cytopenia-fragile patients). LB2501 removes both. Read-through to autoimmune CAR-T (lupus, scleroderma, MS, refractory RA) is bigger than the oncology read-through — the safety asymmetry that has gated chemo-conditioning in non-malignant patients flips if you can dose without lymphodepletion and without ICANS. Caveats: n=6 at DL2, 2.2-mo follow-up, B-NHL is the most CAR-T-tractable indication so cross-disease generalizability is open, lentiviral integration/RCL surveillance regulatory burden persists, head-to-head durability vs liso-cel/axi-cel still years out. Competitive frame: Legend leapfrogs Capstan (LNP-mRNA transient platform), Umoja, and Interius (lentiviral peers) with cleanest efficacy + safety at the top dose. Converging story with yesterday's MonumenTAL-3 talquetamab readout — bispecifics and in vivo CAR-Ts both pursuing CAR-T-grade depth-of-response on an off-the-shelf, no-lymphodepletion footprint, and that competitive pressure now lands on every 2L and late-line B-cell oncology indication over the next 2 years.

Talquetamab — GPRC5D×CD3 bispecific T-cell engager cuts PFS hazard 72% in second-line myeloma in MonumenTAL-3 phase 3, NEJM publication moves GPRC5D from post-BCMA salvage into the earlier-line franchise

Mon, 15 Jun 2026 12:00:00 +0000

MonumenTAL-3 phase 3 of J&J's GPRC5D-targeting bispecific T-cell engager talquetamab (Talvey) plus subcutaneous daratumumab ± pomalidomide in 864 r/r myeloma patients (≥1 prior line, len + PI exposed; 85% len-refractory, 93% refractory to last line), presented at EHA 2026 Stockholm on Saturday (Abstract S100) and simultaneously published in NEJM on June 13 (Mina et al., DOI 10.1056/NEJMoa2604657). Both talquetamab arms beat the daratumumab-pomalidomide-dexamethasone control on PFS: triplet HR 0.28 (72% risk reduction, 95% CI 0.20–0.40, p<0.0001), doublet HR 0.33 (67% reduction). 24-month PFS 81.3% / 77.6% / 51.2%; 24-month OS 89.2% / 87.9% / 79.1% (OS HRs 0.47 and 0.51). ORR 88% on both talquetamab arms vs 78% control; ≥CR 71% vs 35%; MRD-negative ≥CR 52% vs 16%. The safety signal is what differentiates GPRC5D from BCMA-targeted therapy: CRS 68% (mostly G1–2), grade 3+ infections 38% (lower than the 42% on control), but taste changes 73% vs 4%, weight loss 46% vs 7%, plus skin/nail tox — quality-of-life-disrupting on-target effects, not the infection-and-cytopenia profile that has been Tecvayli/Elrexfio's rate-limiting safety signal. Treatment discontinuations 10.5% vs 6.7%. Two takes for the bispecific TCE franchise: (1) GPRC5D is now the proven second non-overlapping myeloma antigen — sequencing post-BCMA salvage moves earlier, and the parallel-franchise positioning works in anti-BCMA-naive patients; (2) the off-the-shelf, infection-light, no-lymphodepletion profile competes directly with BCMA CAR-Ts on access while delivering hazard ratios in the same 0.26–0.33 band as CARVYKTI in second-line. The in-vivo CAR-T programs targeting the second-line slot face a much harder commercial target after this readout. Next inflection: MonumenTAL-6 in frontline on top of dara+len.

AJ1-11095 — Lilly/Ajax Type II JAK2 inhibitor posts 70% SVR35 and 70% TSS50 in post-JAK myelofibrosis at EHA, with mutant allele burden falling in 21 of 23 patients

Sun, 14 Jun 2026 12:00:00 +0000

First clinical readout for AJ1-11095, the first-in-class Type II JAK2 inhibitor Lilly acquired from Ajax Therapeutics in a deal worth up to $2.3B, presented yesterday in an oral session at EHA 2026 in Stockholm (Abstract S218). Phase 1 AJX-101: 23 previously-JAK-inhibitor-treated myelofibrosis patients (median 2 prior lines), five dose levels 25–125 mg QD. Best-response SVR35 70%, week-12 TSS50 70%, and — the disease-modifying signal — driver-mutation VAF reductions in 21/23 patients, with 59% showing ≥20% drop in mutant JAK2 VAF by week 24. Historical post-JAK MF benchmark is 0–32% SVR35 (pacritinib/fedratinib/momelotinib), and ruxolitinib essentially doesn't move VAF — so hitting 70% spleen response with allele-burden reduction is a genuine step change rather than a me-too. Mechanism is the substance behind the marketing: Type I JAK inhibitors (rux et al.) bind the active ATP-competitive conformation in a highly conserved pocket → JAK1/TYK2 spillover → cytopenias and immunosuppression. Type II inhibitors lock the inactive (DFG-out) conformation in a more sequence-divergent pocket, giving selective JAK2 inhibition with deeper, more durable target engagement. Safety: no DLTs; grade ≥3 anemia 52%, thrombocytopenia 30% (on-target, consistent with disease + JAK2 biology); transient LFT elevations at 125 mg; no toxicity-attributed discontinuations. Lilly selected 75 mg for expansion and plans Phase 3 in 2L MF "as quickly as we can," plus high-risk PV and JAK-naive arms. Read-through for immunology: the Type II off-state-lock playbook is the relevant precedent to watch for selective TYK2 and JAK1 programs in autoimmune disease.

Cell-cycle arrest as a CAR-T exhaustion driver — S-to-G2 stall pinpointed upstream of dysfunction

Sat, 13 Jun 2026 12:00:00 +0000

Stanford preprint (Bendall and Mackall labs, posted on bioRxiv 12 June) argues that the cell cycle is upstream of T-cell exhaustion rather than a downstream consequence — and pinpoints an aberrant S-to-G2 arrest signature as the lever in tonic-signaling CARs. Using single-cell mass cytometry (CyTOF), the team measured cell-cycle markers, receptor signaling, differentiation state, and time-since-activation in parallel on single cells, then disentangled them by pharmacologically blocking specific cell-cycle transitions and using tonic-signaling CAR models. Two findings: (1) G1-to-S progression crosstalks with TCR/CAR signaling at the earliest activation step to bias effector-vs-memory fate; (2) tonic-signaling CARs accumulate an aberrant S-to-G2 arrest signature that sits upstream of the exhaustion program, not downstream. The same S-to-G2 arrest signature shows up in CD8 T-cell dysfunction in human tumors in situ and in vivo, so this is not a CAR-engineering artifact. Why it matters for a CAR/TCE program: a new mechanistic target for scFv/hinge/transmembrane tuning or pharmacological co-treatment that nudges cells through the checkpoint; and a candidate early biomarker (cell-cycle state at apheresis or post-manufacturing) that might predict downstream exhaustion before it shows up clinically. Caveat: bioRxiv full text was Cloudflare-blocked at script time, so the rescue/causality experiments and the specific tonic-CAR models (HA.28z vs others) are worth pulling directly from the paper.

GL-4512 — first direct small-molecule modulator of the LILRB4 myeloid checkpoint

Fri, 12 Jun 2026 12:00:00 +0000

Moustafa Gabr's lab at Weill Cornell reports GL-4512, the first direct small-molecule modulator of LILRB4 (ILT3) — an immunosuppressive myeloid checkpoint that has, until now, only been drugged with antibodies (IO-202 from Immune-Onc, J&J's LBL-043 bispecific). LILRB4 is non-enzymatic with no obvious pocket; the team used a Dianthus thermal-shift (TRIC) screen — agnostic to binding site — plus microsecond-scale MD simulations and site-directed mutagenesis to identify a previously unrecognized cryptic pocket in the flexible extracellular domain. GL-4512 binds with nanomolar affinity (confirmed by MST, SPR, CETSA), disrupts the LILRB4-SCG2 axis, suppresses SHP1/SHP2/STAT3, and restores anti-tumor activity (IFN-γ, IL-2, cytotoxic T-cell activation) in patient-derived CRC and AML co-cultures. Once-daily oral dosing suppressed tumor growth in immunocompetent CT26. Two reasons it matters: (1) if selectivity across the LILRB family holds, oral + low-COGS + CNS-accessible expands the deployment story vs antibody LILRB4 blockade; (2) the thermal-shift-plus-MD-cryptic-pocket playbook now has a credible demonstration on a "undruggable" myeloid checkpoint — copy-paste for LILRB1/2, TIM3 relatives, VISTA. Caveats: preprint, single lab, CT26 is forgiving; full-text numbers were behind Cloudflare at script time. (Going off the abstract.)

Lasme-cel — first allogeneic CAR-T with FDA RMAT designation and final Phase 1 readout in r/r B-ALL

Thu, 11 Jun 2026 12:00:00 +0000

Cellectis logged two pieces of news in 24 hours that drag the allogeneic CAR-T thesis back into play: FDA RMAT designation on Tuesday (June 9) for lasme-cel — the first allogeneic CAR-T product with RMAT status and a pivotal trial enrolling — and today's release of final Phase 1 BALLI-01 data from EHA 2026 in Stockholm. Lasme-cel (formerly UCART22) is a CD22-directed allogeneic CAR-T, TALEN-edited at TRAC (anti-GvHD) and CD52 (alemtuzumab resistance for deeper lymphodepletion), for relapsed/refractory B-cell ALL. In the 7-patient Phase 2 target subset (median 5 prior lines): 100% ORR, 57% CR/CRi, 75% of responders MRD-negative; safety was clean — severe CRS in 4%, severe ICANS in 4%, severe IEC-HS in 2%, all resolved. Pivotal Phase 2 BALLI-01 is enrolling with first interim Q4 2026. Eti-cel — CD20×CD22 dual-targeting allogeneic in r/r B-NHL where 93% had failed prior autologous CD19 CAR-T — posted 88% ORR / 63% CR at the optimal dose (n=14). Read-through: the most interesting head-to-head over the next 12 months isn't allogeneic versus autologous — it's allogeneic against in-vivo CAR-T (Legend's LB2501 at this same EHA meeting, Lilly's $2.4B Orna acquisition for circular-RNA in-vivo CAR-T in autoimmune). Two completely different answers to the same logistics problem, reading data into overlapping populations. Cellectis just put down the marker.

Trodelvy + Keytruda — Phase 3 EVOKE-03 halted in first-line PD-L1-high NSCLC

Wed, 10 Jun 2026 12:00:00 +0000

Merck and Gilead jointly halted the Phase 3 KEYNOTE-D46/EVOKE-03 trial of Trodelvy (sacituzumab govitecan) plus Keytruda in previously untreated metastatic non-small cell lung cancer with PD-L1 TPS ≥ 50%. PFS was numerically better for the combination but missed statistical significance; the data monitoring committee judged OS unlikely to hit at the planned final analysis. Two read-throughs: (1) TROP-2 as a target isn't the failure — sac-TMT (sacituzumab tirumotecan, different payload + linker) cut PFS risk ~65% in 1L NSCLC at ASCO this year, so the ADC chemistry mattered more than the antigen. (2) Ivonescimab (Akeso/Summit PD-1×VEGF bispecific) just posted a 4.2-month OS gain + 34% mortality reduction in HARMONi-6 squamous NSCLC, raising the bar any ADC-plus-checkpoint combo has to clear; datopotamab deruxtecan + durvalumab from AstraZeneca/Daiichi Sankyo is the program now carrying the TROP-2 ADC + IO thesis in 1L lung. Bottom line: Trodelvy as a 1L PD-L1-high NSCLC combination expansion is off the table; the PD-1×VEGF and PD-L1×VEGF bispecific class (pumitamig from BioNTech/BMS reading next) is reshaping the setting faster than ADC combos can catch up.